Document:

EX-10.11

 Exhibit 10.11 

 
  
  

 
 OMEGA THERAPEUTICS, INC. 

PACIFIC WESTERN BANK 

LOAN AND SECURITY AGREEMENT 
  

 This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of March 9, 2018, by
and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”) and OMEGA THERAPEUTICS, INC. (“Borrower”). 

RECITALS 
 Borrower wishes to obtain
credit from time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement sets forth the terms on which Bank will advance credit to Borrower, and Borrower will repay the amounts owing to Bank. 

AGREEMENT 
 The parties agree as follows:

  

	1.	 DEFINITIONS AND CONSTRUCTION. 

1.1    Definitions. As used in this Agreement, all capitalized terms shall have the definitions set forth on
Exhibit A. Any term used in the Code and not defined herein shall have the meaning given to the term in the Code. 

1.2    Accounting Terms. Any accounting term not specifically defined on Exhibit A shall be construed
in accordance with GAAP and all calculations shall be made in accordance with GAAP (except for non-compliance with FAS 123R in monthly reporting and recording stock compensation expense, subject to normal year-end adjustments and without all required footnotes). The term “financial statements” shall include the accompanying notes and schedules. 

 

	2.	 LOAN AND TERMS OF PAYMENT. 

2.1    Credit Extensions. 

(a)    Promise to Pay. Borrower promises to pay to Bank, in lawful money of the United States of America, the
aggregate unpaid principal amount of all Credit Extensions made by Bank to Borrower, together with interest on the unpaid principal amount of such Credit Extensions at rates in accordance with the terms hereof. 

(b)    Term Loan. 

(i)    Subject to and upon the terms and conditions of this Agreement, (x) Bank shall make a Term Loan to
Borrower in an aggregate principal amount not to exceed Eight Million Dollars ($8,000,000), consisting of Tranche I and Tranche II, (y) Tranche I shall be funded on or about the Closing Date, and (z) Tranche II shall be
funded upon satisfaction of the conditions set forth in Section 3.2 hereof not later than 18 months from the Closing Date. The proceeds of the Term Loan shall be used for general working capital purposes and for capital expenditures. 

(ii)    Interest shall accrue from the date of a Term Loan is made at the rate specified in Section 2.2(a),
and shall be payable monthly beginning on the ninth (9th) calendar day of the month in which the Term Loan is made, and continuing on the same calendar day of each

  
 1 

 
month therereafter. Borrower shall repay the balance of the Term Loan that is outstanding on the date that is 18 months from the Closing Date, in 30 equal monthly installments of principal,
plus all accrued interest, beginning on the date that is 19 months from the Closing Date, and continuing on the same day of each month thereafter through the Maturity Date, at which time all amounts due in connection with the Term Loan and any
other amounts due under this Agreement shall be immediately due and payable. Borrower may prepay all or any part of the Term Loan without penalty or premium, but may not reborrow any amount, once repaid. 

(iii)    When Borrower desires to obtain a Term Loan, Borrower shall notify Bank (which notice shall be
irrevocable) by facsimile transmission or email to be received no later than 3:30 p.m. Eastern time three (3) Business Days before the day on which the Term Loan is to be made. Such notice shall be given by a Loan Advance/Paydown Request
Form in substantially the form of Exhibit C. The notice shall be signed by an Authorized Officer. Bank shall be entitled to rely on any notice given by a person whom Bank reasonably believes to be an Authorized Officer, and Borrower shall
indemnify and hold Bank harmless for any damages, loss, costs and expenses suffered by Bank as a result of such reliance. 

(c)    Usage of Credit Card Services Under Credit Card Line. 

(i)    Usage Period. Subject to and upon the terms and conditions of this Agreement, at any time through the
Credit Card Maturity Date, Borrower may use the Credit Card Services (as defined below) in amounts and upon terms as provided in this Section. 

(ii)    Credit Card Services. Subject to and upon the terms and conditions of this Agreement, Borrower may
request corporate credit cards and standard e-commerce merchant account services from Bank (collectively, the “Credit Card Services”). The aggregate limit of the corporate credit cards and merchant
credit card processing reserves shall not exceed the Credit Card Line. The terms and conditions (including repayment and fees) of such Credit Card Services shall be subject to the terms and conditions of Bank’s standard forms of application and
agreement for the Credit Card Services, which Borrower hereby agrees to execute. 

(iii)    Collateralization of Obligations Extending Beyond Maturity. If Borrower has not cash secured its
obligations with respect to any Credit Card Services by the Credit Card Maturity Date, then, effective as of such date, the balance in any deposit accounts held by Bank and the certificates of deposit or time deposit accounts issued by Bank in
Borrower’s name (and any interest paid thereon or proceeds thereof, including any amounts payable upon the maturity or liquidation of such certificates or accounts), shall automatically secure such obligations to the extent of the then
continuing or outstanding Credit Card Services. Borrower authorizes Bank to hold such balances in pledge and to decline to honor any drafts thereon or any requests by Borrower or any other Person to pay or otherwise transfer any part of such
balances for so long as the applicable Credit Card Services are outstanding or continue. 
 2.2    Interest
Rates, Payments, and Calculations. 
 (a)    Interest Rate. Except as set forth in Section 2.3(b),
the Term Loan shall bear interest, on the outstanding daily balance thereof, at a floating annual rate equal to the greater of (i) 0.75% above the Prime Rate then in effect and (ii) 5.00%. 

  
 2 

 (b)    Late Fee; Default Rate. If any payment is not made
within 15 days after the date such payment is due, Borrower shall pay Bank a late fee equal to the lesser of (i) 5% of the amount of such unpaid amount or (ii) the maximum amount permitted to be charged under applicable law. All
Obligations shall bear interest, from and after the occurrence and during the continuance of an Event of Default, at a rate equal to 5 percentage points above the interest rate applicable immediately prior to the occurrence of the Event of Default.

 (c)    Payments. Interest shall be due and payable on the ninth (9th) calendar day of each month during
the term hereof. Borrower authorizes Bank to, at its option, charge such interest, all Bank Expenses, and all Periodic Payments against first, deposit account number XXXX and, second, if insufficient funds remain in such account, any of
Borrower’s other deposit accounts, in which case those amounts shall thereafter accrue interest at the rate then applicable hereunder. Any interest not paid when due shall be compounded by becoming a part of the Obligations, and such interest
shall thereafter accrue interest at the rate then applicable hereunder. 
 (d)    Computation. In the
event the Prime Rate is changed from time to time hereafter, the applicable rate of interest hereunder shall be increased or decreased, effective as of the day the Prime Rate is changed, by an amount equal to such change in the Prime Rate. All
interest chargeable under the Loan Documents shall be computed on the basis of a 360-day year for the actual number of days elapsed. 

2.3    Crediting Payments. Unless an Event of Default exists and is continuing, Bank shall credit a wire
transfer of funds, check or other item of payment to such deposit account or Obligation as Borrower specifies. After the occurrence and during the continuance of an Event of Default, Bank shall have the right, in its sole discretion, to immediately
apply any wire transfer of funds, check, or other item of payment Bank may receive to conditionally reduce Obligations, but such applications of funds shall not be considered a payment on account unless such payment is of immediately available
federal funds or unless and until such check or other item of payment is honored when presented for payment. Notwithstanding anything to the contrary contained herein, any wire transfer or payment received by Bank after 5:30 p.m. Eastern Time
shall be deemed to have been received by Bank as of the opening of business on the immediately following Business Day. Whenever any payment to Bank under the Loan Documents would otherwise be due (except by reason of acceleration) on a date that is
not a Business Day, such payment shall instead be due on the next Business Day, and additional fees or interest, as the case may be, shall accrue and be payable for the period of such extension. 

2.4    Fees. Borrower shall pay to Bank the following: 

(a)    Facility Fee. None. 

(b)    Bank Expenses. On the Closing Date, all Bank Expenses incurred through the Closing Date, and, after
the Closing Date, all Bank Expenses, as and when they become due. 
 2.5    Term. This Agreement shall
become effective on the Closing Date and, subject to Section 12.7, shall continue in full force and effect for so long as any Obligations (other than inchoate indemnity obligations) remain outstanding or Bank has any obligation to make Credit

  
 3 

 
Extensions under this Agreement. Notwithstanding the foregoing, Bank shall have the right to terminate its obligation to make Credit Extensions under this Agreement immediately and without notice
upon the occurrence and during the continuance of an Event of Default. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations), Borrower may terminate this Agreement upon three (3) Business Days written
notice to Bank. Following such payment in full in cash of the Obligations (other than inchoate indemnity obligations), at such time as Bank’s obligation to make Credit Extensions has terminated, Bank shall release its Liens in the Collateral
and Bank shall promptly take such action reasonably requested by Borrower, at Borrower’s sole cost and expense, in order to cause such Liens to be terminated of record (including by filing UCC-3 or
similar termination statements with respect to such Liens), and all rights therein shall revert to Borrower. 
  

	3.	 CONDITIONS OF LOANS. 

3.1    Conditions Precedent to Closing. The agreement of Bank to enter into this Agreement on the Closing
Date is subject to the condition precedent that Bank shall have received, in form and substance satisfactory to Bank, each of the following items and completed each of the following requirements: 

(a)    this Agreement; 

(b)    an officer’s certificate of Borrower with respect to incumbency and resolutions authorizing the
execution and delivery of this Agreement; 
 (c)    a financing statement (Form
UCC-1); 
 (d)    a completed Loan Advance Form; 

(e)    payment of the Bank Expenses then due specified in Section 2.5, which may be debited from any of
Borrower’s accounts with Bank; 
 (f)    current SOS Reports indicating that except for Permitted Liens,
there are no other security interests or Liens of record in the Collateral; 
 (g)    Borrower-prepared
consolidated and consolidating balance sheets, income statements, and statements of cash flows for the most recently ended month and fiscal year in accordance with Section 6.2, and such other updated financial information as Bank may reasonably
request; 
 (h)    current Compliance Certificate in accordance with Section 6.2; 

(i)    evidence satisfactory to Bank that the insurance policies required by Section 6.5 hereof are in full
force and effect, together with appropriate evidence showing loss payable and additional insured clauses or endorsements in favor of Bank, 

(j)    a Warrant; 

(k)    a Borrower Information Certificate; 

  
 4 

 (l)    Borrower shall have opened and funded not less than
$50,000 in deposit accounts held with Bank; and 
 (m)    such other documents or certificates, and
completion of such other matters, as Bank may reasonably request. 
 3.2    Conditions Precedent to Tranche
II. The obligation of Bank to lend Tranche II to Borrower is contingent upon Borrower’s compliance with Section 3.1 above, and is further subject to the following conditions: 

(a)    timely receipt by Bank of the Loan Advance/Paydown Request Form; 

(b)    an Event of Default shall not be then continuing; 

(c)    in Bank’s reasonable discretion, there has not been a Material Adverse Effect; 

(d)    the representations and warranties contained in Section 5 shall be true and correct in all material
respects on and as of the date of such Loan Advance/Paydown Request Form and on the effective date of each Credit Extension as though made at and as of each such date, and no Event of Default shall have occurred and be continuing, or would exist
after giving effect to such Credit Extension (provided, however, that those representations and warranties expressly referring to another date shall be true and correct in all material respects as of such date, and provided further that any
representation or warranty that contains a materiality qualification therein shall be true and correct in all respects); 

(e)    Borrower has received at least Eleven Million Dollars ($11,000,000) of net cash proceeds after the Closing
Date from the sale or issuance of its Series A Preferred Stock (second tranche); 
 (f)    Flagship
Pioneering has confirmed in writing to Bank that it is satisfied with Borrower’s preclinical development efforts relative to Borrower’s plan. 
  

	4.	 CREATION OF SECURITY INTEREST. 

4.1    Grant of Security Interest. Borrower grants and pledges to Bank a continuing security interest in the
Collateral to secure prompt repayment of any and all Obligations and to secure prompt performance by Borrower of each of its covenants and duties under the Loan Documents. Except for Permitted Liens or as disclosed in the Schedule, such security
interest constitutes a valid, first priority security interest in the presently existing Collateral, and will constitute a valid, first priority security interest in later-acquired Collateral. Notwithstanding any termination of this Agreement or of
any filings undertaken related to Bank’s rights under the Code, Bank’s Lien on the Collateral shall remain in effect for so long as any Obligations (other than inchoate indemnity obligations) are outstanding. 

4.2    Perfection of Security Interest. Borrower authorizes Bank to file at any time financing statements,
continuation statements, and amendments thereto that (i) either specifically describe the Collateral or describe the Collateral as all assets of Borrower of the kind pledged 

  
 5 

 
hereunder, and (ii) contain any other information required by the Code for the sufficiency of filing office acceptance of any financing statement, continuation statement, or amendment,
including whether Borrower is an organization, the type of organization and any organizational identification number issued to Borrower, if applicable. Borrower shall have possession of the Collateral, except where expressly otherwise provided in
this Agreement or where Bank chooses to perfect its security interest by possession in addition to the filing of a financing statement. Where Collateral is in possession of a third party bailee, Borrower shall take such steps as Bank reasonably
requests for Bank to (i) subject to Section 7.11 below, obtain an acknowledgment, in form and substance reasonably satisfactory to Bank, of the bailee that the bailee holds such Collateral for the benefit of Bank, and (ii) subject to
Section 6.6, obtain “control” of any Collateral consisting of investment property, deposit accounts, letter-of-credit rights or electronic chattel paper
(as such items and the term “control” are defined in Revised Article 9 of the Code) by causing the securities intermediary or depositary institution or issuing bank to execute a control agreement in form and substance reasonably
satisfactory to Bank. Borrower will not create any chattel paper without placing a legend on the chattel paper acceptable to Bank indicating that Bank has a security interest in the chattel paper. Borrower from time to time may deposit with Bank
specific cash collateral to secure specific Obligations; Borrower authorizes Bank to hold such specific balances in pledge and to decline to honor any drafts thereon or any request by Borrower or any other Person to pay or otherwise transfer any
part of such balances for so long as the specific Obligations are outstanding. Borrower shall take such other actions as Bank reasonably requests to perfect its security interests granted under this Agreement. 

 

	5.	 REPRESENTATIONS AND WARRANTIES. 

Borrower represents and warrants as follows: 

5.1    Due Organization and Qualification. Borrower and each Subsidiary is duly existing under the laws of
the state in which it is organized and qualified and licensed to do business in any state in which the conduct of its business or its ownership of property requires that it be so qualified, except where the failure to do so would not reasonably be
expected to cause a Material Adverse Effect. 
 5.2    Due Authorization; No Conflict. The execution,
delivery, and performance of the Loan Documents are within Borrower’s powers, have been duly authorized, and are not in conflict with nor constitute a breach of any provision contained in Borrower’s Certificate of Incorporation or Bylaws,
nor will they constitute an event of default under any material agreement by which Borrower is bound. Borrower is not in default under any agreement by which it is bound, except to the extent such default would not reasonably be expected to cause a
Material Adverse Effect. 
 5.3    Collateral. Borrower has rights in or the power to transfer the
Collateral, and its title to the Collateral is free and clear of Liens, adverse claims, and restrictions on transfer or pledge except for Permitted Liens. All Inventory is in all material respects of good and merchantable quality, free from all
material defects, except for Inventory for which adequate reserves have been made. Except as set forth in the Schedule, none of the Borrower’s Cash is maintained or invested with a Person other than Bank or Bank’s affiliates. 

  
 6 

 5.4    Intellectual Property. Borrower is the sole owner
of the Intellectual Property material to Borrower’s business, except for licenses permitted herein. To the best of Borrower’s knowledge, each of the material Copyrights, Trademarks and Patents is valid and enforceable, and no material part
of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and no claim has been made to Borrower that any material part of the Intellectual Property violates the rights of any third party except to the extent such
claim would not reasonably be expected to cause a Material Adverse Effect. 
 5.5    Name; Location of Chief
Executive Office. Except as disclosed in the Schedule, Borrower has not done business under any name other than that specified on the signature page hereof, and its exact legal name is as set forth in the first paragraph of this Agreement. The
chief executive office of Borrower is located at the address indicated in Section 10 hereof. 

5.6    Litigation. Except as set forth in the Schedule or otherwise disclosed in writing to Bank, there are
no actions or proceedings pending by or against Borrower or any Subsidiary before any court or administrative agency in which a likely adverse decision would reasonably be expected to have a Material Adverse Effect. 

5.7    No Material Adverse Change in Financial Statements. All consolidated (and consolidating, if any)
financial statements related to Borrower and any Subsidiary that are delivered by Borrower to Bank fairly present in all material respects Borrower’s consolidated and consolidating, if any, financial condition as of the date thereof and
Borrower’s consolidated and consolidating, if any, results of operations for the period then ended. Except as disclosed in writing to Bank, there has not been a material adverse change in the consolidated or in the consolidating financial
condition of Borrower since the date of the most recent of such financial statements submitted to Bank. 

5.8    Solvency, Payment of Debts. Borrower is able to pay its debts (including trade debts) as they mature;
the fair saleable value of Borrower’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities; and Borrower is not left with unreasonably small capital after the transactions contemplated by this Agreement.

 5.9    Compliance with Laws and Regulations. Borrower and each Subsidiary have met the minimum funding
requirements of ERISA with respect to any employee benefit plans subject to ERISA. No event has occurred resulting from Borrower’s failure to comply with ERISA that is reasonably likely to result in Borrower’s incurring any liability that
could have a Material Adverse Effect. Borrower is not an “investment company” or a company “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940. Borrower is not engaged
principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulations T and U of the Board of Governors of the Federal Reserve System).
Borrower has not violated any statutes, laws, ordinances or rules applicable to it, the violation of which would reasonably be expected to have a Material Adverse Effect. Borrower and each Subsidiary have filed or caused to be filed all tax returns
required to be filed, and have paid, or have made adequate provision for the payment of, all taxes reflected therein except those being contested in good faith with adequate reserves under GAAP or where the failure to file such returns or pay such
taxes would not reasonably be expected to have a Material Adverse Effect. 

  
 7 

 5.10    Subsidiaries. Borrower does not own any stock,
partnership interest or other equity securities of any Person, except for Permitted Investments. 

5.11    Government Consents. Borrower and each Subsidiary have obtained all consents, approvals and
authorizations of, made all declarations or filings with, and given all notices to, all governmental authorities that are necessary for the continued operation of Borrower’s business as currently conducted, except where the failure to do so
would not reasonably be expected to cause a Material Adverse Effect. 
 5.12    Inbound Licenses. Except
as disclosed on the Schedule or pursuant to Section 6.8, Borrower is not a party to, nor is bound by, any material license or other material agreement important for the conduct of Borrower’s business that prohibits or otherwise restricts
Borrower from granting a security interest in Borrower’s interest in such license or agreement or any other property important for the conduct of Borrower’s business, other than this Agreement or the other Loan Documents. 

5.13    Full Disclosure. No representation, warranty or other statement made by Borrower in any certificate
or written statement furnished to Bank taken together with all such certificates and written statements furnished to Bank contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements
contained in such certificates or statements not misleading in light of the circumstances in which they were made, it being recognized by Bank that the projections and forecasts provided by Borrower in good faith and based upon reasonable
assumptions are not to be viewed as facts and that actual results during the period or periods covered by any such projections and forecasts may differ from the projected or forecasted results. 

 

	6.	 AFFIRMATIVE COVENANTS. 

Borrower shall do all of the following: 

6.1    Good Standing and Government Compliance. Borrower shall maintain its and each of its
Subsidiaries’ corporate existence and good standing in the respective states of formation, shall maintain qualification and good standing in each other jurisdiction in which the failure to so qualify would reasonably be expected to have a
Material Adverse Effect, and shall furnish to Bank the organizational identification number issued to Borrower by the authorities of the state in which Borrower is organized, if applicable. Borrower shall meet, and shall cause each Subsidiary to
meet, the minimum funding requirements of ERISA with respect to any employee benefit plans subject to ERISA. Borrower shall comply, and shall cause each Subsidiary to comply, with all statutes, laws, ordinances and government rules and regulations
to which it is subject, and shall maintain, and shall cause each of its Subsidiaries to maintain, in force all licenses, approvals and agreements, the loss of which or failure to comply with which would reasonably be expected to have a Material
Adverse Effect. 
 6.2    Financial Statements, Reports, Certificates. 

(a)    Borrower shall deliver to Bank: (i) as soon as available, but in any event within 30 days after the
end of each calendar month, a company prepared consolidated and consolidating, if any, balance sheet, income statement, and statement of cash flows covering 

  
 8 

 
Borrower’s operations during such period, in a form reasonably acceptable to Bank and certified by a Responsible Officer; (ii) as soon as available, but in any event within
180 days after the end of Borrower’s fiscal year for each fiscal year after 2017, audited (or such other level as is required by the Investment Agreement) consolidated financial statements of Borrower prepared in accordance with GAAP
(excluding recording stock compensation expense, subject to normal year-end adjustments and without all required footnotes), consistently applied, together with an opinion which is either unqualified,
qualified only for going concern so long as Borrower’s investors provide additional equity as needed or otherwise consented to in writing by Bank on such financial statements of an independent certified public accounting firm reasonably
acceptable to Bank; (iii) annual budget approved by Borrower’s Board of Directors as soon as available but not later than 45 days after the last day of the preceding fiscal year during the term hereof; (iv) if applicable, copies of
all statements, reports and notices sent or made available generally by Borrower to its security holders or to any holders of Subordinated Debt (excluding any materials provided to such security holders, stockholders or holders of Subordinated Debt
solely in their capacity as members of Borrower’s board of directors) and all reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission;
(v) promptly upon receipt of notice thereof, a report of any legal actions pending or threatened against Borrower or any Subsidiary that could reasonably be expected to result in damages or costs to Borrower of $250,000 or more or a Material
Adverse Effect; (vi) promptly upon receipt, each management letter prepared by Borrower’s independent certified public accounting firm regarding Borrower’s management control systems, (vii) periodic informal clinical updates on
any material developments therein as Borrower may determine appropriate or at the reasonable request of Bank, and (viii) such other information as Bank may reasonably request. Any items that are required to be delivered under this Agreement
which are made publicly available via filing with the Securities and Exchange Commission or on Borrower’s website shall be deemed delivered on the date made publicly available. 

(b)    Within 30 days after the last day of each month, Borrower shall deliver to Bank with the monthly
financial statements a Compliance Certificate certified as of the last day of the applicable month and signed by a Responsible Officer in substantially the form of Exhibit D hereto. 

(c)    Within 90 days after the Closing Date, Borrower shall deliver the final Flagship License Agreement duly
executed by the parties thereto. 
 (d)    As soon as possible and in any event within 3 Business Days after
becoming aware of the occurrence or existence of an Event of Default hereunder, a written statement of a Responsible Officer setting forth details of the Event of Default, and the action which Borrower has taken or proposes to take with respect
thereto. 
 (e)    Bank (through any of its officers, employees, or agents) shall have the right, upon reasonable
prior notice, from time to time during Borrower’s usual business hours but no more than once a year (unless an Event of Default has occurred and is continuing), to inspect Borrower’s Books and to make copies thereof and to check, test,
inspect, audit and appraise the Collateral at Borrower’s expense in order to verify Borrower’s financial condition or the amount, condition of, or any other matter relating to, the Collateral. 

  
 9 

 Borrower may deliver to Bank on an electronic basis any certificates, reports or information
required pursuant to this Section 6.2, and Bank shall be entitled to rely on the information contained in the electronic files, provided that Bank in good faith believes that the files were delivered by a Responsible Officer. Borrower shall
include a submission date on any certificates and reports to be delivered electronically. 
 6.3    Inventory
and Equipment; Returns. Borrower shall keep all Inventory and Equipment in good and merchantable condition, free from all material defects except for Inventory and Equipment (i) sold in the ordinary course of business, and (ii) for
which adequate reserves have been made, in all cases in the United States and such other locations as to which Borrower gives prior written notice. Returns and allowances, if any, as between Borrower and its account debtors shall be on the same
basis and in accordance with the usual customary practices of Borrower, as they exist on the Closing Date. Borrower shall promptly notify Bank of all returns and recoveries and of all disputes and claims involving inventory having a book value of
more than $250,000. 
 6.4    Taxes. Borrower shall make, and cause each Subsidiary to make, due and
timely payment or deposit of all material federal, state, and local taxes, assessments, or contributions required of it by law, including, but not limited to, those laws concerning income taxes, F.I.C.A., F.U.T.A. and state disability, and will
execute and deliver to Bank, on demand, proof satisfactory to Bank indicating that Borrower or a Subsidiary has made such payments or deposits and any appropriate certificates attesting to the payment or deposit thereof; provided that Borrower or a
Subsidiary need not make any payment if the amount or validity of such payment is contested in good faith by appropriate proceedings and is reserved against (to the extent required by GAAP) by Borrower or such Subsidiary. 

6.5    Insurance. Borrower, at its expense, shall (i) keep the Collateral insured against loss or
damage, and (ii) maintain liability and other insurance, in each case as ordinarily insured against by other owners in businesses similar to Borrower’s. All such policies of insurance shall be in such form, with such companies, and in such
amounts as reasonably satisfactory to Bank. All policies of property insurance shall contain a lender’s loss payable endorsement, in a form satisfactory to Bank, showing Bank as lender’s loss payee. All liability insurance policies shall
show, or have endorsements showing, Bank as an additional insured. Any such insurance policies shall specify that the insurer must give at least 20 days’ notice to Bank before canceling its policy for any reason, except in the event of
cancellation for non-payment of premium; in this circumstance, the insurer must give at least 10 days’ notice to the Bank. Within 30 days of the Closing Date, Borrower shall cause to be
furnished to Bank a copy of its policies including any endorsements covering Bank or showing Bank as an additional insured. Upon Bank’s request, Borrower shall deliver to Bank certified copies of the policies of insurance and evidence of all
premium payments. Proceeds payable under any casualty policy will, at Borrower’s option, be payable to Borrower to replace the property subject to the claim, provided that any such replacement property shall be deemed Collateral in which Bank
has been granted a first priority security interest, provided that if an Event of Default has occurred and is continuing, all proceeds payable under any such policy shall, at Bank’s option, be payable to Bank to be applied on account of the
Obligations. 

  
 10 

 6.6    Primary Depository. Subject to the provisions of
Section 3.1(l), within 45 days of the Closing Date and at all times thereafter, Borrower shall maintain its primary depository and operating accounts with Bank and its primary investment accounts with Bank or Bank’s affiliates;
provided that prior to maintaining any investment accounts with Bank’s affiliates, Borrower, Bank, and any such affiliate shall have entered into a securities account control agreement with respect to any such investment accounts, in form and
substance satisfactory to Bank. Notwithstanding the above, Borrower may (i) maintain Cash and/or Investments in one or more accounts outside of Bank or Bank’s affiliates, subject to control agreements in favor of Bank, so long as the total
aggregate amount of Cash maintained by Borrower in accounts with Bank or Bank’s affiliates equals or exceeds 200% of the Term Loan and (ii) permit Borrower’s MSC Subsidiary, if any, to maintain Cash in accounts outside of Bank and not
subject to a control agreement in favor of any Person, so long as the total aggregate amount of Cash maintained by Borrower in accounts with Bank or Bank’s affiliates equals or exceeds 120% of the outstanding balance of the Term Loan. 

6.7    Financial Covenants. None. 

6.8    Inbound Licenses. Promptly after entering into or becoming bound by any material inbound license or
material agreement, Borrower shall in the Compliance Certificate next due after entering into or becoming bound, provide written notice to Bank of the material terms of such license or agreement with a description of its likely impact on
Borrower’s business or financial condition. 
 6.9    Creation/Acquisition of Subsidiaries. In
the event any Borrower or any Subsidiary of any Borrower creates or acquires any Subsidiary, Borrower or such Subsidiary shall promptly notify Bank of such creation or acquisition, and Borrower or such Subsidiary shall take all actions reasonably
requested by Bank to achieve any of the following with respect to such “New Subsidiary” (defined as a Subsidiary formed after the date hereof during the term of this Agreement): (i) to cause New Subsidiary to become either a co-Borrower hereunder, if such New Subsidiary is organized under the laws of the United States, or a secured guarantor with respect to the Obligations; and (ii) to grant and pledge to Bank a perfected security
interest in 100% of the stock, units or other evidence of ownership held by Borrower or its Subsidiaries of any such New Subsidiary which is organized under the laws of the United States, and 65% of the stock, units or other evidence of ownership
held by Borrower or its Subsidiaries of any such New Subsidiary which is not organized under the laws of the United States. This Section shall not apply to the MSC Subsidiary. 

6.10    Further Assurances. At any time and from time to time Borrower shall execute and deliver such
further instruments and take such further action as may reasonably be requested by Bank to effect the purposes of this Agreement. 
  

	7.	 NEGATIVE COVENANTS. 

Borrower shall not do any of the following: 

7.1    Dispositions. Convey, sell, lease, license, transfer or otherwise dispose of (collectively, to
“Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, or move cash balances on deposit with Bank to accounts opened at another financial institution not permitted by Section 6.6, in
each case, other than Permitted Transfers. 

  
 11 

 7.2    Change in Name, Location, Executive Office, or
Executive Management; Change in Business; Change in Fiscal Year; Change in Control. Change its name or the state of Borrower’s formation or relocate its chief executive office without 30 days’ prior written notification to Bank;
replace or suffer the departure of its chief executive officer or chief financial officer without delivering written notification to Bank within 15 days; suffer a change on its board of directors which results in the failure of at least one
partner of Flagship Pioneering or its Affiliates to serve as a voting member, in such case without the prior written consent of Bank which may be withheld in Bank’s reasonable discretion; take action to liquidate, wind up, or otherwise cease to
conduct business in the ordinary course; engage in any business, or permit any of its Subsidiaries to engage in any business, other than or reasonably related or incidental to the businesses currently engaged in by Borrower; change its fiscal year
end; have a Change in Control. 
 7.3    Mergers or Acquisitions. Merge or consolidate, or permit any of
its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower), or acquire, or permit any of its Subsidiaries to acquire, all or
substantially all of the capital stock or property of another Person except where (a) each of the following conditions is applicable: (i) the consideration paid in connection with such transactions (including assumption of liabilities)
does not in the aggregate exceed $250,000 during any fiscal year, (ii) no Event of Default has occurred, is continuing or would exist after giving effect to such transactions, (iii) such transactions do not result in a Change in Control,
and (iv) Borrower is the surviving entity; provided that any Subsidiary may merge or consolidate into Borrower or may be dissolved or (b) the Obligations (other than inchoate indemnity obligations) are repaid in full concurrently with the
closing of any merger or consolidation of Borrower in which Borrower is not the surviving entity; provided, however, that Borrower shall not, without Bank’s prior written consent, enter into any binding contractual arrangement with any Person
to attempt to facilitate a merger or acquisition of Borrower; provided however, Borrower may enter into any such agreement without Bank’s prior written consent so long as (i) no Event of Default exists when such agreement is entered into
by Borrower, and (ii) Borrower notifies Bank upon entering into such an agreement (provided, the failure to give such notification shall not be deemed a material breach of this Agreement). 

7.4    Indebtedness. Create, incur, assume, guarantee or be or remain liable with respect to any
Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness, or prepay any Indebtedness prior to the scheduled maturity date or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except
Indebtedness to Bank. 
 7.5    Encumbrances. Create, incur, assume or allow any Lien with respect to its
property, or assign or otherwise convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or covenant to any other Person (other than (i) the licensors of in-licensed property with respect to such property or (ii) the lessors of specific equipment or lenders financing specific equipment with respect to such leased or financed equipment) that Borrower in the
future will refrain from creating, incurring, assuming or allowing any Lien with respect to any of Borrower’s property other than in connection with Permitted Liens. 

  
 12 

 7.6    Distributions. Pay any dividends or make any other
distribution or payment on account of or in redemption, retirement or purchase of any capital stock in cash, except that Borrower may (i) repurchase the stock of former employees, officers, consultants or directors pursuant to stock repurchase
agreements in an aggregate amount not to exceed $250,000 in any fiscal year, as long as an Event of Default does not exist prior to such repurchase or would not exist after giving effect to such repurchase, (ii) repurchase the stock of former
employees, officers, consultants or directors pursuant to stock repurchase agreements by the cancellation of indebtedness owed by such former employees or directors to Borrower regardless of whether an Event of Default exists,
(iii) Borrower’s Subsidiaries may make dividends and distributions to Borrower; (iv) Borrower may convert convertible equity securities; and (v) Borrower may convert Subordinated Debt into equity securities of Borrower to the
extent permitted under the terms of the applicable subordination or intercreditor agreement with Bank. 

7.7    Investments. Directly or indirectly acquire or own an Investment in, or make any Investment in or to
any Person, or permit any of its Subsidiaries to do so, other than Permitted Investments, or, subject to Section 6.6, maintain or invest any of its investment property with a Person other than Bank or Bank’s Affiliates or permit any
Subsidiary to do so unless such Person has entered into a control agreement with Bank, in form and substance reasonably satisfactory to Bank, or suffer or permit any Subsidiary to be a party to, or be bound by, an agreement that restricts such
Subsidiary from paying dividends or otherwise distributing property to Borrower. 
 7.8    Capitalized
Expenditures. Make Capitalized Expenditures in excess of 175% of the amount approved by Borrower’s board of directors and set forth in the most recently approved operating plan delivered to Bank. 

7.9    Transactions with Affiliates. Directly or indirectly enter into or permit to exist any material
transaction with any Affiliate of Borrower except for (i) transactions that are in the ordinary course of Borrower’s business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an arm’s
length transaction with a non-affiliated Person, (ii) the sale of Borrower’s equity securities (or Subordinated Debt) in bona fide transactions that do not result in a Change in Control,
(iii) the Flagship License Agreement, and (iv) customary compensation agreements approved by Borrower’s board of directors. 

7.10    Subordinated Debt. Make any payment in respect of any Subordinated Debt, or permit any of its
Subsidiaries to make any such payment, except in compliance with the terms of such Subordinated Debt, or amend any provision affecting Bank’s rights contained in any documentation relating to the Subordinated Debt, to the extent prohibited by
the applicable subordination agreement, without Bank’s prior written consent. 
 7.11    Inventory and
Equipment. Store the Inventory or the Equipment of a book value in excess of $500,000 with a bailee, warehouseman, collocation facility or similar third party unless the third party has been notified of Bank’s security interest and Borrower
has used commercially reasonable efforts to (a) receive and deliver to Bank an acknowledgment from the third party that it is holding or will hold the Inventory or Equipment for Bank’s benefit or (b) is in possession of Bank the
warehouse receipt, where negotiable, covering such Inventory or Equipment. Except for Inventory sold in the ordinary course of business and for movable items of personal property having an aggregate book value not in excess of $500,000, and except
for such 

  
 13 

 
other locations as Bank may approve in writing, Borrower shall keep the Inventory and Equipment only at the location set forth in Section 10 and such other locations of which Borrower gives
Bank prior written notice and as to which Bank is able to take such actions as may be necessary to perfect its security interest or as to which Borrower uses commercially reasonable efforts to obtain a bailee’s acknowledgment of Bank’s
rights in the Collateral. 
 7.12    No Investment Company; Margin Regulation. Become or be controlled by
an “investment company,” within the meaning of the Investment Company Act of 1940, or become principally engaged in, or undertake as one of its important activities, the business of extending credit for the purpose of purchasing or
carrying margin stock, or use the proceeds of any Credit Extension for such purpose. 
  

	8.	 EVENTS OF DEFAULT. 

Any one or more of the following events shall constitute an Event of Default by Borrower under this Agreement: 

8.1    Payment Default. If Borrower fails to pay any of the Obligations when due; 

8.2    Covenant Default. 

(a)    If Borrower fails to perform any obligation under Sections 6.2 (financial reporting), 6.4 (taxes), 6.5
(insurance), or 6.6 (primary accounts), or violates any of the covenants contained in Article 7 of this Agreement; or 

(b)    If Borrower fails or neglects to perform or observe any other material term, provision, condition, covenant
contained in this Agreement, in any of the Loan Documents, or in any other present or future agreement between Borrower and Bank and as to any default under such other term, provision, condition or covenant that can be cured, has failed to cure such
default within 15 days after Borrower receives notice thereof or any officer of Borrower becomes aware thereof; provided, however, that if the default cannot by its nature be cured within the 15-day
period or cannot after diligent attempts by Borrower be cured within such 15-day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional reasonable
period (which shall not in any case exceed 30 days) to attempt to cure such default, and within such reasonable time period the failure to have cured such default shall not be deemed an Event of Default but no Credit Extensions will be made;

 8.3    Material Adverse Change. If there occurs any circumstance or any circumstances which would
reasonably be expected to have a Material Adverse Effect; 
 8.4    Attachment. If any material portion of
Borrower’s assets is attached, seized, subjected to a writ or distress warrant, or is levied upon, or comes into the possession of any trustee, receiver or person acting in a similar capacity and such attachment, seizure, writ or distress
warrant or levy has not been removed, discharged or rescinded within 10 days, or if Borrower is enjoined, restrained, or in any way prevented by court order from continuing to conduct all or any material part of its business affairs, or if a
judgment or other claim becomes a lien or encumbrance upon any material portion of Borrower’s assets, or if a notice of lien, levy, or assessment is filed of record with respect to any material portion of Borrower’s assets by the United
States Government, 

  
 14 

 
or any department, agency, or instrumentality thereof, or by any state, county, municipal, or governmental agency, and the same is not paid within ten days after Borrower receives notice
thereof, provided that none of the foregoing shall constitute an Event of Default where such action or event is stayed or an adequate bond has been posted pending a good faith contest by Borrower; 

8.5    Insolvency. If Borrower becomes insolvent, or if an Insolvency Proceeding is commenced by Borrower,
or if an Insolvency Proceeding is commenced against Borrower and is not dismissed or stayed within 45 days; 

8.6    Other Agreements. If (a) there is an uncured default or other uncured failure to perform in any
agreement to which Borrower is a party with a third party or parties (i) resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of $250,000,
(ii) in connection with any lease of real property, or (iii) that would reasonably be expected to have a Material Adverse Effect or (b) any default or event of default (however designated) shall occur with respect to any Subordinated
Debt which is not cured within any applicable cure period; 
 8.7    Judgments. If a final, uninsured
judgment or judgments for the payment of money in an amount, individually or in the aggregate, of at least $250,000 shall be rendered against Borrower and shall remain unsatisfied and unstayed for a period of 10 days; or 

8.8    Misrepresentations. If any material misrepresentation or material misstatement exists now or
hereafter in any warranty or representation set forth herein or in any certificate delivered to Bank by any Responsible Officer pursuant to this Agreement or to induce Bank to enter into this Agreement or any other Loan Document. 

 

	9.	 BANK’S RIGHTS AND REMEDIES. 

9.1    Rights and Remedies. Upon the occurrence and during the continuance of an Event of Default, Bank may,
at its election, without notice of its election and without demand, do any one or more of the following, all of which are authorized by Borrower: 

(a)    Declare all Obligations, whether evidenced by this Agreement, by any of the other Loan Documents, or
otherwise, immediately due and payable (provided that upon the occurrence of an Event of Default described in Section 8.5 (insolvency), all Obligations shall become immediately due and payable without any action by Bank); 

(b)    Demand that Borrower (i) deposit cash with Bank in an amount equal to the amount of any Letters of
Credit remaining undrawn, as collateral security for the repayment of any future drawings under such Letters of Credit, and (ii) pay in advance all Letter of Credit fees scheduled to be paid or payable over the remaining term of the Letters of
Credit, and Borrower shall promptly deposit and pay such amounts; 
 (c)    Cease advancing money or extending
credit to or for the benefit of Borrower under this Agreement or under any other agreement between Borrower and Bank; 

(d)    Settle or adjust disputes and claims directly with account debtors for amounts, upon terms and in whatever
order that Bank reasonably considers advisable; 

  
 15 

 (e)    Make such payments and do such acts as Bank considers
necessary or reasonable to protect its security interest in the Collateral. Borrower agrees to assemble the Collateral if Bank so requires, and to make the Collateral available to Bank as Bank may designate. Borrower authorizes Bank to enter the
premises where the Collateral is located, to take and maintain possession of the Collateral, or any part of it, and to pay, purchase, contest, or compromise any encumbrance, charge, or lien which in Bank’s determination appears to be prior or
superior to its security interest and to pay all expenses incurred in connection therewith. With respect to any of Borrower’s owned premises, Borrower hereby grants Bank a license to enter into possession of such premises and to occupy the
same, without charge, in order to exercise any of Bank’s rights or remedies provided herein, at law, in equity, or otherwise; 

(f)    place a “hold” on any account maintained with Bank and/or deliver a notice of exclusive control,
any entitlement order, or other directions or instructions pursuant to any control agreement or similar agreements providing control of any Collateral; 

(g)    Set off and apply to the Obligations any and all (i) balances and deposits of Borrower held by Bank,
and (ii) indebtedness at any time owing to or for the credit or the account of Borrower held by Bank; 

(h)    Ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell (in
the manner provided for herein) the Collateral. Bank is hereby granted a license or other right, solely pursuant to the provisions of this Section 9.1, to use, without charge, Borrower’s labels, patents, copyrights, rights of use of any
name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any property of a similar nature, as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in
connection with Bank’s exercise of its rights under this Section 9.1, Borrower’s rights under all licenses and all franchise agreements shall inure to Bank’s benefit; 

(i)    Sell the Collateral at either a public or private sale, or both, by way of one or more contracts or
transactions, for cash or on terms, in such manner and at such places (including Borrower’s premises) as Bank determines is commercially reasonable, and apply any proceeds to the Obligations in whatever manner or order Bank deems appropriate.
Bank may sell the Collateral without giving any warranties as to the Collateral. Bank may specifically disclaim any warranties of title or the like. This procedure will not be considered adversely to affect the commercial reasonableness of any sale
of the Collateral. If Bank sells any of the Collateral upon credit, Borrower will be credited only with payments actually made by the purchaser, received by Bank, and applied to the indebtedness of the purchaser. If the purchaser fails to pay for
the Collateral, Bank may resell the Collateral and Borrower shall be credited with the proceeds of the sale; 

(j)    Bank may credit bid and purchase at any public sale; 

(k)    Apply for the appointment of a receiver, trustee, liquidator or conservator of the Collateral, without
notice and without regard to the adequacy of the security for the Obligations and without regard to the solvency of Borrower, any guarantor or any other Person liable for any of the Obligations; and 

  
 16 

 (l)    Any deficiency that exists after disposition of the
Collateral as provided above will be paid immediately by Borrower. 
 Bank may comply with any applicable state or federal law requirements in connection
with a disposition of the Collateral and compliance will not be considered adversely to affect the commercial reasonableness of any sale of the Collateral. 

9.2    Power of Attorney. Effective only upon the occurrence and during the continuance of an Event of
Default, Borrower hereby irrevocably appoints Bank (and any of Bank’s designated officers, or employees) as Borrower’s true and lawful attorney to: (a) send requests for verification of Accounts or notify account debtors of
Bank’s security interest in the Accounts; (b) endorse Borrower’s name on any checks or other forms of payment or security that may come into Bank’s possession; (c) sign Borrower’s name on any invoice or bill of lading
relating to any Account, drafts against account debtors, schedules and assignments of Accounts, verifications of Accounts, and notices to account debtors; (d) dispose of any Collateral; (e) make, settle, and adjust all claims under and
decisions with respect to Borrower’s policies of insurance; (f) settle and adjust disputes and claims respecting the accounts directly with account debtors, for amounts and upon terms which Bank determines to be reasonable; and
(g) file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral; provided Bank may exercise such power of attorney to sign the name of Borrower on any of the documents
described in clause (g) above, regardless of whether an Event of Default has occurred. The appointment of Bank as Borrower’s attorney in fact, and each and every one of Bank’s rights and powers, being coupled with an interest, is
irrevocable until all of the Obligations (other than inchoate indemnity obligations) have been fully repaid and performed and Bank’s obligation to provide advances hereunder is terminated. 

9.3    Accounts Collection. At any time after the occurrence and during the continuation of an Event of
Default, Bank may notify any Person owing funds to Borrower of Bank’s security interest in such funds and verify the amount of such Account. Borrower shall collect all amounts owing to Borrower for Bank, receive in trust all payments as
Bank’s trustee, and immediately deliver such payments to Bank in their original form as received from the account debtor, with proper endorsements for deposit. 

9.4    Bank Expenses. If Borrower fails to pay any amounts or furnish any required proof of payment due to
third persons or entities, as required under the terms of this Agreement, then Bank may do any or all of the following after reasonable notice to Borrower: (a) make payment of the same or any part thereof; and/or (b) obtain and maintain
insurance policies of the type discussed in Section 6.5 of this Agreement, and take any action with respect to such policies as Bank deems prudent. Any amounts so paid or deposited by Bank shall constitute Bank Expenses, shall be immediately
due and payable, and shall bear interest at the then applicable rate hereinabove provided, and shall be secured by the Collateral. Any payments made by Bank shall not constitute an agreement by Bank to make similar payments in the future or a waiver
by Bank of any Event of Default under this Agreement. 
 9.5    Bank’s Liability for Collateral. Bank
has no obligation to clean up or otherwise prepare the Collateral for sale. All risk of loss, damage or destruction of the Collateral shall be borne by Borrower. 

  
 17 

 9.6    No Obligation to Pursue Others. Bank has no
obligation to attempt to satisfy the Obligations by collecting them from any other person liable for them and Bank may release, modify or waive any collateral provided by any other Person to secure any of the Obligations, all without affecting
Bank’s rights against Borrower. Borrower waives any right it may have to require Bank to pursue any other Person for any of the Obligations. 

9.7    Remedies Cumulative. Bank’s rights and remedies under this Agreement, the Loan Documents, and
all other agreements shall be cumulative. Bank shall have all other rights and remedies not inconsistent herewith as provided under the Code, by law, or in equity. No exercise by Bank of one right or remedy shall be deemed an election, and no waiver
by Bank of any Event of Default on Borrower’s part shall be deemed a continuing waiver. No delay by Bank shall constitute a waiver, election, or acquiescence by it. No waiver by Bank shall be effective unless made in a written document signed
on behalf of Bank and then shall be effective only in the specific instance and for the specific purpose for which it was given. Borrower expressly agrees that this Section 9.7 may not be waived or modified by Bank by course of performance,
conduct, estoppel or otherwise. 
 9.8    Demand; Protest. Except as otherwise provided in this Agreement,
Borrower waives demand, protest, notice of protest, notice of default or dishonor, notice of payment and nonpayment and any other notices relating to the Obligations. 
  

	10.	 NOTICES. 

Unless otherwise provided in this Agreement, all notices or demands by any party relating to this Agreement or any other agreement entered into
in connection herewith shall be in writing and (except for financial statements and other reporting required pursuant to Section 6.2 of this Agreement, which shall be sent as directed in the monthly reporting forms provided by Bank) shall be
personally delivered or sent by a recognized overnight delivery service, certified mail, postage prepaid, return receipt requested, or by telefacsimile or electronic mail to Borrower or to Bank, as the case may be, at its addresses set forth below:

  

			
	If to Borrower:	  	 OMEGA THERAPEUTICS, INC.
 55 Cambridge
Parkway, Suite 800E
 Cambridge, MA 02142
 Attn:
President

		
	with a copy (which shall not constitute notice) to:	  	 LATHAM & WATKINS LLP
 505 Montgomery
Street, Suite 2000
 San Francisco, CA 94111
 Attention:
[XXX]
 Facsimile: (415) 395-8095

Email: [XXX]@lw.com

  
 18 

			
	If to Bank:	  	 Pacific Western Bank
 406 Blackwell Street,
Suite 240
 Durham, North Carolina 27701
 Attn: Loan Operations
Manager
 FAX: (919) 314-3080

E-Mail: loannotices@square1bank.com

		
	with a copy to:	  	 Pacific Western Bank
 131 Oliver Street,
Suite 250
 Boston, MA 02110
 Attn: [XXX]

Email: [XXX]@square1bank.com

 The parties hereto may change the address at which they are to receive notices hereunder, by notice in writing
in the foregoing manner given to the other. 
  

	11.	 CHOICE OF LAW AND VENUE; JURY TRIAL AND WAIVER. 

This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of North Carolina, without regard to principles of
conflicts of law. Jurisdiction shall lie in the State of North Carolina. All disputes, controversies, claims, actions and similar proceedings arising with respect to Borrower’s account or any related agreement or transaction shall be brought in
the General Court of Justice of North Carolina sitting in Durham County, North Carolina or the United States District Court for the Middle District of North Carolina, except as provided below with respect to arbitration of such matters. BANK AND
BORROWER EACH ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED. EACH OF THEM, AFTER CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT, WITH COUNSEL OF THEIR CHOICE, KNOWINGLY, VOLUNTARILY AND
INTENTIONALLY WAIVES ANY RIGHT ANY OF THEM MAY HAVE TO A TRIAL BY JURY IN ANY LITIGATION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY RELATED INSTRUMENT OR LOAN DOCUMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT OR ANY COURSE
OF CONDUCT, DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN), OR ACTION OF ANY OF THEM. THESE PROVISIONS SHALL NOT BE DEEMED TO HAVE BEEN MODIFIED IN ANY RESPECT OR RELINQUISHED BY BANK OR BORROWER, EXCEPT BY A WRITTEN INSTRUMENT EXECUTED BY EACH OF
THEM. If the jury waiver set forth in this Section 11 is not enforceable, then any dispute, controversy, claim, action or similar proceeding arising out of or relating to this Agreement, the Loan Documents or any of the transactions
contemplated therein shall be settled by final and binding arbitration held in Durham County, North Carolina in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association by one arbitrator appointed in
accordance with those rules. The arbitrator shall apply North Carolina law to the resolution of any dispute, without reference to rules of conflicts of law or rules of statutory arbitration. Judgment upon any award resulting from arbitration may be
entered into and enforced by any state or federal court having jurisdiction thereof. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel arbitration in
accordance with this Section. The costs and expenses of the arbitration, including without limitation, the arbitrator’s 

  
 19 

 
fees and expert witness fees, and reasonable attorneys’ fees, incurred by the parties to the arbitration may be awarded to the prevailing party, in the discretion of the arbitrator, or may
be apportioned between the parties in any manner deemed appropriate by the arbitrator. Unless and until the arbitrator decides that one party is to pay for all (or a share) of such costs and expenses, both parties shall share equally in the payment
of the arbitrator’s fees as and when billed by the arbitrator. 
  

	12.	 GENERAL PROVISIONS. 

12.1    Successors and Assigns. This Agreement shall bind and inure to the benefit of the respective
successors and permitted assigns of each of the parties and shall bind all persons who become bound as a debtor to this Agreement; provided, however, that neither this Agreement nor any rights hereunder may be assigned by Borrower without
Bank’s prior written consent, which consent may be granted or withheld in Bank’s sole but reasonable discretion. Bank shall have the right without the consent of or notice to Borrower to sell, assign, transfer, negotiate, or grant
participation in all or any part of, or any interest in, Bank’s obligations, rights and benefits hereunder. Notwithstanding the foregoing, so long as no Event of Default has occurred and is continuing, Bank shall not assign its interest herein
or the Loan Documents to any Person who is (i) a direct competitor of Borrower, whether as an operating company or direct or indirect parent with voting control over such operating company, or (ii) a vulture or distressed debt fund. 

12.2    Indemnification. Borrower shall defend, indemnify and hold harmless Bank and its officers,
employees, and agents against: (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this Agreement; and (b) all losses or Bank Expenses in any way
suffered, incurred, or paid by Bank, its officers, employees and agents as a result of or in any way arising out of, following, or consequential to transactions between Bank and Borrower whether under this Agreement, or otherwise (including without
limitation reasonable attorneys’ fees and expenses), except for losses caused by Bank’s gross negligence or willful misconduct. 

12.3    Time of Essence. Time is of the essence for the performance of all obligations set forth in this
Agreement. 
 12.4    Severability of Provisions. Each provision of this Agreement shall be severable from
every other provision of this Agreement for the purpose of determining the legal enforceability of any specific provision. 

12.5    Amendments in Writing, Integration. All amendments to or terminations of this Agreement or
the other Loan Documents must be in writing. All prior agreements, understandings, representations, warranties, and negotiations between the parties hereto with respect to the subject matter of this Agreement and the other Loan Documents, if any,
are merged into this Agreement and the Loan Documents. 
 12.6    Counterparts. This Agreement may be
executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same
Agreement. Executed copies of the signature pages of this Agreement sent by 

  
 20 

 
facsimile or transmitted electronically in Portable Document Format (“PDF”), or any similar format, shall be treated as originals, fully binding and with full legal force and effect,
and the parties waive any rights they may have to object to such treatment. 
 12.7    Survival. All
covenants, representations and warranties made in this Agreement shall continue in full force and effect so long as any Obligations remain outstanding or Bank has any obligation to make any Credit Extension to Borrower. The obligations of Borrower
to indemnify Bank with respect to the expenses, damages, losses, costs and liabilities described in Section 12.2 shall survive until all applicable statute of limitations periods with respect to actions that may be brought against Bank have
run. 
 12.8    Confidentiality. In handling any confidential information, Bank and Borrower and all
employees and agents of such party shall exercise the same degree of care that such party exercises with respect to its own proprietary information of the same types to maintain the confidentiality of any
non-public information thereby received or received pursuant to this Agreement except that disclosure of such information may be made (i) in the case of Bank, to the subsidiaries or Affiliates of Bank or
Borrower in connection with their present or prospective business relations with Borrower, (ii) in the case of Bank, to prospective transferees or purchasers of any interest in the Credit Extensions, provided that they have entered into a
comparable confidentiality agreement in favor of Borrower and have delivered a copy to Borrower, (iii) as required by law, regulations, rule or order, subpoena, judicial order or similar order, (iv) in the case of Bank, as may be required
in connection with the examination, audit or similar investigation of Bank and (v) as Bank may determine in connection with the enforcement of any remedies hereunder. Confidential information hereunder shall not include information that either:
(a) is in the public domain or in the knowledge or possession of the receiving party when disclosed to such party, or becomes part of the public domain after disclosure to such receiving party through no fault of such receiving party; or
(b) is disclosed to the receiving party by a third party, provided such receiving party does not have actual knowledge that such third party is prohibited from disclosing such information. 

  
 21 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first above
written. 
  

			
	OMEGA THERAPEUTICS, INC.
		
	By	 	 /s/ David Berry

	Name:	 	 David Berry

	Title:	 	 President

	
	PACIFIC WESTERN BANK
		
	By:	 	 /s/ Scott Hansen

	Name:	 	 Scott Hansen

	Title:	 	 Senior Vice President

 EXHIBIT A 

DEFINITIONS 
 “Accounts” means all presently
existing and hereafter arising accounts, contract rights, payment intangibles and all other forms of obligations owing to Borrower arising out of the sale or lease of goods (including, without limitation, the licensing of software and other
technology) or the rendering of services by Borrower and any and all credit insurance, guaranties, and other security therefore, as well as all merchandise returned to or reclaimed by Borrower and Borrower’s Books relating to any of the
foregoing. 
 “Affiliate” means, with respect to any Person, any Person that owns or controls directly or indirectly such Person, any Person that
controls or is controlled by or is under common control with such Person, and each of such Person’s senior executive officers, directors, and general partners. 

“Authorized Officer” means someone designated as such in the corporate resolution provided by Borrower to Bank in which this Agreement and the
transactions contemplated hereunder are authorized by Borrower’s board of directors. If Borrower provides subsequent corporate resolutions to Bank after the Closing Date, the individual(s) designated as “Authorized Officer(s)” in the
most recently provided resolution shall be the only “Authorized Officers” for purposes of this Agreement. 
 “Bank Expenses” means all
reasonable costs or expenses (including reasonable attorneys’ fees and expenses, whether generated by in-house or by outside counsel) incurred in connection with the preparation, negotiation,
administration, and enforcement of the Loan Documents; reasonable Collateral audit fees; and Bank’s reasonable attorneys’ fees and expenses (whether generated in-house or by outside counsel) incurred
in amending, enforcing or defending the Loan Documents (including fees and expenses of appeal), incurred before, during and after an Insolvency Proceeding, whether or not suit is brought. 

“Borrower’s Books” means all of Borrower’s books and records including: ledgers; records concerning Borrower’s assets or liabilities,
the Collateral, business operations or financial condition; and all computer programs, or tape files, and the equipment, containing such information. 

“Business Day” means any day that is not a Saturday, Sunday, or other day on which banks in the State of North Carolina or Massachusetts are
authorized or required to close. 
 “Capitalized Expenditures” means current period unfinanced cash expenditures that are capitalized and
amortized over a period of time in accordance with GAAP, including but not limited to capitalized cash expenditures for capital equipment, capitalized manufacturing and labor costs as they relate to inventory, and capitalized cash expenditures for
software development. 
 “Cash” means cash and cash equivalents. 

“Change in Control” shall mean a transaction other than an initial public offering or a bona fide equity financing or series of financings on terms
reasonably acceptable to Bank in which any 

 
“person” or “group” (within the meaning of Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934) becomes the “beneficial owner” (as defined in Rule
13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of Borrower ordinarily entitled to vote in the election of
directors, empowering such “person” or “group” to elect a majority of the Board of Directors of Borrower, who did not have such power before such transaction. 

“Closing Date” means the date of this Agreement. 

“Code” means the North Carolina Uniform Commercial Code as amended or supplemented from time to time. 

“Collateral” means the property described on Exhibit B attached hereto, except to the extent any such property (i) is nonassignable by its
terms without the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, Sections §25-9-406 and §25-9-408 of the Code), (ii) the granting of a security interest therein is contrary to applicable
law, provided that upon the cessation of any such restriction or prohibition, such property shall automatically become part of the Collateral, (iii) constitutes the capital stock of a controlled foreign corporation (as defined in the IRC), in
excess of 65% of the voting power of all classes of capital stock of such controlled foreign corporations entitled to vote, or (iv) property (including any attachments, accessions or replacements) that is subject to a Lien that is permitted
pursuant to clause (c) of the definition of Permitted Liens, if the grant of a security interest with respect to such property pursuant to this Agreement would be prohibited by the agreement creating such Permitted Lien or would otherwise
constitute a default thereunder, provided, that such property will be deemed “Collateral” hereunder upon the termination and release of such Permitted Lien. 

“Compliance Certificate” means a compliance certificate, in substantially the form of Exhibit E attached hereto, executed by a Responsible
Officer of the Borrower. 
 “Contingent Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of
that Person with respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including, without limitation, any such obligation directly or indirectly guaranteed, endorsed,
co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit,
corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or
other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for
collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is
made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the
obligations under the guarantee or other support arrangement. 

 “Copyrights” means any and all copyright rights, copyright applications, copyright registrations
and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held. 

“Credit Card Line” means a Credit Extension of up to $100,000, to be used exclusively for the provision of Credit Card Services. 

“Credit Card Maturity Date” means March 8, 2019. 

“Credit Extension” means the Term Loan and any other extension of credit by Bank to or for the benefit of Borrower hereunder. 

“Environmental Laws” means all laws, rules, regulations, orders and the like issued by any federal state, local foreign or other governmental or
quasi-governmental authority or any agency pertaining to the environment or to any hazardous materials or wastes, toxic substances, flammable, explosive or radioactive materials, asbestos or other similar materials. 

“Equipment” means all present and future machinery, equipment, tenant improvements, furniture, fixtures, vehicles, tools, parts and attachments in
which Borrower has any interest. 
 “ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations thereunder.

 “Event of Default” has the meaning assigned in Article 8. 

“Flagship License Agreement” means that certain License Agreement, expected to be effective after the Closing Date, by and between Borrower and
certain investors that will be party thereto, as amended. 
 “GAAP” means generally accepted accounting principles, consistently applied, as in
effect from time to time in the United States. 
 “Indebtedness” means (a) all indebtedness for borrowed money or the deferred purchase price
of property or services, including without limitation reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital
lease obligations, and (d) all Contingent Obligations, including but not limited to any sublimit contained herein. 
 “Insolvency Proceeding”
means any proceeding commenced by or against any Person or entity under any provision of the United States Bankruptcy Code, as amended, or under any other bankruptcy or insolvency law, including assignments for the benefit of creditors, formal or
informal moratoria, compositions, extension generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 

“Intellectual Property” means all of Borrower’s right, title, and interest in and to any Copyrights, Trademarks and Patents. 

 “Inventory” means all present and future inventory in which Borrower has any interest. 

“Investment” means any beneficial ownership of (including stock, partnership or limited liability company interest or other securities) any Person,
or any loan, advance or capital contribution to any Person. 
 “Investment Agreement” means, collectively, Borrower’s stock purchase and
other agreement(s) pursuant to which Borrower most recently issued its preferred stock. 
 “IRC” means the Internal Revenue Code of 1986, as
amended, and the regulations thereunder. 
 “Lien” means any mortgage, lien, deed of trust, charge, pledge, security interest or other
encumbrance. 
 “Loan Documents” means, collectively, this Agreement, any note or notes executed by Borrower, and any other document, instrument
or agreement entered into in connection with this Agreement, all as amended or extended from time to time. 
 “Material Adverse Effect” means a
material adverse effect on (i) the operations, business or financial condition of Borrower and its Subsidiaries taken as a whole, (ii) the ability of Borrower to repay the Obligations or otherwise perform its obligations under the Loan
Documents, or (iii) Borrower’s interest in, or the value, perfection or priority of Bank’s security interest in the Collateral. 

“Maturity Date” means March 9, 2022. 

“MSC Subsidiary” means a Subsidiary of Borrower classified as a security corporation by the Massachusetts Department of Revenue. 

“Negotiable Collateral” means all of Borrower’s present and future letters of credit of which it is a beneficiary, drafts, instruments
(including promissory notes), securities, documents of title, and chattel paper, and Borrower’s Books relating to any of the foregoing. 

“Obligations” means all debt, principal, interest, Bank Expenses and other amounts owed to Bank by Borrower pursuant to this Agreement or any other
agreement, whether absolute or contingent, due or to become due, now existing or hereafter arising, including any interest that accrues after the commencement of an Insolvency Proceeding and including any debt, liability, or obligation owing from
Borrower to others that Bank may have obtained by assignment or otherwise. Notwithstanding the foregoing, “Obligations” shall not include any warrant or equity-related investments. 

“Patents” means all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals,
reissues, extensions and continuations-in-part of the same. 

“Periodic Payments” means all installments or similar recurring payments that Borrower may now or hereafter become obligated to pay to Bank pursuant
to the terms and provisions of any instrument, or agreement now or hereafter in existence between Borrower and Bank. 

 “Permitted Indebtedness” means: 

(a)    Indebtedness of Borrower in favor of Bank arising under this Agreement or any other Loan Document; 

(b)    Indebtedness existing on the Closing Date and disclosed in the Schedule; 

(c)    Indebtedness not to exceed $250,000 in the aggregate at any time secured by a lien described in
clause (c) of the defined term “Permitted Liens,” provided such Indebtedness does not exceed at the time it is incurred the lesser of the cost or fair market value of the property financed with such Indebtedness; 

(d)    Subordinated Debt; 

(e)    Indebtedness to trade creditors incurred in the ordinary course of business; 

(f)    Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of
business; 
 (g)    on or before the date 45 days following the Closing Date, Indebtedness of Borrower with
respect to corporate credit cards with financial institutions other than Bank in an aggregate amount outstanding not to exceed $10,000 at any time; 

(h)    letters of credit in the ordinary course of business in connection with the leasing of real property; 

(i)    additional unsecured Indebtedness not to exceed $250,000 in the aggregate at any time; and 

(j)    Extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal
amount is not increased or the terms modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be. 
 “Permitted
Investment” means: 
 (a)    Investments existing on the Closing Date disclosed in the Schedule; 

(b)    (i) Marketable direct obligations issued or unconditionally guaranteed by the United States of America
or any agency or any State thereof maturing within one year from the date of acquisition thereof, (ii) commercial paper maturing no more than one year from the date of creation thereof and currently having rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s Investors Service, (iii) Bank’s certificates of deposit maturing no more than one
year from the date of investment therein, and (iv) Bank’s money market accounts; (v) Investments in regular deposit or checking accounts held with Bank or as otherwise permitted by, and subject to the terms and conditions of,
Section 6.6 of this Agreement; and (vi) Investments consistent with any investment policy adopted by the Borrower’s board of directors; 

(c)    Investments accepted in connection with Permitted Transfers; 

 (d)    Investments in the MSC Subsidiary, to the extent permitted
under Section 6.6; 
 (e)    Investments of Subsidiaries in or to other Subsidiaries or Borrower and
Investments by Borrower in Subsidiaries not to exceed $250,000 in the aggregate in any fiscal year; 

(f)    Investments not to exceed $250,000 outstanding in the aggregate at any time consisting of (i) travel
advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries
pursuant to employee stock purchase plan agreements approved by Borrower’s Board of Directors; 

(g)    Investments (including debt obligations) received in connection with the bankruptcy or reorganization of
customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; 

(h)    Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to
customers and suppliers who are not Affiliates, in the ordinary course of business, provided that this subparagraph (g) shall not apply to Investments of Borrower in any Subsidiary; 

(i)    Joint ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the non-exclusive licensing of technology, the development of technology or the providing of technical support, provided that any cash Investments by Borrower do not exceed $250,000 in the aggregate in any fiscal year;

 (j)    Permitted Licenses; and 

(k)    Investments permitted under Section 7.3. 

“Permitted Licenses” are (A) licenses of over-the-counter
software that are commercially available to the public, (B) non-exclusive licenses for the use of the Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary course of
business and (C) exclusive licenses for the use of the Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary course of business, provided, that, with respect to each such license described in this
clause (C), (i) any such license could not result in a legal transfer of title of the licensed property but may be exclusive in respects other than territory and may be exclusive as to territory only as to discrete geographical areas
outside of the United States; and (ii) all upfront payments, royalties, milestone payments or other proceeds arising from the licensing agreement that are payable to Borrower or any of its Subsidiaries are paid to a deposit account at Bank,
(D) the Flagship License Agreement and sublicenses permitted under the Flagship License Agreement, and (E) licenses disclosed to Bank on the Closing Date. 

 “Permitted Liens” means the following: 

(a)    Any Liens existing on the Closing Date and disclosed in the Schedule (excluding Liens to be satisfied with
the proceeds of the Credit Extensions) or arising under this Agreement, the other Loan Documents, or any other agreement in favor of Bank; 

(b)    Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being
contested in good faith by appropriate proceedings and for which Borrower maintains adequate reserves; 

(c)    Liens not to exceed $250,000 in the aggregate at any time (i) upon or in any Equipment acquired or held
by Borrower or any of its Subsidiaries to secure the purchase price of such Equipment or indebtedness incurred solely for the purpose of financing the acquisition or lease of such Equipment, or (ii) existing on such Equipment at the time of its
acquisition, in each case provided that the Lien is confined solely to the property so acquired and improvements thereon, and the proceeds of such Equipment; 

(d)    statutory Liens securing claims or demands of materialmen, mechanics, carriers, repairmen, or other like
Liens imposed without the action of such parties arising in the ordinary course of business; 
 (e)    Liens to
secure payment for workers’ compensation, employment insurance, old age pensions, social security or other like obligations incurred in the ordinary course of business; 

(f)    Permitted Licenses; 

(g)    Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens
of the type described in clauses (a) through (f) above, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness being extended,
renewed or refinanced does not increase; 
 (h)    Liens arising from judgments, decrees or attachments in
circumstances not constituting an Event of Default under Sections 8.4 (attachment) or 8.8 (judgments); and 

(i)    Liens securing Subordinated Debt. 

“Permitted Transfer” means the conveyance, sale, lease, transfer or disposition by Borrower or any Subsidiary of: 

(a)    Inventory in the ordinary course of business; 

(b)    licenses and similar arrangements for the use of the property of Borrower or its Subsidiaries in the
ordinary course of business and Permitted Licenses; 
 (c)    worn-out,
surplus or obsolete Equipment; 

 (d)    grants of security interests and other Liens that
constitute Permitted Liens; and 
 (e)    transfers that constitute Permitted Investments; 

(f)    Cash in the ordinary course of business unless otherwise prohibited by the terms of this Agreement; and 

(g)    other assets of Borrower or its Subsidiaries that do not in the aggregate exceed $250,000 during any fiscal
year. 
 “Person” means any individual, sole proprietorship, partnership, limited liability company, joint venture, trust, unincorporated
organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or governmental agency. 

“Prime Rate” means the variable rate of interest, per annum, most recently announced by Bank, as its “prime rate,” whether or not such
announced rate is the lowest rate available from Bank. 
 “Responsible Officer” means each of the Chief Executive Officer, the Chief Operating
Officer, the Chief Financial Officer, Vice President of Finance and the Controller of Borrower, as well as any other officer or employee identified as an Authorized Officer in the corporate resolution delivered by Borrower to Bank in connection with
this Agreement. 
 “Schedule” means the schedule of exceptions attached hereto and approved by Bank, if any. 

“Shares” means (i) sixty-five percent (65%) of the issued and outstanding capital stock, membership units or other securities owned or held of
record by Borrower in any Subsidiary of Borrower which is not an entity organized under the laws of the United States or territory thereof, and (ii) one hundred percent (100%) of the issued and outstanding capital stock, membership units or
other securities owned or held of record by Borrower in any Subsidiary of Borrower which is an entity organized under the laws of the United States or any territory thereof. 

“SOS Reports” means the official reports from the Secretaries of the state where Borrower’s chief executive office is located, the state of
Borrower’s formation and other applicable federal, state or local government offices identifying all current security interests filed in the Collateral and Liens of record as of the date of such report. 

“Subordinated Debt” means any debt incurred by Borrower that is subordinated in writing to the debt owing by Borrower to Bank on terms reasonably
acceptable to Bank (and identified as being such by Borrower and Bank). 
 “Subsidiary” means any corporation, partnership or limited liability
company or joint venture in which (i) any general partnership interest or (ii) more than 50% of the stock, limited liability company interest or joint venture of which by the terms thereof ordinary voting power to elect the Board of
Directors, managers or trustees of the entity, at the time as of which any determination is being made, is owned by Borrower, either directly or through an Affiliate. 

“Term Loan” is the term loan made under Section 2.1(b), consisting of Tranche I and Tranche II. 

 “Trademarks” means any trademark and servicemark rights, whether registered or not, applications
to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks. 

“Tranche I” means Three Million Five Hundred Thousand Dollars ($3,500,000) of the Term Loan. 

“Tranche II” means Four Million Five Hundred Thousand Dollars ($4,500,000) of the Term Loan. 

DEBTOR                       OMEGA
THERAPEUTICS, INC. 
 SECURED PARTY:     PACIFIC WESTERN BANK 

EXHIBIT B 
 COLLATERAL
DESCRIPTION ATTACHMENT TO LOAN AND SECURITY AGREEMENT 
 All personal property of Borrower (herein referred to as “Borrower” or
“Debtor”) whether presently existing or hereafter created or acquired, and wherever located, including, but not limited to: 

(a)    all accounts (including health-care-insurance receivables), chattel paper (including tangible and electronic
chattel paper), deposit accounts, documents (including negotiable documents), equipment (including all accessions and additions thereto), financial assets, general intangibles (excluding patents, trademarks, copyrights, goodwill, payment
intangibles, domain names, software and other Intellectual Property), goods (including fixtures), instruments (including promissory notes), inventory (including all goods held for sale or lease or to be furnished under a contract of service, and
including returns and repossessions), investment property (including securities and securities entitlements), letter of credit rights, money, and all of Debtor’s books and records with respect to any of the foregoing, and the computers and
equipment containing said books and records; 
 (b)    any and all cash proceeds and/or noncash proceeds of any
of the foregoing, including, without limitation, insurance proceeds, and all supporting obligations and the security therefor or for any right to payment. All terms above have the meanings given to them in the North Carolina Uniform Commercial Code,
as amended or supplemented from time to time, including revised Division 9 of the Uniform Commercial Code- Secured Transactions. 

Notwithstanding the foregoing, the Collateral shall not include (i) property nonassignable by its terms without the consent of the
licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, §25-9-406
and §25-9-408 of the Uniform Commercial Code), (ii) property the granting of a security interest therein is contrary to applicable law, provided that upon the
cessation of any such restriction or prohibition, such property shall automatically become part of the Collateral, (iii) more than 65% of the stock, units or other evidence of ownership held by Borrower or its Subsidiaries of any Subsidiary
which is not organized under the laws of the United States, (iv) property (including any attachments, accessions or replacements) that is subject to an Equipment lien, if the grant of a security interest with respect to such property would be
prohibited by the agreement creating such lien or would otherwise constitute a default thereunder and (v) any intellectual property, in any medium, of any kind or nature whatsoever, now or hereafter owned or acquired or received by Borrower, or
in which Borrower now holds or hereafter acquires or receives any right or interest (collectively, the “Intellectual Property”); provided, however, that the Collateral shall include all accounts and general intangibles (including patents,
trademarks, copyrights, goodwill, payment intangibles, domain names and software) that consist of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the foregoing (the “Rights to
Payment”). 

 Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court)
holds that a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of March 9, 2018, include the Intellectual
Property to the extent and only to the extent necessary to permit perfection of Bank’s security interest in the Rights to Payment, and further provided, however, that Bank’s enforcement rights with respect to any security interest in the
Intellectual Property shall be absolutely limited to the Rights to Payment only, and Bank shall have no recourse whatsoever with respect to the underlying Intellectual Property. 

 EXHIBIT C 

LOAN ADVANCE / PAYDOWN REQUEST FORM 

[Please refer to New Borrower Kit] 

 EXHIBIT D 

COMPLIANCE CERTIFICATE 

[Please refer to New Borrower Kit] 

 SCHEDULE OF EXCEPTIONS 

Permitted Indebtedness (Exhibit A) – The following letters of credit: 

 

									
	Issuing Bank	  	Beneficiary	  	 Relationship to

Company
	  	Amount	 
	 Silicon Valley Bank
	  	Surface Oncology	  	Landlord	  	$	85,188.00	 
	 Silicon Valley Bank
	  	BMR-325 Vassar Street
LLC	  	Landlord	  	$	339,570.00	 

 Permitted Investments (Exhibit A) – None. 

Permitted Liens (Exhibit A) – None. 
 Prior
Names (Section 5.5) – VL42, Inc. 
 Litigation (Section 5.6) – None. 

Inbound Licenses (Section 5.12) – Flagship License Agreement 

 CORPORATE RESOLUTION 

The undersigned duly elected and qualified Secretary of OMEGA THERAPEUTICS, Inc. (the “Company”), solely in his or her capacity as an officer of the
company, and not in his or her individual capacity, does hereby certify that the following is a true and correct copy of certain resolutions adopted by the Company’s Board of Directors in accordance with applicable law and the Company’s
bylaws, and that such resolutions are now unmodified and in full force and effect: 
 BE IT RESOLVED, that: 

 

	1)	 Any one (1) of the following, duly elected officers of the Company (each, an “Authorized
Officer”) whose genuine original signature appears next to his or her name is authorized to act for, on behalf of, and in the name of the Company in connection with the resolutions below: 

 

							
	 	 	 Title
	  	 Name
	  	 Authorized Signature

		 		  		  	
		 	  
	  	  
	  	  

		 		  		  	
		 	  
	  	  
	  	  

		 		  		  	
		 	  
	  	  
	  	  

		 		  		  	
		 	  
	  	  
	  	  

  

	2)	 Any Authorized Officer may: 

 

	 	a)	 Borrow money from time to time from Pacific Western Bank (the “Bank”), and may negotiate and procure
loans, letters of credit, foreign exchange contracts and other financial accommodations from Bank, including without limitation, that certain Loan and Security Agreement dated as of March 9, 2018, and also to execute and deliver to Bank one or
more renewals, extensions, or modifications thereof; 

  

	 	b)	 Give security for any liabilities of the Company to Bank by grant, security interest, assignment, lien, deed of
trust or mortgage upon any real or personal property, tangible or intangible of the Company; 

  

	 	c)	 Purchase, sell, exchange, assign, endorse for transfer and/or deliver certificates and/or instruments
representing stocks, bonds, evidences of Indebtedness or other securities owned by the Company, whether or not registered in the name of the Company; 

  

	 	d)	 Discount with the Bank, commercial or other business paper belonging to the Company made or drawn by or upon
third parties, without limit as to amount; 

  

	 	e)	 Authorize and direct the Bank to pay the proceeds of any such loans or discounts as directed by the persons so
authorized to sign; 

	 	f)	 Issue a warrant or warrants to purchase the Company’s capital stock; 

 

	 	g)	 Execute and deliver in form and content as may be required by the Bank any and all notes, evidences of
indebtedness, applications for letters of credit, guaranties, subordination agreements, loan and security agreements, financing statements, assignments, liens, deeds of trust, mortgages, trust receipts and other agreements, instruments or documents
to carry out the purposes of these Resolutions, any or all of which may relate to all or to substantially all of the Company’s property and assets; 

  

	3)	 The Authorized Officers may designate additional or alternate individuals as being authorized to request loan
advances, to do and perform such other acts and things, to pay any and all fees and costs, and to execute and deliver such other documents and agreements as he or she may in his or her discretion deem reasonably necessary or proper in order to carry
into effect the provisions of these Resolutions. 

  

	4)	 Any and all acts authorized pursuant to these resolutions and performed prior to the passage of these
resolutions are hereby ratified and approved, and the authority conferred herein may be exercised singly by any such officer, and these resolutions shall continue in full force and effect until written notice of modification or revocation is
received and accepted by Bank (such notice to have no effect on any action previously taken by the Bank in reliance on these Resolutions). Bank may rely upon any form of notice, which it in good faith believes to be genuine or what it purports to
be. 

  

	5)	 The Resolutions are in full force and effect as of the date of this Certificate and are intended to replace, as
of this date, any Resolutions previously given by the Company to Bank in connection with the matters described herein; these Resolutions and any borrowings or financial accommodations under these Resolutions have been properly noted in the corporate
books and records, and have not been rescinded, revoked or modified; neither the foregoing Resolutions nor any actions to be taken pursuant to them are or will be in contravention of any provision of the articles of incorporation or bylaws of the
Company or of any agreement, indenture or other instrument to which the Company is a party or by which it is bound; and to the extent the articles of incorporation or bylaws of the Company or any agreement, indenture or other instrument to which the
Company is a party or by which it is bound require the vote or consent of shareholders of the Company to authorize any act, matter or thing described in the foregoing Resolutions, such vote or consent has been obtained. 

In Witness Whereof, I have affixed my name as Secretary and have caused the corporate seal (where available) of said Company to be affixed on March 9,
2018. 
  

	
	  
 Secretary*

  

	*	 If the certifying officer is designated as the only signer in these resolutions then another corporate officer
must also sign. 

 USA PATRIOT ACT 

NOTICE 
 OF 

CUSTOMER IDENTIFICATION 

IMPORTANT INFORMATION ABOUT PROCEDURES FOR OPENING A NEW ACCOUNT 

To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to
obtain, verify, and record information that identifies each person who opens an account. 
 WHAT THIS MEANS FOR YOU: when you open an
account, we will ask your name, address, date of birth, and other information that will allow us to identify you. We may also ask to see your driver’s license or other identifying documents. 

	
	 PACIFIC WESTERN BANK

AUTOMATIC DEBIT AUTHORIZATION
 Member
FDIC

  

	
	 To:     PACIFIC WESTERN BANK 

 
 Re:     Loan
#                                         
                   
  

You are hereby authorized and instructed to charge account No.
                     in the name of OMEGA THERAPEUTICS, INC.

 

	
	
for facility fees, principal, interest and other payments due on above referenced loan as set forth below and credit the loan referenced above.

 

                     Debit the
Facility Fee as it becomes due according to the terms of the Loan and Security Agreement and any renewals or amendments thereof.
  

                     Debit each
interest payment as it becomes due according to the terms of the Loan and Security Agreement and any renewals or amendments thereof.
  

                     Debit each
principal payment as it becomes due according to the terms of the Loan and Security Agreement and any renewals or amendments thereof.
  

                     Debit each
payment for Bank Expenses as it becomes due according to the terms of the Loan and Security Agreement and any renewals or amendments thereof.
  

This Authorization is to remain in full force and effect until revoked in writing.

 

  

			
	Borrower Signature	  	Date March 9, 2018
	 	  	 
	 	  	 

 INSURANCE CHECKLIST 

In connection with the closing of your credit facility with Pacific Western Bank (the “Bank”), the following conditions related to insurance must be
satisfied: 
  

	1.	 Insurance Company Requirements. All insurance required pursuant to the loan documents shall be issued by
insurance companies in good standing with a current rating of A- or better by A.M. Best Company and a Financial Size Category of VIII or higher. 

 

	2.	 Property Insurance. 

 

	 	a.	 Pre-Closing: The Borrower must provide an Acord Form 28 showing
evidence of property insurance, naming Pacific Western Bank as a certificate holder. 

  

	 	b.	 Post-Closing: Within thirty days following closing, Borrower must provide Bank with a Lender’s Loss
Payable endorsement showing Pacific Western Bank as a lender’s loss payee. 

  

	3.	 Liability Insurance. 

 

	 	a.	 Pre-Closing: The Borrower must provide an Acord Form 25 showing
Pacific Western Bank as a certificate holder. 

  

	 	b.	 Post-Closing: Within thirty days following closing, Borrower must provide Bank with an endorsement to
Borrower’s liability insurance policy showing Pacific Western Bank as an additional insured. 

  

	4.	 Name and Address. The Bank name and address format on all insurance related documentation should be as
follows: 

 Pacific Western Bank, its successors and assigns, 

406 Blackwell Street, Suite 240, Durham, NC 27701 

Attn: Loan Operations Department 
 Please email
copies of any documentation related to insurance to insurance@square1bank.com, and if you have any questions related to the insurance requirements associated with the closing of your credit facility please contact Lisa Stansell at [XXX] or via email
at [XXX]@square1bank.com. 

 FIRST AMENDMENT TO 

LOAN AND SECURITY AGREEMENT 

This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of September 30, 2019,
by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and OMEGA THERAPEUTICS, INC. (“Borrower”), 

RECITALS 
 Borrower
and Bank are parties to that certain Loan and Security Agreement dated as of March 9, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Agreement”). The parties desire to amend the
Agreement in accordance with the terms of this Amendment. 
 NOW, THEREFORE, the parties agree as follows: 

 

	1)	 Amendments. 

  

	 	a)	 Section 2.1(b)(i) of the Agreement is hereby amended and restated to read as follows:

 (i)    As of the First Amendment Date, Bank has made Term Loans in aggregate
original principal amount of $8,000,000 pursuant to Tranche I and Tranche II. Subject to and upon the terms and conditions of this Agreement, on the First Amendment Date, Borrower shall request, and Bank shall make, an additional Term Loan pursuant
to a new Tranche III to Borrower, in an aggregate principal amount of Twelve Million Dollars ($12,000,000) (“Tranche III”). The proceeds of the Term Loan pursuant to Tranche III shall be applied first to the repayment in full of all
outstanding principal and accrued interest pursuant to the then outstanding Term Loans, and the balance shall be disbursed to Borrower and used for general working capital purposes, and for capital expenditures. 

 

	 	b)	 Section 2.1(b)(ii) of the Agreement is hereby amended and restated to read as follows:

 (ii)    Interest shall accrue from the date a Term Loan is made at the rate
specified in Section 2.2(a), and prior to the Amortization Date shall be payable monthly in arrears beginning on the ninth (9th) calendar day of the month in which the Term Loan is made, and continuing on the same calendar day of each month
thereafter. Any Term Loan that is outstanding on the Amortization Date shall be payable in 27 equal monthly installments of principal, plus all accrued but unpaid interest, beginning on the Amortization Date and continuing on the same calendar day
of each month thereafter through the Maturity Date, at which time all amounts due in connection with the Term Loan and any other amounts due under this Agreement shall be immediately due and payable, provided that if the Amortization Date is
extended pursuant to the definition of “Amortization Date” set forth herein, such Term Loan shall be payable in 30 equal monthly installments of principal, plus all accrued but unpaid interest, beginning on the Amortization Date and
continuing on the same calendar day of each month thereafter through the Maturity Date as extended pursuant to the definition of “Maturity Date” set forth herein. Borrower may prepay all or any portion of the Term Loans, provided that
Borrower may not reborrow any amount, once repaid, provided, that in connection with any prepayment prior to the Maturity Date, including without limitation a payment upon acceleration of the maturity date prior to the Maturity Date upon the
occurrence of an Event of Default that continues, Borrower shall pay, in addition to the applicable portion of the outstanding principal and accrued interest on the Term Loans being repaid, the applicable portion of the Prepayment Fee. 

	 	c)	 Section 2.2(a) of the Agreement is hereby amended and restated to read as follows: 

(a)    Interest Rate. Except as set forth in Section 2.3(b), the Term Loan shall bear interest,
on the outstanding daily balance thereof, at a floating annual rate equal to the greater of (i) 0.75% above the Prime Rate then in effect and (ii) 6.00%. 
  

	 	d)	 Section 2.4(a) of the Agreement is hereby amended and restated to read as follows: 

(a)    Facility Fee. On or before the First Amendment Date, a fee equal to $15,000, which shall be
fully earned and nonrefundable. 
  

	 	e)	 A new Section 2.4(c) is hereby added to the Agreement to read as follows: 

(c)    Prepayment Fee. The Prepayment Fee as and when due pursuant to Section 2.1(b)(ii). 

 

	 	f)	 Section 3.2 of the Agreement is hereby amended by amending and restating the title and first clause
thereof to read as follows: 

 3.2    Conditions Precedent to all Credit
Extensions. The obligation of Bank to make any Credit Extensions after the Closing Date to Borrower is contingent upon Borrower’s compliance with Section 3.1 above, and is further subject to the following conditions: 

 

	 	g)	 Clauses (e) and (f) of Section 3.2 of the Agreement are each hereby amended by inserting at the
beginning of such clause the following: “with respect to Tranche II,”. 

  

	 	h)	 New clauses (g) and (h) are hereby added to Section 3.2 of the Agreement in appropriate alphabetical
order, to read as follows: 

 (g)    [Reserved]. 

(h)    with respect to Tranche III, Borrower has received a letter of support from Flagship, in form and
substance reasonably satisfactory to Bank, confirming Flagship’s intent to fund Borrower as needed (a “Flagship Letter of Support”). 
  

	 	i)	 Section 6.2(a)(ii) is hereby amended and restated to read as follows: 

(ii)    as soon as available, but in any event within 180 days after the end of Borrower’s fiscal year
for each fiscal year after 2018, audited (or such other level as is required by the Investment Agreement) consolidated financial statements of Borrower prepared in accordance with GAAP (excluding recording stock compensation expense, subject to
normal year-end adjustments and without all required footnotes), consistently applied, together with an opinion which is either unqualified, qualified only for going concern so long as Borrower’s
investors provide additional equity as needed or otherwise consented to in writing by Bank on such financial statements of an independent certified public accounting firm reasonably acceptable to Bank, provided that Borrower may deliver the audited
financial statements for fiscal year 2018 no later than June 30, 2020; 
  

	 	j)	 Section 6.2(f) is hereby added to the Agreement to read as follows: 

(f)    If at any time after the First Amendment Date but prior to the date Bank has received evidence
reasonably satisfactory to Bank that Borrower has satisfied the Cash Proceeds Milestone, the aggregate cash balance maintained by Borrower at Bank is less than Three Million Dollars ($3,000,000), then Borrower shall cause Flagship to provide an
updated Flagship Letter of Support upon any occurrence thereof concurrently with the delivery of such month’s Compliance Certificate. 

	 	k)	 Exhibit A to the Agreement is hereby amended by amending or restating, or adding, in appropriate alphabetical
order, as applicable, the following defined terms to read as follows: 

 “Amortization
Date” means January 9, 2020, provided that if Borrower shall have provided evidence satisfactory to Bank that (i) Borrower has satisfied the Cash Proceeds Milestone, and (ii) Flagship has confirmed in writing to Bank that
it is satisfied with Borrower’s preclinical development efforts relative to Borrower’s plan and remains supportive of Borrower, the Amortization Date shall be extended to January 9, 2021. 

“Cash Proceeds Milestone” means Borrower has received after the First Amendment Date gross cash
proceeds in an amount not less than $35,000,000 from the issuance of a new series of preferred stock on terms reasonably satisfactory to Bank, or as non-refundable strategic collaboration cash payments
(including upfront or other milestone payments, but excluding cost-sharing payments) prior to January 8, 2020. 

“Credit Card Maturity Date” means September 28, 2020. 

“First Amendment Date” means September 30, 2019. 

“Maturity Date” means March 9, 2022, provided that if Borrower shall have provided evidence
reasonably satisfactory to Bank that (i) Borrower has satisfied the Cash Proceeds Milestone, and (ii) Flagship has confirmed in writing to Bank that it is satisfied with Borrower’s preclinical development efforts relative to
Borrower’s plan and remains supportive of Borrower, the Maturity Date shall be extended to June 9, 2023. 

“Prepayment Fee” means, with respect to any prepayment of the Term Loan, an amount equal to: 

(a)    if the prepayment occurs no later than the one year anniversary of the First Amendment Date, an
amount equal to the principal amount of the Term Loan being prepaid multiplied by 1.50%; 
 (b)    if the
prepayment occurs after the one year anniversary of the First Amendment Date, but no later than the two year anniversary of the First Amendment Date, an amount equal to the principal amount of the Term Loan being prepaid multiplied by 0.50%; 

(c)    if the prepayment occurs after the two year anniversary of the First Amendment Date, the Prepayment
Fee shall be zero. 
 “Tranche III” has the meaning assigned to such term in Section 2.1(b)(i).

  

	 	l)	 Exhibit D to the Agreement is hereby amended and restated as set forth in Exhibit D attached hereto.

  

	2)	 Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the
Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects, Except as expressly set forth herein, the execution, delivery,
and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness
of all agreements entered into in connection with the Agreement and the security interest as granted as of the Closing Date continues without novation. 

  

	3)	 Borrower represents and warrants that the representations and warranties contained in the Agreement are true
and correct in all material respects as of the date of this Amendment (provided, that those representations and 

	 	
warranties expressly referring to another date shall be true and correct in all material respects as of such date, and provided further that any representation or warranty that contains a
materiality qualification therein shall be true and correct in all respects). This Amendment constitutes a legal, valid and binding obligation enforceable against Borrower in accordance with its terms, except as enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity. No Event of Default or failure of condition has occurred or exists, or
would exist with notice or lapse of time or both under the Agreement or any other Loan Document. A true and correct copy of the certificate of incorporation and bylaws, as in effect as of the First Amendment Date have been delivered to Bank.

  

	4)	 This Amendment and any documents executed in connection herewith or pursuant hereto contain the entire
agreement between the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, offers and negotiations, oral or written, with respect thereto and no extrinsic evidence whatsoever may be introduced in any
judicial or arbitration proceeding, if any, involving this Amendment; except that any financing statements or other agreements or instruments filed by Bank with respect to Borrower shall remain in full force and effect. 

 

	5)	 This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one instrument. 

  

	6)	 The terms of Section 11 of the Agreement are incorporated by reference herein, mutatis mutandis.

  

	7)	 As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance
reasonably satisfactory to Bank, the following: 

  

	 	a)	 this Amendment, duly executed by Borrower and Bank; 

 

	 	b)	 an Amended and Restated Warrant, duly executed by Borrower; 

 

	 	c)	 an officer’s certificate of Borrower with respect to incumbency and resolutions authorizing the execution
and delivery of this Amendment and issuance of the Warrant; 

  

	 	d)	 payment of the fee of $15,000 due on the First Amendment Date in accordance with Section 2.4(a) of the
Agreement, as amended, and all Bank Expenses, including Bank’s expenses for the documentation of this amendment and any related documents, and any UCC, good standing or intellectual property search or filing fees, which may be debited from any
of Borrower’s deposit account maintained with Bank; 

  

	 	e)	 a duly completed Loan Advance/Paydown Request Form with respect to the Term Loan to be made on the First
Amendment Date; 

  

	 	f)	 the Flagship Letter of Support in accordance with Section 3.2 of the Agreement, as amended; and

  

	 	g)	 such other documents and completion of such other matters, as Bank may reasonably deem necessary or
appropriate. 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 [SIGNATURE PAGE TO FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT] 

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written. 

 

									
	OMEGA THERAPEUTICS, INC.	 		 	PACIFIC WESTERN BANK
					
	By:	 	 /s/ Mahesh Karande
	 		 	By:	 	 /s/ Scott Hansen

	Name:	 	 Mahesh Karande
	 		 	Name:	 	 Scott Hansen

	Title:	 	 President & CEO
	 		 	Title:	 	 Managing Director

 EXHIBIT D 

COMPLIANCE CERTIFICATE 

[See attached.] 

 

 
 Compliance Certificate 
  

			
	Borrower:	  	 Omega Therapeutics, Inc.

 The undersigned officer of _______________________________ hereby certifies that in accordance with the terms and
conditions of the LSA, (i) Borrower is in complete compliance for the period ending _______________, with all covenants except as noted below; and (ii) all representations and warranties of Borrower stated in the LSA are true and
correct as of the date hereof. Attached herewith are the required documents supporting the above certification. The officer further certifies that these are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are
consistently applied from one period to the next, except as explained an accompanying letter or footnotes. 
 Reporting Covenants 

Please indicate compliance status by circling YES or NO under the COMPLIES column. 

 

									
	COVENANTS	  	REQUIRED	  	COMPLIES
	Monthly Financial Statements (P&L, BS, CF)*	  	Monthly, within 30 days	  	YES	  	NO	  	 
	 *Preferred format: monthly trended in excel
	  		  		  		  	 
	Compliance Certificate	  	Monthly, within 30 days	  	YES	  	NO	  	 
	Letter of Support Stating Intent to Fund Borrower	  	Monthly, within 30 days if Cash is below $3MM	  	YES	  	NO	  	N/A  
	Informal Clinical Updates on Material Developments	  	As Company may determine or at Bank’s request	  	YES	  	NO	  	N/A  
	Collateral Audit	  	Up to once per year	  	YES	  	NO	  	N/A  
	Annual Audited Financials (2018 audit due 6/30/2020)	  	FYE within 180 days (beginning with FY2019)	  	YES	  	NO	  	N/A  
	Annual Board Approved Financial Projections	  	FYE within 45 days	  	YES	  	NO	  	N/A  
	Notice of New Material Inbound License or Agreements	  	(as applicable)	  	YES	  	NO	  	N/A  
	10K and 10Q	  	(as applicable)	  	YES	  	NO	  	N/A  

 Banking Relationship 

Please indicate Banking Relationship below and circle YES or NO under the COMPLIES column. 

 

															
	  	  	  	  	COMPLIES	 
	Total Amount of Borrower’s Cash and Investments at Bank and its Affiliates	  	                    	  				  				  			 
	 				 
	 Cash & Investments at MSC
Subsidiary*
	  	                    	  				  				  			 
	 Other Cash & Investments outside
PWB and MSC*
	  	                    	  	 	    YES	 	  	 	NO	 	  	 	N/A	 
	 				 
	Total amount of Borrower’s Cash and Investments	  	                    	  	 	 	 	  	 	 	 	  	 	 	 

 *Borrower shall maintain its primary depository, operating, and investment accounts with Bank. 

*Borrower’s MSC Subsidiary permitted to maintain Cash outside Bank so long as the total aggregate amount of Cash at PWB equals or exceeds 120% the
aggregate outstanding prinicpal balance of the Term Loan. 
 *Borrower permitted to maintain Cash and/or investments outside of Bank (subject to an Account
Control Agreement) so long as the total aggregate amount of Cash at PWB equals or exceeds 200% of the aggregate amount of Bank’s commitment with respect to the Term Loan as of the closing date. 

Comments 

 

     

     

 By signing
below, the officer further acknowledges that at any time Borrower is not in compliance with all the terms set forth in the LSA, including, without limitation, the financial covenants, and such non-compliance
results in an Event of Default and such Event of Default is continuing, then Bank shall have no obligation to make any credit extensions. 
  

							
		  		  	 Please Send All Required Reporting to:

	 X
	  	  
	  	 address
	  	Pacific Western Bank
	 authorized signature
	  	 date
	  		  	ATTN: Portfolio Analysis
		  		  		  	406 Blackwell Street., Suite 240
	     
	  		  	Durham, NC 27701
	 name
	  		  	 website
	  	pacwest.com
	     
	  	 phone
	  	919.314.3040
	 title
	  		  	 fax
	  	919.314.3090
	Thank you for signing with a “wet ink” signature!	  	 email
	  	 lsnereports@pacwest.com

  

					
	revised: 4.2.19	  	Pacific Western Bank Confidential	  	Page 1 | 9/3/2019

 SECOND AMENDMENT TO 

LOAN AND SECURITY AGREEMENT 
 This
Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of January 22, 2020, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and
OMEGA THERAPEUTICS, INC. (“Borrower”). 
 RECITALS 

Borrower and Bank are parties to that certain Loan and Security Agreement dated as of March 9, 2018 (as amended, restated, supplemented or otherwise
modified from time to time, the “Agreement”). The parties desire to amend the Agreement in accordance with the terms of this Amendment. 

NOW, THEREFORE, the parties agree as follows: 
  

	1)	 Section 2.1(b)(ii) of the Agreement is hereby amended and restated to read as follows:

 (ii)    Interest shall accrue from the date a Term Loan is made at the rate
specified in Section 2.2(a), and prior to the Amortization Date shall be payable monthly in arrears beginning on the ninth (9th) calendar day of the month in which the Term Loan is made, and
continuing on the same calendar day of each month thereafter. Any Term Loan that is outstanding on the Amortization Date shall be payable in 26 equal monthly installments of principal, plus all accrued but unpaid interest, beginning on the
Amortization Date and continuing on the same calendar day of each month thereafter through the Maturity Date, at which time all amounts due in connection with the Term Loan and any other amounts due under this Agreement shall be immediately due and
payable, provided that if the Amortization Date is extended pursuant to the definition of “Amortization Date” set forth herein, such Term Loan shall be payable in 30 equal monthly installments of principal, plus all accrued but unpaid
interest, beginning on the Amortization Date and continuing on the same calendar day of each month thereafter through the Maturity Date as extended pursuant to the definition of “Maturity Date” set forth herein. Borrower may prepay all or
any portion of the Term Loans, provided that Borrower may not reborrow any amount, once repaid, provided, that in connection with any prepayment prior to the Maturity Date, including without limitation a payment upon acceleration of the maturity
date prior to the Maturity Date upon the occurrence of an Event of Default that continues, Borrower shall pay, in addition to the applicable portion of the outstanding principal and accrued interest on the Term Loans being repaid, the applicable
portion of the Prepayment Fee. 
  

	2)	 The following defined terms in Exhibit A to the Agreement are hereby amended and restated, as follows:

 “Amortization Date” means February 9, 2020, provided that if Borrower shall have provided
evidence satisfactory to Bank that (i) Borrower has satisfied the Cash Proceeds Milestone, and (ii) Flagship has confirmed in writing to Bank that it is satisfied with Borrower’s preclinical development efforts relative to
Borrower’s plan and remains supportive of Borrower, the Amortization Date shall be extended to January 9, 2021. 

“Cash Proceeds Milestone” means Borrower has received after the First Amendment Date gross cash proceeds in an amount
not less than $35,000,000 from the issuance of a new series of preferred stock on terms reasonably satisfactory to Bank, or as non-refundable strategic collaboration cash payments (including upfront or other
milestone payments, but excluding cost-sharing payments) prior to February 8, 2020. 

  
 Omega Therapeutics, Inc. – 2nd Amendment to LSA - Execution 

	3)	 Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the
Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery,
and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness
of all agreements entered into in connection with the Agreement. 

  

	4)	 Borrower represents and warrants that the representations and warranties contained in the Agreement are true
and correct in all material respects as of the date of this Amendment (provided, that those representations and warranties expressly referring to another date shall be true and correct in all material respects as of such date, and provided further
that any representation or warranty that contains a materiality qualification therein shall be true and correct in all respects). 

  

	5)	 This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one instrument. 

  

	6)	 As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance
reasonably satisfactory to Bank, the following: 

  

	 	a)	 this Amendment, duly executed by Borrower; 

 

	 	b)	 payment of a $500 facility fee, which may be debited from any of Borrower’s accounts;

  

	 	c)	 payment of all Bank Expenses, including Bank’s expenses for the documentation of this Amendment and any
related documents, and any UCC, good standing or intellectual search or filing fees, which may be debited from any of Borrower’s accounts; and 

  

	 	d)	 such other documents and completion of such other matters, as Bank may reasonably deem necessary or
appropriate. 

 [Signature Page Follows] 

  
 Omega Therapeutics, Inc. – 2nd Amendment to LSA - Execution 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written. 

 

									
	OMEGA THERAPEUTICS, INC.	 		 	PACIFIC WESTERN BANK
					
	By:	 	 /s/ Mahesh Karande
	 		 	By:	 	 /s/ Katherine A. Meeks

	Name:	 	 Mahesh Karande
	 		 	Name:	 	 Katherine A. Meeks

	Title:	 	 President & CEO
	 		 	Title:	 	 Vice President – Venture Banking

 [Signature Page to Second Amendment to Loan and Security Agreement] 

  
 Omega Therapeutics, Inc. – 2nd Amendment to LSA - Execution 

 THIRD AMENDMENT TO 

LOAN AND SECURITY AGREEMENT 

This Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of December 30, 2020,
by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and OMEGA THERAPEUTICS, INC. (“Borrower”), 

RECITALS 
 Borrower
and Bank are parties to that certain Loan and Security Agreement dated as of March 9, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Agreement”). The parties desire to amend the
Agreement in accordance with the terms of this Amendment. 
 NOW, THEREFORE, the parties agree as follows: 

 

	1)	 Amendments. 

  

	 	a)	 Section 2.1(b)(ii) of the Agreement is hereby amended and restated to read as follows:

 (ii)     Interest shall accrue from the date a Term Loan is made at the rate
specified in Section 2.2(a), and prior to the Amortization Date shall be payable monthly in arrears beginning on the first calendar day of the month in which the Term Loan is made, and continuing on the same calendar day of each month
thereafter. Any Term Loan that is outstanding on the Amortization Date shall be payable in 24 equal monthly installments of principal, plus all accrued but unpaid interest, beginning on the Amortization Date and continuing on the first calendar day
of each month thereafter through the Maturity Date, at which time all amounts due in connection with the Term Loan and any other amounts due under this Agreement shall be immediately due and payable. Borrower may prepay all or any portion of the
Term Loans, provided that Borrower may not reborrow any amount, once repaid, provided, that in connection with any prepayment prior to the Maturity Date, including without limitation a payment upon acceleration of the maturity date prior to the
Maturity Date upon the occurrence of an Event of Default that continues, Borrower shall pay, in addition to the applicable portion of the outstanding principal and accrued interest on the Term Loans being repaid, the applicable portion of the
Prepayment Fee. 
  

	 	b)	 Section 2.4(a) of the Agreement is hereby amended and restated to read as follows: 

(a)     Facility Fee. On or before the Third Amendment Date, a fee equal to $15,000, which shall be
fully earned and nonrefundable. 
  

	 	c)	 A new Section 2.4(d) is added to the Agreement to read as follows: 

(d)     Success Fee. Upon a Success Fee Event, Borrower shall pay to Bank a fee of $200,000 (the
“Success Fee”). This Section 2.4(d) shall survive any termination of this Agreement until the earliest to occur of (a) 10 years from the Third Amendment Date and (b) the payment of the Success Fee. If this Agreement is terminated
prior to payment of the Success Fee, Borrower shall give Bank written notice of the first Success Fee Event to occur thereafter, and pay the Success Fee upon the closing of such Success Fee Event. 

 

	 	d)	 Section 3.2 (h) of the Agreement is amended to read as follows: 

(h)     [Reserved]. 
  

	 	e)	 Section 6.2(f) of the Agreement is amended to read as follows: 

(f)     [Reserved]. 

	 	f)	 Section 6.6 of the Agreement is amended to read as follows: 

Section 6.6     Primary Depository. Borrower shall maintain its primary depository and operating
accounts with Bank and its primary investment accounts with Bank or Bank’s Affiliates; provided that prior to maintaining any investment accounts with Bank’s Affiliates, Borrower, Bank, and any such Affiliate shall have entered into a
securities account control agreement with respect to any such investment accounts, in form and substance satisfactory to Bank. Notwithstanding the foregoing, Borrower may permit Borrower’s MSC Subsidiary, if any, to maintain Cash in accounts
outside of Bank and not subject to a control agreement in favor of any Person, so long as the total aggregate amount of Cash maintained by Borrower in accounts with Bank equals or exceeds 105% of the outstanding principal and accrued interest of the
Term Loan. 
  

	 	g)	 Borrower’s address for purposes of Section 10 of the Agreement is amended to read as follows:

 If to Borrower:                 OMEGA
THERAPEUTICS, INC. 
 20 Acorn Park Drive, Suite 400 

Cambridge, MA 02140 

Attn: President 

Email: [XXX]@omegatherapeutics.com 
  

	 	h)	 Exhibit A to the Agreement is hereby amended by amending or restating, or adding, in appropriate alphabetical
order, as applicable, the following defined terms to read as follows: 

 “Amortization
Date” means June 30, 2021, provided that if Borrower shall have provided evidence satisfactory to Bank that Borrower has satisfied the Cash Proceeds Milestone, the Amortization Date shall be extended to December 31, 2021. 

“Credit Card Line” means a Credit Extension of up to $250,000, to be used exclusively for the provision
of Credit Card Services. 
 “Credit Card Maturity Date” means June 30, 2023, provided that upon
Borrower’s satisfaction of the Cash Proceeds Milestone, the Credit Card Maturity Date shall be extended to December 31, 2023. 

“Cash Proceeds Milestone” means Borrower has received after the Third Amendment Date
gross cash proceeds in an amount not less than $50,000,000 from the issuance of new preferred stock on terms reasonably satisfactory to Bank, Subordinated Debt, convertible notes, or as non-refundable
strategic collaboration cash payments (including upfront or other milestone payments, but excluding cost-sharing payments) prior to June 30, 2021. 

“Maturity Date” means June 30, 2023, provided that upon Borrower’s satisfaction of the Cash
Proceeds Milestone, the Maturity Date shall be extended to December 31, 2023. 
 “Obligations”
means all debt, principal, interest, Bank Expenses and other amounts owed to Bank by Borrower pursuant to this Agreement or any other agreement, whether absolute or contingent, due or to become due, now existing or hereafter arising, including any
interest that accrues after the commencement of an Insolvency Proceeding and including any debt, liability, or obligation owing from Borrower to others that Bank may have obtained by assignment or otherwise. Notwithstanding the foregoing,
“Obligations” shall not include any warrant or any other equity-related investments and the Success Fee after the termination of this Agreement.  

 “Prepayment Fee” means, with respect to any
prepayment of the Term Loan, an amount equal to: 
 (a)     if the prepayment occurs on or before
December 31, 2021, an amount equal to the principal amount of the Term Loan being prepaid multiplied by 1.50%; 

(b)     if the prepayment occurs after December 31, 2021, but on or before December 31, 2022, an
amount equal to the principal amount of the Term Loan being prepaid multiplied by 0.50%; 
 (c)     if
the prepayment occurs after December 31, 2022, the Prepayment Fee shall be zero. 
 “Success Fee
Event” means (a) any sale, license, or other disposition of all or substantially all of the assets (including intellectual property) of Borrower and its Subsidiaries taken as a whole, (b) any reorganization, consolidation,
merger or sale of the voting securities of Borrower or any other transaction where the holders of a Borrower’s securities before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after
the transaction, or (c) the sale or issuance of Borrower’s or its Affiliate’s equity securities in connection with an initial public offering, an alternative public offering, a reverse merger, or any similar transaction in which
Borrower or its Affiliate receives cash proceeds from such sale or issuance and Borrower’s or its Affiliate’s equity securities may thereafter be traded in a public market. 

“Third Amendment Date” means December 30, 2020. 

 

	2)	 Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the
Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects, Except as expressly set forth herein, the execution, delivery,
and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness
of all agreements entered into in connection with the Agreement and the security interest as granted as of the Closing Date continues without novation. 

  

	3)	 Borrower represents and warrants that the representations and warranties contained in the Agreement are true
and correct in all material respects as of the date of this Amendment (provided, that those representations and warranties expressly referring to another date shall be true and correct in all material respects as of such date, and provided further
that any representation or warranty that contains a materiality qualification therein shall be true and correct in all respects). This Amendment constitutes a legal, valid and binding obligation enforceable against Borrower in accordance with its
terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity. No Event of Default or
failure of condition has occurred or exists, or would exist with notice or lapse of time or both under the Agreement or any other Loan Document. A true and correct copy of the certificate of incorporation and bylaws, as in effect as of the Third
Amendment Date have been delivered to Bank.  

  

	4)	 This Amendment and any documents executed in connection herewith or pursuant hereto contain the entire
agreement between the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, offers and negotiations, oral or written, with respect thereto and no extrinsic evidence whatsoever may be introduced in any
judicial or arbitration proceeding, if any, involving this Amendment; except that any financing statements or other agreements or instruments filed by Bank with respect to Borrower shall remain in full force and effect. 

 

	5)	 This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one instrument. 

	6)	 The terms of Section 11 of the Agreement are incorporated by reference herein, mutatis mutandis.

  

	7)	 As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance
reasonably satisfactory to Bank, the following: 

  

	 	a)	 this Amendment, duly executed by Borrower and Bank; 

 

	 	b)	 an officer’s certificate of Borrower with respect to incumbency and resolutions authorizing the execution
and delivery of this Amendment; 

  

	 	c)	 payment of the fee of $15,000 due on the Third Amendment Date in accordance with Section 2.4(a) of the
Agreement, as amended, and all Bank Expenses, including Bank’s expenses for the documentation of this amendment and any related documents, and any UCC, good standing or intellectual property search or filing fees, which may be debited from any
of Borrower’s deposit account maintained with Bank; and 

  

	 	d)	 such other documents and completion of such other matters, as Bank may reasonably deem necessary or
appropriate. 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 [SIGNATURE PAGE TO THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT] 

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written. 

 

									
	OMEGA THERAPEUTICS, INC.	 		 	PACIFIC WESTERN BANK
					
	By:	 	 /s/ Mahesh Karande
	 		 	By:	 	 /s/ Katherine Meeks

	Name:	 	 Mahesh Karande
	 		 	Name:	 	 Katherine Meeks

	Title:	 	 President & CEO
	 		 	Title:	 	 Vice President

 CORPORATE RESOLUTION 

The undersigned duly elected and qualified Secretary of OMEGA THERAPEUTICS, Inc. (the “Company”), solely in his or her capacity as an officer of the
company, and not in his or her individual capacity, does hereby certify that the following is a true and correct copy of certain resolutions adopted by the Company’s Board of Directors in accordance with applicable law and the Company’s
bylaws, and that such resolutions arc now unmodified and in full force and effect: 
 BE IT RESOLVED, that: 

 

	1)	 Any one (1) of the following, duly elected officers of the Company (each, an “Authorized Officer”)
whose genuine original signature appears next to his or her name is authorized to act for, on behalf of, and in the name of the Company in connection with the resolutions below: 

 

					
	 Title
	  	 Name
	  	 Authorized Signature

	 Mahesh Karande
	  	President & CEO	  	/s/ Mahesh Karande
	  
	  	  
	  	  

	  
	  	  
	  	  

	  
	  	  
	  	  

  

	2)	 Any Authorized Officer may: 

 

	 	a)	 Borrow money from time to time from Pacific Western Bank (the “Bank”), and may negotiate and procure
loans, letters of credit, foreign exchange contracts and other financial accommodations from Bank, including without limitation, pursuant to that certain Loan and Security Agreement dated as of March 9, 2018, as amended by that certain Third
Amendment to Loan and Security Agreement, dated as of December 30, 2020, and also to execute and deliver to Bank one or more renewals, extensions, or modifications thereof; 

 

	 	b)	 Give security for any liabilities of the Company to Bank by grant, security interest, assignment, lien, deed of
trust or mortgage upon any real or personal property, tangible or intangible of the Company; 

  

	 	c)	 Purchase, sell, exchange, assign, endorse for transfer and/or deliver certificates and/or instruments
representing stocks, bonds, evidences of Indebtedness or other securities owned by the Company, whether or not registered in the name of the Company; 

  

	 	d)	 Discount with the Bank, commercial or other business paper belonging to the Company made or drawn by or upon
third parties, without limit as to amount; 

  

	 	e)	 Authorize and direct the Bank to pay the proceeds of any such loans or discounts as directed by the persons so
authorized to sign; 

  

	 	f)	 Execute and deliver in form and content as may be required by the Bank any and all notes, evidences of
indebtedness, applications for letters of credit, guaranties, subordination agreements, loan and security agreements, financing statements, assignments, liens, deeds of trust, mortgages, trust receipts and other agreements, instruments or documents
to carry out the purposes of these Resolutions, any or all of which may relate to all or to substantially all of the Company’s property and assets; 

  

	3)	 The Authorized Officers may designate additional or alternate individuals as being authorized to request loan
advances, to do and perform such other acts and things, to pay any and all fees and costs, and to execute and deliver such other documents and agreements as he or she may in his or her discretion deem reasonably necessary or proper in order to carry
into effect the provisions of these Resolutions. 

  

	4)	 Any and all acts authorized pursuant to these resolutions and performed prior to the passage of these
resolutions are hereby ratified and approved, and the authority conferred herein may be exercised singly by any such officer, and these resolutions shall continue in full force and effect until written notice of modification or revocation is
received and accepted by Bank (such notice to have no effect on any action previously taken by the Bank in reliance on these Resolutions). Bank may rely upon any form of notice, which it in good faith believes to be genuine or what it purports to
be. 

	5)	 The Resolutions are in full force and effect as of the date of this Certificate and are intended to replace, as
of this date, any Resolutions previously given by the Company to Bank in connection with the matters described herein; these Resolutions and any borrowings or financial accommodations under these Resolutions have been properly noted in the corporate
books and records, and have not been rescinded, revoked or modified; neither the foregoing Resolutions nor any actions to be taken pursuant to them are or will be in contravention of any provision of the articles of incorporation or bylaws of the
Company or of any agreement, indenture or other instrument to which the Company is a party or by which it is bound; and to the extent the articles of incorporation or bylaws of the Company or any agreement, indenture or other instrument to which the
Company is a party or by which it is bound require the vote or consent of shareholders of the Company to authorize any act, matter or thing described in the foregoing Resolutions, such vote or consent has been obtained. 

In Witness Whereof, I have affixed my name as Secretary and have caused the corporate seal (where available) of said Company to be affixed on
December 30, 2020. 
  

	
	 /s/ Barbara Chan

	Secretary*

  

	*	 If the certifying officer is designated as the only signer in these resolutions then another corporate officer
must also sign.EX-10.15

 Exhibit 10.15 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
 DEVELOPMENT AND OPTION AGREEMENT BETWEEN ACUITAS THERAPEUTICS, INC. AND 

OMEGA THERAPEUTICS, INC. 
 EXECUTION
COPY 
 Development and Option Agreement 

by and between 
 ACUITAS
THERAPEUTICS, INC. 
 and 

OMEGA THERAPEUTICS, INC. 

dated 
 October 5,
2020 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
 TABLE OF CONTENTS 

 

							
	 ARTICLE 1 Definitions
	  	 	1	 
		
	 ARTICLE 2 Governance
	  	 	9	 
	 2.1
	 	Management	  	 	9	 
	 2.2
	 	Joint Development Committee	  	 	9	 
		
	 ARTICLE 3 The Program
	  	 	10	 
	 3.1
	 	Program Generally	  	 	10	 
	 3.2
	 	FTEs	  	 	12	 
	 3.3
	 	Program Records, Reports and Materials	  	 	13	 
	 3.4
	 	Program Licenses	  	 	14	 
		
	 ARTICLE 4 Reserved Targets
	  	 	15	 
	 4.1
	 	Generally	  	 	15	 
	 4.2
	 	Reserved Target List, Restricted Target List and Target Notices	  	 	15	 
	 4.3
	 	Expiration of Pre-Existing Restrictions	  	 	16	 
	 4.4
	 	Fees	  	 	17	 
		
	 ARTICLE 5 Omega License Options
	  	 	17	 
	 5.1
	 	Option	  	 	17	 
	 5.2
	 	Omega’s Exercise of Option	  	 	17	 
		
	 ARTICLE 6 Ownership of Program Technology
	  	 	18	 
	 6.1
	 	Disclosure of LNP Know-How	  	 	18	 
	 6.2
	 	Ownership	  	 	18	 
	 6.3
	 	Assignment	  	 	19	 
	 6.4
	 	Prosecution and Maintenance	  	 	19	 
	 6.5
	 	Patent Enforcement and Defense	  	 	19	 
		
	 ARTICLE 7 Confidentiality
	  	 	20	 
	 7.1
	 	Confidential Information	  	 	20	 
	 7.2
	 	Restrictions	  	 	20	 
	 7.3
	 	Exceptions	  	 	20	 
	 7.4
	 	Permitted Disclosures	  	 	21	 
	 7.5
	 	Return of Confidential Information	  	 	21	 
	 7.6
	 	Publications	  	 	22	 
	 7.7
	 	Patents	  	 	22	 
	 7.8
	 	Terms of this Agreement; Publicity	  	 	22	 
		
	 ARTICLE 8 Warranties; Covenants; Limitations of Liability;
Indemnification
	  	 	22	 
	 8.1
	 	Representations and Warranties	  	 	22	 
	 8.2
	 	Additional Representations and Warranties of Acuitas	  	 	23	 
	 8.3
	 	Disclaimers	  	 	24	 
	 8.4
	 	No Consequential Damages	  	 	24	 
	 8.5
	 	Performance by Others	  	 	24	 
	 8.6
	 	Indemnification	  	 	25	 
	 8.7
	 	Insurance	  	 	26	 

  
 i 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

							
	 ARTICLE 9 Term and Termination
	  	 	27	 
	 9.1
	 	Term	  	 	27	 
	 9.2
	 	Termination by Omega	  	 	27	 
	 9.3
	 	Termination by Acuitas	  	 	27	 
	 9.4
	 	Termination Upon Bankruptcy	  	 	28	 
	 9.5
	 	Effects of Termination	  	 	28	 
	 9.6
	 	Survival	  	 	29	 
		
	 ARTICLE 10 Miscellaneous
	  	 	29	 
	 10.1
	 	Dispute Resolution	  	 	29	 
	 10.2
	 	Invoices and Payments	  	 	30	 
	 10.3
	 	Relationship of Parties	  	 	30	 
	 10.4
	 	Compliance with Law	  	 	30	 
	 10.5
	 	Governing Law	  	 	30	 
	 10.6
	 	Counterparts; Facsimiles	  	 	30	 
	 10.7
	 	Headings; Rule of Construction; Interpretation	  	 	31	 
	 10.8
	 	Further Assurances	  	 	31	 
	 10.9
	 	Binding Effect	  	 	31	 
	 10.10
	 	Assignment	  	 	31	 
	 10.11
	 	Notices	  	 	31	 
	 10.12
	 	Amendment and Waiver	  	 	32	 
	 10.13
	 	Severability	  	 	32	 
	 10.14
	 	Entire Agreement	  	 	32	 
	 10.15
	 	Force Majeure	  	 	32	 

  
 ii 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 List of Exhibits 

 

			
	Exhibit 1.1	  	Patents in the Acuitas Background Technology
		
	Exhibit 3.1(a)	  	Workplan
		
	Exhibit 3.1(f)	  	[***]
		
	Exhibit 4.2	  	Form of Target Notice
		
	Exhibit 5.2(b)	  	Form of Non-Exclusive License Agreement

  
 iii 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
 DEVELOPMENT AND OPTION AGREEMENT 

THIS DEVELOPMENT AND OPTION AGREEMENT (this “Agreement”), dated as of October 5, 2020 (the “Effective
Date”), is made by and between Omega Therapeutics, Inc. a Delaware corporation (“Omega”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of Omega and Acuitas may be referred
to herein as a “Party” or together as the “Parties.” 
 WHEREAS, Acuitas has expertise and
intellectual property relating to the development of LNP Technologies (as defined below); 
 WHEREAS, Omega has expertise and
intellectual property relating to gene modulating therapeutics, including Genome Modulating Constructs that encode Omega Controllers (as defined below); and 

WHEREAS, the Parties believe that certain proprietary Acuitas LNP Technology (as defined below) could be useful for the formulation and
delivery of Omega’s proprietary Genome Modulating Constructs; and 
 WHEREAS, the Parties are interested in evaluating the
development of products incorporating Acuitas LNP Technology and Omega Technology (as defined below), and accordingly conducted certain studies under the Evaluation Agreement (as defined below) prior to the Effective Date; and 

WHEREAS, Acuitas wishes to grant to Omega, and Omega wishes to obtain, an option to obtain a license under the Acuitas LNP Technology
to develop and commercialize one or more specific products of Omega, all in accordance with the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the amount
and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE 1 

Definitions 
 The following terms
and their correlatives will have the following meanings: 
 1.1 “Acuitas Background Technology” means any and all
proprietary LNP Technology that is owned or Controlled by Acuitas or its Affiliates (a) as of the Effective Date of this Agreement, or (b) generated, developed or obtained by Acuitas outside of the scope of this Agreement and the
Evaluation Agreement, and in each case necessary or useful for the conduct of the Workplan or the research, development, manufacturing and commercialization of Licensed Products. The Patents in the Acuitas Background Technology as of the Effective
Date are listed in Exhibit 1.1 attached hereto. 
 1.2 “Acuitas Indemnitees” has the meaning set forth in
Section 8.6(b). 
 1.3 “Acuitas LNP Technology” means the Acuitas Background Technology and the Acuitas Sole
Technology. For the avoidance of doubt, any LNP or component thereof that is proprietary to Acuitas and provided by or on behalf of Acuitas to Omega pursuant to this Agreement or the Evaluation Agreement shall be Acuitas Background Technology and,
therefore, Acuitas LNP Technology under this Agreement. 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 1.4 “Acuitas Sole Technology” means, without regard to inventorship, all
Technology (other than Workplan Data) that arises from the Workplan or the work conducted under the Evaluation Agreement that is solely an Improvement of Acuitas Background Technology and does not incorporate or consist of an Improvement to the
Omega Background Technology. For clarity, any Technology arising out of the Workplan or the work conducted under the Evaluation Agreement that (a) is an Improvement of Acuitas Background Technology and (b) specifically relates to
any Genome Modulating Construct provided or used by Omega under the Workplan or the work conducted under the Evaluation Agreement or any Omega Controller encoded by such Genome Modulating Construct is Joint IP and not Acuitas Sole Technology. 

1.5 “Acuitas Workplan Leader” has the meaning set forth in Section 2.1. 

1.6 “Affiliate” of a person or entity means any other person or entity which (directly or indirectly) is controlled by,
controls or is under common control with such person or entity. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common
control with”) as used with respect to an entity will mean (a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast more than fifty percent (50%) of the votes in the election
of directors or (b) in the case of a non-corporate entity, direct or indirect ownership of more than fifty percent (50%) of the equity interests with the power to direct the management and policies of such entity,
provided that if local Law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local Law, be owned by foreign interests. 

1.7 “Agreement” has the meaning set forth in the Preamble. 

1.8 “Backup Licensed Product” means, with respect to a Licensed Product directed to a [***] that is the then-current subject
of a Non-Exclusive License (“Original Licensed Product”), any other Licensed Product that (a) is directed to [***], and (b) includes Omega Controller(s) (i) [***] and
(ii) that results from [***] in such Original Licensed Product. 
 1.9 “Business Day” means mean a day on which
banking institutions in both Boston, Massachusetts, USA and Vancouver, British Columbia, Canada are open for business. 
 1.10
“Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. provided, that the first Calendar Quarter of the Term will begin
on the Effective Date and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term will end on the last day of the Term. 

1.11 “CMO” has the meaning set forth in Section 3.1(f). 

1.12 “Collaboration Partner” means with respect to any Third Party (other than a CMO, Contract Research Organization or other
permitted subcontractors pursuant to Section 3.1(i)) to whom Omega wishes to disclose Acuitas Confidential Information or transfer Acuitas LNP Technology or Materials provided by Acuitas to Omega, any Third Party that is also a licensee
or sublicensee or assignee of Omega Technology and deemed to be a Collaboration Partner pursuant to Section 3.1(h). 
 1.13
“Concurrent Reserved List Limits” has the meaning set forth in Section 4.2(e). 
 1.14 “Confidential
Disclosure Agreement” means the Confidential Disclosure Agreement between the Parties dated December 17, 2019. 
 1.15
“Confidential Information” has the meaning set forth in Section 7.1. 

  
 2 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 1.16 “Contract Research Organization” means an entity in the business of
providing specialized research, development and manufacturing services (including CMOs) on a fee for service basis pursuant to agreements that include terms that provide that all data, materials and intellectual property generated in performing such
services be owned by the contracting party in accordance with Section 3.1(i), excluding Improvements to such entity’s Technology that is used to perform such services. 

1.17 “Contract Year” will refer to the twelve (12)-month period beginning on the Effective Date and on each anniversary
thereafter during the Term. 
 1.18 “Control” or “Controlled” means, with respect to a particular
Technology and Party, that such Party owns or has a license to use and practice such Technology and has the right to grant a license or sublicense to such Technology without violating the terms of any agreement with any Third Party and without owing
any milestone, royalty or other monetary obligations to a Third Party under the terms of any agreement with such Third Party. 
 1.19
“Debar”, “Debarred” or “Debarment” means (a) being debarred, or being subject to a pending debarment, pursuant to Section 306 of the FDCA, 21 U.S.C. § 335a, (b)
being listed by any federal or state agencies, excluded, debarred, suspended or otherwise made ineligible to participate in federal or state healthcare programs or federal procurement or non-procurement programs (as that term is defined in
42 U.S.C. § 1320a-7b(f)), or being subject to any pending process by which any such listing, exclusion, debarment, suspension or other ineligibility could occur, (c) being disqualified by any government or
regulatory agency from performing specific services, or being subject to a pending disqualification proceeding, or (d) being convicted of a criminal offense related to the provision of healthcare items or services or being subject to any
pending criminal action related to the provision of healthcare items or services. 
 1.20 [***]. 

1.21 “Diligent Efforts” means, with respect to the efforts to be expended by each Party with respect to any activity set
forth in the Workplan, active and sustained efforts to conduct the applicable activity, or to attempt to achieve the applicable requirement or goal, in a prompt and expeditious manner, as is reasonably practicable under the circumstances consistent
with the Workplan ([***]) and the terms of this Agreement. 
 1.22 “Disclosing Party” has the meaning set forth in
Section 7.1. 
 1.23 “Dollars” means United States dollars. 

1.24 “Effective Date” has the meaning set forth in the Preamble. 

1.25 “Escrow Agent” means the Third Party escrow agent designated by Acuitas and reasonably acceptable to Omega, which escrow
agent will initially be [***]. 
 1.26 “Evaluation Agreement” means the Technology Evaluation Agreement between the Parties
effective as of March 11, 2020. 
 1.27 “Executive Officers” has the meaning set forth in Section 2.2(d).

 1.28 “Field of Use” means all human therapeutic or prophylactic uses. 

  
 3 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 1.29 “Formulated Product” means product produced by Acuitas in accordance
with the Workplan or under the Evaluation Agreement that incorporates Omega proprietary Genome Modulating Constructs formulated with Acuitas LNP Technology. 

1.30 “Formulated Product Fee” means the fees to be charged by Acuitas for supply of Formulated Product to Omega under this
Agreement, which fees are set forth in the Workplan and will include FTE Costs and reasonable Third Party costs for materials used in the Formulated Product or its manufacture. 

1.31 “FTE” means the work of a full-time person for one year, or more than one person working the equivalent of a full-time
person for one year, where “full-time” is determined by the standard practices in the biopharmaceutical industry in the geographic area in which such personnel are working, but means 1840 hours per year, in the performance of the Works and
Services, including scientific management oversight as reasonably required. 
 1.32 “FTE Costs” mean the Dollar amount
obtained by multiplying the number of actual FTEs employed by Acuitas in the conduct of the Works and Services by an annual rate per FTE equal to [***] Dollars (US$[***]). [***]. 

1.33 “Genome Modulate” means to downregulate or upregulate the expression of a Human Genome Target for human therapeutic or
prophylactic applications. 
 1.34 “Genome Modulating Construct” means a construct consisting of one or more mRNA
Constructs that encode [***] Protein Targets that are Omega Controllers designed to Genome Modulate [***] Human Genome Targets. 
 1.35
“GMP” means current Good Manufacturing Practices as specified in Parts 210 and 211 of Title 21 of the U.S. C.F.R., ICH Guideline Q7A, or equivalent Laws of an applicable regulatory authority at the time of manufacture. 

1.36 “Human Genome Target” means 

(a) a naturally occurring human gene, including all coding, non-coding and regulatory regions thereof,
as identified by the applicable transcript identifier (i.e., NCBI Refseq transcript ID), gene identifier (i.e., NCBI Refseq Gene ID), gene name and synonyms and nucleotide sequence coordinates, gene transcript and nucleotide sequence;
or 
 (b) any naturally occurring non-coding region of the human genome including transcriptional
regulatory elements, non-protein coding RNA and intergenic regions; or 
 (c) a gene encoded by any
nucleotide sequence of a human pathogen residing in a human cell in vivo; or 
 (d) any gene that is not covered by subclause
(a) or (b) above, together with any variants of such gene, including the wild type and naturally occurring mutant and allelic variants, provided however that any such variant (i) encodes a protein with substantially
similar mechanism of action and biological activity to the protein product of the original (reference) gene and (ii) has a coding region with [***] percent ([***]%) sequence identity to the coding region of the original (reference) gene. 

For clarity, a nucleotide sequence may be considered to encode a protein regardless of whether such sequence contains a start codon. 

  
 4 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 1.37 “Improvement” means, with respect to Technology including the Acuitas
Background Technology or the Omega Background Technology, as applicable, any improvement, enhancement, change, modification, variation or derivative of such Technology. 

1.38 “Indemnification Claim Notice” has the meaning set forth in Section 8.6(c). 

1.39 “Indemnified Party” has the meaning set forth in Section 8.6(c). 

1.40 “Insolvency Legislation” has the meaning set forth in Section 10.1(a). 

1.41 “Insulated Genomic Domain” means [***]. 

1.42 “JDC” has the meaning set forth in Section 2.2(a). 

1.43 “JDC Deadlock” has the meaning set forth in Section 2.2(d). 

1.44 “Joint IP” means, without regard to inventorship, each of the following: (a) Technology that arises out of the
Workplan or the work conducted under the Evaluation Agreement that relates to, constitutes an Improvement to or incorporates both the Acuitas Background Technology and the Omega Background Technology, (b) any other Technology that arises
out of the Workplan or the work conducted under the Evaluation Agreement that in each case does not constitute either Acuitas Sole Technology or Omega Sole Technology and (c) the Workplan Data. 

1.45 “Joint Prosecution and Maintenance Agreement” has the meaning set forth in Section 6.4(a). 

1.46 “Know-How” means all Materials and all confidential and proprietary information including commercial, technical,
scientific and other know-how and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly
procedures, computer programs, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety, manufacturing and quality control data and
know-how, and including study designs and protocols), in all cases, provided that such information is confidential and proprietary, and regardless of whether patentable, in written, electronic or any other form now known or hereafter developed. 

1.47 “Law” or “Laws” means all laws, statutes, rules, regulations, orders, judgments or ordinances having
the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. 
 1.48
“Licensed Product” means either (a) any product that consists of [***] Genome Modulating Constructs that collectively encode [***] Protein Targets that are Omega Controllers designed to Genome Modulate [***] Human Genome
Targets within a single Insulated Genomic Domain or (b) any product that consists of Genome Modulating Constructs that collectively encode [***] Protein Targets that are Omega Controllers designed to Genome Modulate a single Human Genome
Target, in each case (a) and (b) where such product is derived from, incorporates, or utilizes, any LNP Technology that is Controlled by Acuitas or its Affiliates as of the Effective Date or at any time during the Term. For clarity, each
Licensed Product will consist of a specific combination of Omega Controllers and Human Genome Targets. 

  
 5 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 1.49 “Licensed Technology” means LNP Technology that is
(a) Controlled by Acuitas or its Affiliates, (i) as of the Effective Date, or (ii) generated or obtained during the Term (including the Acuitas Background Technology and the Acuitas Sole Technology), and
(b) necessary or useful for the research, development, manufacture, use, sale or other exploitation of a Licensed Product. Licensed Technology does not include Acuitas’ interest in any Joint IP. 

1.50 “LNP” means lipid nanoparticles. 

1.51 “LNP Technology” means any Technology that claims, embodies or incorporates delivery systems (and components thereof)
based on or incorporating LNPs. 
 1.52 “Losses” has the meaning set forth in Section 8.6(a). 

1.53 “Materials” means any tangible chemical or biological material, including any compounds, LNP, DNA, RNA (including mRNA),
clones, cells, and any expression product, progeny, derivative or other improvement thereto, along with any tangible chemical or biological material embodying any Know-How including Formulated Product and Genome Modulating Constructs. 

1.54 “mRNA Construct” means any mRNA that encodes [***] Protein Targets and any associated non-coding sequences, including
any cap sequence, 5’ UTR, 3’UTR, and any polyadenylation sequences. The term “mRNA Construct” also includes the chemistry of natural and non-natural nucleic acids, and other chemical modifications associated with such mRNA and
associated non-coding sequences. 
 1.55 “Non-Exclusive License” means a
non-exclusive license in the form attached hereto as Exhibit 5.2(b). 
 1.56 “Omega Background Technology” means any
and all patented and unpatented proprietary Technology owned or controlled by Omega that relates to Omega Controllers, including Genome Modulating Constructs and their component mRNA Construct(s), Genome Modulation by an Omega Controller and the
related mechanism of action or biological activity used in the conduct of the Workplan or the work conducted under the Evaluation Agreement. Notwithstanding the foregoing, Omega Background Technology shall not include any Patent that claims Genome
Modulating Constructs or Omega Controllers and that includes data from, or is enabled by, or conceived as a result of, the work conducted under the Evaluation Agreement. 

1.57 “Omega Controller(s)” means a Protein Target that has a DNA targeting domain and an effector domain and that is designed
to Genome Modulate either (a) a single Human Genome Target or (b) multiple Human Genome Targets within a single Insulated Genomic Domain. 

1.58 “Omega Indemnitees” has the meaning set forth in Section 8.6(a). 

1.59 “Omega Sole Technology” means without regard to inventorship, all Technology (other than Workplan Data) that arises out
of the Workplan or the work conducted under the Evaluation Agreement and is solely an Improvement to the Omega Background Technology and that does not incorporate or consist of an Improvement to the Acuitas Background Technology. For clarity, any
Technology arising out of the Workplan or the work conducted under the Evaluation Agreement that (a) is an Improvement to Omega Background Technology and (b) relates to any LNP Technology provided or used by Acuitas under the
Workplan (whether specifically or generically) or the work conducted under the Evaluation Agreement is Joint IP and not Omega Sole Technology. 

  
 6 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 1.60 “Omega Technology” means Omega Background Technology and Omega Sole
Technology. For the avoidance of doubt, any Genome Modulating Construct or component thereof that is proprietary to Omega and provided by or on behalf of Omega to Acuitas and any Omega Controller encoded by such Genome Modulating Construct, will be
Omega Background Technology (which for avoidance of doubt will not include any Patent that includes data from, or is enabled, or conceived as a result of, the work conducted under the Evaluation Agreement), and, therefore, Omega Technology under
this Agreement. 
 1.61 “Omega Workplan Leader” has the meaning set forth in Section 2.1. 

1.62 “Option” has the meaning set forth in Section 5.1. 

1.63 “Option Exercise Fees” means (a) for the first Non-Exclusive License taken by Omega hereunder, One Million Five
Hundred Thousand Dollars (US$1,500,000) payable on the effective date of such Non-Exclusive License and (b) for the second Non-Exclusive License taken by Omega hereunder, One Million Seven Hundred Fifty Thousand Dollars (US$1,750,000)
payable on the Non-Exclusive License effective date of such Non-Exclusive License. 
 1.64 “Option Limit” has the meaning
set forth in Section 5.1(c). 
 1.65 “Option Notice” has the meaning set forth in Section 5.2(a). 

1.66 “Party” and “Parties” have the meaning set forth in the Preamble. 

1.67 “Patent(s)” means an (a) issued patent, a patent application and a future patent issued from any such patent
application, (b) a future patent issued from a patent application filed in any country worldwide that claims priority from a patent or patent application included in (a), (c) any additions, divisions, continuations, continuations-in-part,
invention certificates, substitutions, reissues, reexaminations, extensions, registrations, utility models, supplementary protection certificates and renewals based on any patent or patent application under (a) or (b), but not including
any rights that give rise to regulatory exclusivity periods (other than supplementary protection certificates, which will be treated as “Patents” hereunder), and (d) any counterpart of any patent or patent application under
(a), (b) or (c) filed in any country worldwide. 
 1.68 “Pre-Existing Restrictions” means, with respect to a
particular Target as of the date of the applicable Target Notice, that (a) Acuitas or its Affiliates are precluded from granting Omega a Non-Exclusive License under the Acuitas LNP Technology (as set forth in this Agreement) due to a
conflicting grant of rights (or an outstanding option to obtain such a grant of rights) or covenant to a Third Party with respect to such Target pursuant to a bona fide written agreement that is executed in good faith in the ordinary
course of business prior to the date of the Target Notice for such Target that is still in effect on such date or (b) such Target is currently internally reserved by Acuitas. 

1.69 “Program” means the program of activities using Acuitas LNP Technology and Omega Technology for the development of
Licensed Products incorporating Omega’s Genome Modulating Constructs that the Parties engage in under this Agreement pursuant to the Workplan. 

1.70 “Protein Target” means either 

(a) any naturally occurring protein encoded by a specific gene locus, as identified by the applicable transcript identifier (i.e., NCBI
Refseq transcript ID), gene identifier (i.e., NCBI Refseq Gene ID), gene name and synonyms and DNA sequence coordinates and the applicable amino acid sequence, together with all variants of such protein, including the wild type, naturally
occurring variants, engineered variants wherein modifications to the native amino acid sequence have been introduced (for example, mutated versions, derivatives or fragments), and species homologs and orthologs thereof, provided
however that any such naturally occurring variant, engineered variant, or species homolog or ortholog possesses substantially similar mechanism of action and biological activity to the naturally occurring human protein (for example
immunogenicity in case of antigens); or 

  
 7 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (b) any protein that is not covered by subclause (a) above (together with any variants,
mutated versions, derivatives or fragments of such protein, provided that any such variant, mutated version, derivative or fragment possesses substantially similar mechanism of action and biological activity as such protein) and has
greater than [***] percent ([***]%) sequence identity to the reference amino acid sequence provided by Omega to the Escrow Agent for such Protein Target. 

1.71 “Receiving Party” has the meaning set forth in Section 7.1. 

1.72 “Records” has the meaning set forth in Section 3.3(a). 

1.73 “Reserved Target” means a Target with respect to which Omega shall have delivered to the Escrow Agent a Target Notice
and that is deemed to be added to the Reserved Target List in accordance with Section 4.2(d)(ii). A Target that is removed from or replaced on the Reserved Target List pursuant to Section 4.2 will no longer be deemed a Reserved
Target. For avoidance of doubt, the term Reserved Target includes all variants of such Target set forth within the definition of Target. 

1.74 “Reserved Target List” means collectively, the list of all Reserved Targets. 

1.75 “Restricted Target List” has the meaning set forth in Section 4.2(b). 

1.76 “Target” means, collectively, one or more Omega Controllers and up to [***] Human Genome Targets, as the case may be,
each, as identified in the appropriate nomination form pursuant to Section 4.2(c). 
 1.77 “Target Notice” has the
meaning set forth in Section 4.2(c). 
 1.78 “Target Reservation and Maintenance Fees” means the annual fees set forth
in Section 4.4(a). 
 1.79 “Target Acceptance Notice” has the meaning set forth in Section 4.2(d)(ii). 

1.80 “Target Rejection Notice” has the meaning set forth in Section 4.2(d)(i). 

1.81 “Target Response Notice” has the meaning set forth in Section 4.2(d). 

1.82 “Technology” means collectively Patents and Know-How. 

1.83 “Technology Access Fee” has the meaning set forth in Section 3.4(d). 

1.84 “Term” has the meaning set forth in Section 9.1. 

1.85 “Territory” means worldwide. 

1.86 “Third Party” means any person or entity other than Omega, Acuitas and their respective Affiliates. 

1.87 “Third Party Claims” has the meaning set forth in Section 8.6(a). 

1.88 “Workplan” has the meaning set forth in Section 3.1(a). 

  
 8 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 1.89 “Workplan Data” means the results of studies using Formulated Product
conducted in accordance with the Workplan or the work conducted pursuant to the Evaluation Agreement. For avoidance of doubt, the results of LNP formulation studies conducted by Acuitas and Genome Modulating Construct studies conducted by Omega
which, in each case, support the Formulated Product studies but do not use Formulated Product, will not be Workplan Data. 
 1.90
“Workplan Leaders” has the meaning set forth in Section 2.1. 
 1.91 “Works and Services” means the
activities to be performed by Acuitas or Omega, as applicable, pursuant to the Workplan. 
 ARTICLE 2 

Governance 
 2.1
Management. Management of the Program activities will be under the responsibility of [***], for Acuitas (the “Acuitas Workplan Leader”), and [***] for Omega (the “Omega Workplan Leader,” and together with the
Acuitas Workplan Leader, or such other individuals as the Parties may designate in writing from time to time (the “Workplan Leaders”)). Each Workplan Leader will be the primary point of contact for the other Party on all matters
relating to the Program activities. 
 2.2 Joint Development Committee. 

(a) Development Committee. As soon as practicable, the Parties will establish a joint development committee, comprised of at least one
(1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s
Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the
JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be
bound to the same extent as a permitted subcontractor under Section 3.1(i). 
 (b) Meetings. During the Term, the JDC
will meet [***] by teleconference, videoconference or in person unless agreed otherwise by the JDC representatives. The JDC will have a quorum if at least one (1) representative of each Party is present or participating. Each Party will be
responsible for all of its own expenses of participating in the JDC meetings. The Parties will endeavor to schedule meetings of the JDC at least [***] ([***]) weeks in advance. The Parties will alternate in preparing the meeting agenda, and the
Party that was responsible for preparing the meeting agenda will prepare and circulate for review and approval by the other Party written minutes of such meeting within [***] ([***]) days after such meeting. The Parties will agree on the
minutes of each meeting promptly, but in no event later than [***] ([***]) days after such meeting. 
 (c) Responsibilities. The
JDC will oversee and supervise the overall performance of the Workplan and within such scope will: 
 (i) review the efforts of the Parties
in the performance of the Workplan and allocate those resources for the Workplan committed by Acuitas (FTE Costs and external costs) hereunder; 

(ii) revise and approve any revisions to the Workplan, or confirm that no revisions are necessary, on a regular basis and in any event before
the start of each Calendar Quarter during the Term; 

  
 9 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (iii) form such other committees as the JDC may deem appropriate, provided
that such committees may make recommendations to the JDC but may not be delegated JDC decision-making authority; 
 (iv) address
such other matters (A) relating to the activities of the Parties under the Workplan as either Party may bring before the JDC, (B) that are delegated to the JDC under this Agreement, or (C) as may be mutually agreed by the Parties from
time to time; and 
 (v) attempt to resolve any disputes within the scope of the JDC’s authority on an informal basis. 

(d) Decision-making. The JDC will make decisions only by consensus with each Party having collectively one (1) vote. In the
event the JDC is unable to reach agreement as to a matter within the JDC’s jurisdiction within [***] ([***]) days after it has first met and attempted to reach agreement (such event, a “JDC Deadlock”), upon the written
request of a Party, such matter will be referred to a senior executive of each Party that is not on the JDC (the “Executive Officers”) (or their designees, provided that such designee is not on the JDC and has decision-making
authority on behalf of such Party), who will attempt in good faith to resolve such JDC Deadlock by negotiation and consultation for a [***] ([***]) day period following receipt of such written notice. If, despite such efforts, agreement on a
particular matter cannot be reached by the Executive Officers within such [***] ([***]) day period, then Omega will have the final decision-making authority with respect to such JDC Deadlock, subject to Section 3.1(c). 

(e) Limits on JDC Authority. Each Party will retain the rights, powers and discretion granted to it under this Agreement and no such
rights, powers, or discretion will be delegated to or vested in the JDC unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. The JDC will not have the power to amend,
modify or waive compliance with this Agreement (other than as expressly permitted hereunder). 
 ARTICLE 3 

The Program 
 3.1
Program Generally. The Parties will jointly conduct the Program. It is intended that Acuitas will be responsible for the lipid chemistry and LNP formulation and characterization work, Omega will be responsible for Genome Modulating Construct
and Omega Controller development and Acuitas and Omega will each undertake preclinical studies as set forth in the Workplan. It is intended that upon completion of the Workplan activities with respect to a Licensed Product, the Parties will have
optimized the formulation for such Licensed Product such that GMP activities can be initiated by Omega upon exercise of an Option with respect to that Licensed Product. 

(a) Workplan Preparation. The development activities to be undertaken by the Parties with respect to each Reserved Target will be
described in a detailed written development plan (the “Workplan”). The initial Workplan is attached hereto as Exhibit 3.1(a). 

(b) Workplan Contents. The goal of the Workplan and the Program will be to evaluate and produce LNP formulations that are safe and
efficacious for delivery of Omega’s Genome Modulating Constructs and to advance the development of such Genome Modulating Construct-LNP formulations as therapeutic or prophylactic drug candidates. All
activities using Acuitas LNP Technology will be limited to Reserved Targets and will be only as set forth in the Workplan. The Workplan will include [***]. The Workplan will be comprehensive and include all activities using the Acuitas LNP
Technology by both Parties commencing after the Effective Date, including [***], to be undertaken prior to Omega exercising an Option for a Non-Exclusive License. No Acuitas LNP Technology or Formulated
Product will be used by Omega outside of the Workplan prior to Omega exercising an Option for a Non-Exclusive License and then only to the extent permitted under the
Non-Exclusive License agreement. 

  
 10 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (c) Amendments to the Workplan. The Workplan will be reviewed as necessary at each
meeting of the JDC, and at any other time upon the reasonable request of either Party, and will be modified in a manner that is consistent with the requirements for the Workplan set forth in Section 3.1(b) and otherwise at the direction of the
JDC to reflect material scientific (and other) developments. Each [***], the JDC will update the Workplan to cover at least the subsequent [***] ([***]) months of the Program in detail or confirm that no updates are necessary. In all events,
the Workplan will be consistent and not conflict with the terms of this Agreement, and in the event of any conflict between the Workplan and this Agreement, the terms of this Agreement will control. The Workplan may be amended by the JDC to
accelerate, decelerate, add or remove activities thereunder, including reducing or eliminating Acuitas’ responsibilities for an activity thereunder; provided, that [***]. Acuitas will use commercially reasonable efforts and cooperate
with Omega to comply with Omega’s requests. Omega may not exercise its final decision-making authority to amend the Workplan to include any activities that conflict with Pre-Existing Restrictions. 

(d) Obligations Under the Workplan. During the Term, each Party will perform the Works and Services in a professional manner and in
accordance with the Workplan and all applicable Laws, and each Party will use Diligent Efforts to meet the objectives and timelines set forth therein. Neither Party shall knowingly employ (or use a subcontractor that employs) in the performance of
the Works and Services any individual or entity that is Debarred or subject to Debarment. It is understood that the activities and goals of the Workplan are experimental and that successful results cannot be guaranteed. The Parties will otherwise
conduct the Program on the terms and conditions set forth in this Agreement and in accordance with the Workplan. Each Party will cooperate with and provide reasonably requested non-financial support to the
other Party in such other Party’s performance of its responsibilities under the Workplan. In addition to the reporting obligations set forth in Section 3.3(b), each Party will keep the other Party reasonably informed of such Party’s
activities under the Workplan through the JDC or as otherwise reasonably requested by the other Party. 
 (e) Supply of Formulated
Product. Acuitas will use Diligent Efforts to manufacture and supply Omega with Formulated Product as set forth in the Workplan and Omega will pay to Acuitas the Formulated Product Fee for such Formulated Product meeting the specifications and
other requirements of the Workplan. Acuitas and Omega will use the Formulated Product solely for research purposes in laboratory animals or in vitro studies as set forth in the Workplan and will not use Formulated Product in humans.
The Formulated Product will be manufactured and supplied by Acuitas (i) in accordance with the specifications set forth in the Workplan, (ii) in compliance with applicable Laws, and (iii) by the delivery date set forth in the
Workplan. No Formulated Product will be used outside of the Workplan. Omega will not perform any chemical analysis or testing of Formulated Product except as set forth in the Workplan and specifically will not attempt to determine the lipid
composition or lipid structures or in any way seek to reverse-engineer any Formulated Product. Further Omega will not provide any Formulated Product to a Third Party unless previously approved by Acuitas in writing. 

(f) Technology Transfer to Contract Manufacturing Organization. Prior to Omega’s exercise of an Option for a Licensed Product,
Acuitas will be responsible for the Genome Modulating Construct-LNP formulation, including analytical testing and documentation for all Licensed Products directed to Reserved Targets. Following the completion
of the Workplan for a Licensed Product and execution of a Non-Exclusive License agreement, Acuitas will promptly (and in any event within [***] ([***]) days following designation by Omega of the applicable GMP
contract manufacturing organization (a “CMO”), provided such CMO is able to support this timeline) transfer Know-How relating to the then-current formulation process, raw materials
supply, and analytical characterization for the manufacture of 

  
 11 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 
such Licensed Product to a single CMO determined by Omega and [***]. Acuitas will provide reasonable assistance to enable the CMO to manufacture such Licensed Product. Initiation of such
technology transfer will be determined by Omega and will be for the then current formulation of the Licensed Product. For clarity, the then current formulation of the Licensed Product shall mean a single LNP formulation previously tested by Omega in
accordance with the Workplan. [***]. 
 (g) Payment for External Expenses. On [***], Omega will reimburse Acuitas for any reasonable
external costs that are incurred by Acuitas in connection with performing the Works and Services in accordance with the Workplan and Workplan budget, provided that such external costs have been specified in the Workplan or, if agreed
by the JDC, are promptly added to the Workplan. [***]. 
 (h) Collaboration Partners. Omega may conduct parts of the Program together
with a Third Party other than as set forth in subsection (i) below (Permitted Subcontracting); provided that [***]. Omega shall provide written notice to Acuitas of its execution of each agreement with a Collaboration Partner.
Omega will ensure that each Collaboration Partner is subject to terms and conditions consistent with the terms and conditions in this Agreement (i) protecting and limiting use and disclosure of Confidential Information and Materials and Know-How, and (ii) requiring such Collaboration Partner and its personnel to assign to Omega all right, title and interest in and to any Technology created, conceived, developed or reduced to practice in the
performance of the Workplan, in order to give effect to the provisions of ARTICLE 6 and 7, as applicable, excluding any such arising Technology that is an Improvement to Technology of such Collaboration Partner and does not incorporate or consist of
an Improvement to Acuitas Background Technology or Acuitas Sole Technology. For avoidance of doubt, breach of any of the terms or conditions of this Agreement by a Collaboration Partner shall be a breach by Omega. 

(i) Permitted Subcontracting. Each Party may subcontract activities to be performed under the Workplan to any of its Affiliates,
subject to the Affiliate’s compliance with the terms and conditions of this Agreement including Article 6 and ARTICLE 7 below. In addition, each Party may subcontract its activities to be performed under the Workplan to a Contract Research
Organization. Any such Contract Research Organization will have entered into a written agreement with the subcontracting Party that includes terms and conditions protecting and limiting use and disclosure of Confidential Information, Materials and
Know-How at least to the same extent as under this Agreement, and requiring such Contract Research Organization and its personnel to assign to the subcontracting Party all right, title and interest in and to any Patents and Know-How and Materials
created, conceived, developed or reduced to practice in connection with the performance of subcontracted activities in accordance with this Agreement in order to give effect to the provisions of ARTICLE 6 and Article 7, as applicable,
excluding any Improvement to such Contract Research Organization’s Technology that does not incorporate or consist of an Improvement to Acuitas Background Technology or Acuitas Sole Technology. Any such subcontracting activities will be
described in the reports for the Program required by Section 3.3(b). 
 3.2 FTEs. 

(a) Generally. Acuitas will perform the Works and Services assigned to it under the Workplan and as part of the Program. The
actual number of Acuitas FTEs committed to work on the Program at any particular point in time will be set forth in the Workplan. The Parties will prepare the Workplan, which will determine the number of Acuitas FTEs to be funded each year.
Notwithstanding anything to the contrary set forth herein, in no event will (i) Acuitas be required to devote any FTEs to the conduct of the Program other than those funded by Omega or (ii) Omega be required to fund more than the actual
number of FTEs devoted by Acuitas to the Workplan. 

  
 12 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (b) FTEs. Acuitas will ensure that those individuals selected by Acuitas to
perform the Works and Services and otherwise support the activities to be undertaken by Acuitas pursuant to the Workplan will have sufficient scientific expertise, skill, training and competency to perform the proposed work and have similar skills,
training and competency as those FTEs employed by Acuitas to perform work on Acuitas’ internal programs and for Third Parties. In the event that Omega has concerns regarding the selection of an individual to perform Works and Services or other
activities under this Agreement, the Parties will discuss such concerns in good faith through the JDC. 
 (c) FTE Costs. Omega will
fund Acuitas FTEs based on the number of hours actually worked by such FTEs and otherwise as set forth in the Workplan. Omega will reimburse Acuitas for FTE Costs on a Calendar
Quarter-by-Calendar Quarter basis. Upon request by Omega, Acuitas will provide an estimate of Calendar Quarter FTE costs within [***] ([***]) days of such request.
Acuitas will send a reasonably detailed invoice to Omega no later than [***] ([***]) days after the end of each Calendar Quarter, which invoice shall include a summary of all activities by the name of each individual, number of hours devoted by
each such individual, and Works and Services type/activity performed by each such individual during such Calendar Quarter. Omega agrees to pay undisputed amounts in each such invoice within [***] ([***]) days of Omega’s receipt thereof.

 3.3 Program Records, Reports and Materials. 

(a) Records. Each Party will maintain, or cause to be maintained, records of its activities under the Program and the work conducted
under the Evaluation Agreement in sufficient detail and in good scientific manner appropriate for scientific, Patent and regulatory purposes, that will properly reflect all work included in the Program and the Evaluation Agreement
(“Records”) for a period of at least [***] ([***]) years after the creation of such Records or such longer period required by applicable Laws. Omega will have the right to request and receive a copy of any such Records maintained by
Acuitas; and Acuitas will have the right to request and receive a copy of any such Records maintained by Omega to the extent such Records are required by Acuitas to exercise its rights under this Agreement. 

(b) Data and Program Reports. Acuitas and Omega will share with one another through the JDC the Workplan Data. The Parties will not
share with each other Confidential Information or Know-How relating to their Background Technologies or the Acuitas Sole Technology or Omega Sole Technology, respectively, including, in the case of Acuitas,
LNP formulation information, except as provided in Section 3.1(f). Omega will share with Acuitas Workplan Data regarding the Genome Modulating Constructs and Omega Controllers only as and if needed by Acuitas to evaluate performance of the LNP
Technology in order to conduct the Program. Acuitas may disclose Workplan Data in connection with the filing of patent applications for Acuitas Sole Technology (so long as no Omega Confidential Information is disclosed). Omega may disclose Workplan
Data in connection with the filing of patent applications for Omega Sole Technology (so long as no Acuitas Confidential Information is disclosed). Omega may only use Workplan Data for the performance of its obligations under this Agreement and for
internal research and development activities (which, for clarity, shall not include regulatory approval or commercial exploitation of a product) and for avoidance of doubt may disclose Workplan Data for such purposes to Third Parties so long as no
Acuitas Confidential Information is disclosed; provided that following Omega’s exercise of an Option, Omega may also use such Workplan Data as set forth in a Non-Exclusive License. Acuitas
may only use Workplan Data for the performance of its obligations under this Agreement and for internal research and development activities (which, for clarity, shall not include regulatory approval or commercial exploitation of a product) and for
avoidance of doubt may disclose Workplan Data to Third Parties for such purposes so long as no Omega Confidential Information is disclosed. During the Term, each Party will furnish to the JDC a summary written report within [***] ([***]) days after
[***] describing its progress under the Workplan and evaluating such work in relation to the goals of the Workplan as well as provide such other information as reasonably requested by the JDC. Within [***] ([***]) days following expiration or
earlier termination of this Agreement, each Party will furnish to the JDC a final summary written report. 

  
 13 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (c) Materials. 

(i) Each Party will, during the Term, furnish to each other samples of Materials which comprise, embody or incorporate Omega Technology or
Acuitas LNP Technology, as the case may be, only as expressly set forth in the Workplan. Acuitas will furnish to Omega the quantities of Formulated Product as set forth in the Workplan and will use commercially reasonable efforts to provide any
additional quantities which will be required in performance of the Program. In addition, each Party will, upon the other Party’s reasonable written request, furnish to such other Party other samples of Materials which comprise, embody or
incorporate Omega Technology or Acuitas LNP Technology that are in such Party’s Control and are reasonable (both in quantity and identity) and useful for the other Party to carry out its responsibilities under the Workplan, provided
(A) such Materials are reasonably and readily available in excess of the providing Party’s own requirements, and (B) supply of such Materials will not, in the providing Party’s reasonable judgment, (1) conflict with the
providing Party’s internal or Third Party research programs, (2) conflict with the providing Party’s internal policies regarding such Materials, or (3) violate any agreement to which the providing Party is a party. Upon
termination or expiration of this Agreement and unless such Material is the GMP ready formulation as set forth in Section 3.1(f) of a Licensed Product under a Non-Exclusive License agreement, Materials
will, at the providing Party’s option and request to be made (if at all) within [***] ([***]) months after such termination or expiration or the effective date of termination, be returned to the providing Party or destroyed. The provision
of Materials hereunder by either Party will not constitute any grant, option or license under any Patents or Know-How, except as expressly set forth herein. 

(ii) Each Party will use such Materials only in accordance with the Workplan and otherwise in accordance with the terms and conditions of
this Agreement. Except as otherwise specified in the Workplan or except with the prior written consent of the supplying Party, the Party receiving any Materials will not distribute or otherwise allow the release of Materials to any Third Party,
except, with respect to either Party, to any permitted subcontractors under Section 3.1(i) and, with respect to Omega, to any Collaboration Partners. All Materials delivered to the receiving Party will remain the sole property of the providing
Party (except that the Formulated Product will be the property of both Parties) and will be used in compliance with all applicable Laws and only to perform activities set forth in the Workplan. Formulated Product will be destroyed by both Parties
upon written request by either Party. The Materials supplied under this Agreement will be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known. 

3.4 Program Licenses. 

(a) By Acuitas. Subject to the terms and conditions of this Agreement, Acuitas hereby grants to Omega (and to its Affiliates) a
worldwide, non-exclusive, royalty-free license under the Acuitas LNP Technology, solely to the extent necessary to enable Omega (and its Affiliates) to perform its activities set forth in the Workplan and for no other purpose. The foregoing license
will not include the right to grant sublicenses, except to permitted Collaboration Partners and Contract Research Organizations in accordance with Sections 3.1(i) and 3.1(h). 

(b) By Omega. Subject to the terms and conditions of this Agreement, Omega hereby grants to Acuitas a worldwide, non-exclusive, royalty-free license under the (i) Omega Technology Controlled by Omega, solely to the extent needed to enable Acuitas to perform its activities set forth in the Workplan and for no other
purpose. The foregoing license will not include the right to grant sublicenses, except to permitted Contract Research Organizations in accordance with Section 3.1(i). 

  
 14 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (c) No Other Licenses. No license or right is or will be created or granted hereunder
by implication, estoppel or otherwise. All licenses and rights are or will be granted only as expressly provided in this Agreement. 
 (d)
Technology Access Fee. For each Option, Omega will pay to Acuitas a technology access fee equal to [***] Dollars (US$[***]) (“Technology Access Fee”) within [***] ([***]) Business Days following the Effective Date,
and thereafter on each anniversary of the Effective Date during the Term, Omega will pay to Acuitas a Technology Access Fee of [***] Dollars (US$[***]) for each Option not exercised prior to such anniversary. [***]. 

ARTICLE 4 
 Reserved
Targets 
 4.1 Generally. Omega will have the right, but not the obligation, to non-exclusively reserve Targets for potential
use in the Workplan, in accordance with this ARTICLE 4. Omega will select the Targets that will be the subject of the work performed as part of the Program from the Reserved Targets specified in accordance with this ARTICLE 4. The initial Reserved
Target for the Program has been confirmed by a Target Response Notice from the Escrow Agent dated the Effective Date. Additionally, Omega shall have the right, but not the obligation, to exercise Options in accordance with this ARTICLE 4 and ARTICLE
5. 
 4.2 Reserved Target List, Restricted Target List and Target Notices. 

(a) Escrow Agent. The Escrow Agent will maintain in confidence the Restricted Target List and respond to
Omega’s Target Notices and Option Notices on behalf of Acuitas. The Escrow Agent shall not inform Acuitas of any Omega potential Reserved Targets or any Omega Reserved Targets, including any Omega Controller sequence information or the Human
Genome Target(s) that any such Omega Controller is designed to Genome Modulate, without Omega’s prior written consent. For the avoidance of doubt, the Escrow Agent shall not notify Acuitas if a potential Reserved Target has been rejected from
the Reserved Target List under this Section 4.2. All costs and expenses incurred through the Escrow Agent will be borne by Acuitas. 

(b) Pre-Existing Restrictions. Acuitas will maintain, at the Escrow Agent, a current and
up-to-date list of Targets that are subject to Pre-Existing Restrictions (the “Restricted Target List”). Such list will also identify the scope of the Pre-Existing Restrictions. Acuitas
represents, warrants and covenants to Omega that (i) the Restricted Target List is and will at all times be accurate and (ii) neither Acuitas nor any of its Affiliates will grant any licenses, options or other rights in or to the
Acuitas LNP Technology that would preclude Acuitas from granting to Omega a Non-Exclusive License for each Reserved Target as set forth herein. The decision of the Escrow Agent with respect to the Targets subject to Pre-Existing Restrictions will be conclusive unless there is fraud on the part of Acuitas in which case Omega reserves all rights against Acuitas but absent fraud on the part of the Escrow Agent, Omega shall have no
recourse against the Escrow Agent. 
 (c) Target Notices. If (i) Omega desires to add or remove a Target from the Reserved
Target List, or (ii) Omega desires to exercise an Option for a Licensed Product, Omega will notify the Escrow Agent in writing of the same. Such notice will identify as applicable, in addition to the information relating to such proposed
Targets set forth on the form of Target Notice attached hereto as Exhibit 4.2, (A) in the case of clause (i) above, whether Omega wishes to non-exclusively reserve such Target or remove such
Target from the Reserved Target List, (B) in the case of clause (ii) above, if Omega wishes to exercise an Option (each such notice, a “Target Notice”). Each Target Notice will specify the Omega Controller(s) and the Human
Genome Target(s) that each Omega Controller is designed to Genome Modulate. No Target will include more than [***] ([***]) Human Genome Targets. 

  
 15 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (d) Target Response Notices. The Escrow Agent, on behalf of Acuitas, will review each
Target Notice provided by Omega and, within [***] of the Escrow Agent’s receipt of a Target Notice, the Escrow Agent will provide Omega with written notice that includes the following information (each such notice, a “Target Response
Notice”): 
 (i) If, as of the date of Omega’s Target Notice for a Target, such Target is on the Restricted Target List and
is listed as being subject to Pre-Existing Restrictions that restrict Acuitas from taking the action requested by Omega in the Target Notice, or if the action requested by Omega would exceed the applicable
Concurrent Reserved List Limit or the Option Limit, then the Target Response Notice issued for such Target will so certify to Omega and will specify whether such applicable Target is subject to a Pre-Existing Restriction (such notice, a
“Target Rejection Notice”). For clarity, the Target Rejection Notice will specify which Target (Human Genome Target or Omega Controller) is subject to a Pre-Existing Restriction. 

(ii) If, as of the date of Omega’s Target Notice for a Target, such Target is not subject to any
Pre-Existing Restrictions that would prevent the action requested by Omega in the Target Notice, and the action requested by Omega would not exceed the applicable Concurrent Reserved List Limit or the Option
Limit, then such Target shall, consistent with the Target Notice, automatically be as of the date of the Target Notice (A) added or removed from the Reserved Target List on a non-exclusive basis, and (B) deemed to be subject to an
Option exercised by Omega on a non-exclusive basis subject to terms and conditions of Section 5.2, including the payment of the applicable Option Exercise Fee, and the Target Response Notice issued for the Targets included in the Licensed Product
will certify the same to Omega (such notice, an “Target Acceptance Notice”). So long as a Target is on the Reserved Target List and Omega has an Option with respect to such Target, Acuitas and its Affiliates will not exclusively
internally reserve such Target or grant to any Third Party an exclusive license (or an option to obtain such a grant of rights) under the Acuitas LNP Technology with respect to such Target. This Section 4.2(d)(ii) shall survive the termination or
expiration of this Agreement solely in the event that the Parties enter into a Non-Exclusive License prior to such termination or expiration. 

(e) Concurrent Reserved List Limits. During the Term, Omega will have the right to select up to two (2) Reserved Targets at any one
time to be placed on the Reserved Target List (the “Concurrent Reserved List Limit”). Targets can be removed from the Reserved Target List, added to the Reserved Target List or replaced on the Reserved Target List at any time
subject to the limitations on the total numbers of each Target. The Concurrent Reserved List Limit will be reduced by one for each Option exercised such that the number of Reserved Targets plus the number of Options exercised shall not exceed two
(2). 
 (f) Minimum Target Reservation Requirement. Subject to the Concurrent Reserved List Limit and the availability of potential
Reserved Targets for reservation pursuant to this Section 4.2, Omega will elect and maintain at least one (1) Target to be placed on the Reserved Target List at all times (“Minimum Target Reservation Requirement”). 

4.3 Expiration of Pre-Existing Restrictions. If any
Pre-Existing Restrictions identified in a Target Rejection Notice that precluded Acuitas from taking the action requested by Omega in a Target Notice later expire or otherwise are modified or terminate such
that Acuitas is no longer precluded from taking the action requested by Omega in a Target Notice, the Escrow Agent will notify Omega of such event and Omega will have an option, for a period of [***] ([***]) days following delivery of such
notice to Omega, to (a) add such Target to the Reserved Target List, or (b) exercise an Option with respect to a 

  
 16 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 
Licensed Product directed to such Target, as the case may be, in each case ((a) and (b)), subject to the Concurrent Reserved List Limits and the Option Limit. For clarity, Omega will at all times
thereafter have the right to provide a Target Notice for such Target to the Escrow Agent pursuant to Section 4.2(c) but such Target Notice will be subject to any intervening Pre-Existing Restrictions.

 4.4 Fees. 

(a) Target Reservation and Maintenance Fees. Omega will pay to Acuitas [***] Dollars (US$[***]) per [***] for each Reserved Target
until such Target is removed from the Reserved Target List or Omega exercises an Option with respect to such Reserved Target. Target(s) removed from the Reserved Target List shall be available to Third Parties and [***]. 

(b) [***]. 
 ARTICLE 5

 Omega License Options 

5.1 Option. From the period commencing on the Effective Date and, subject to Section 9.2(a) and Section 10.15, ending on
the expiration of the Term, Acuitas hereby grants to Omega the options (each, an “Option”) set forth below. Omega’s Option is non-exclusive with respect to Licensed Products directed to a Reserved Target. 

(a) Non-Exclusive License. An Option shall include the right to enter into a non-exclusive, worldwide, license, with a right to sub-license through multiple tiers, under the Licensed Technology to research, develop, make, have made, keep, use, sell,
offer to sell, have sold, import, export or otherwise commercialize and exploit Licensed Products directed to a Reserved Target in the Field of Use in the Territory. The Option to obtain a Non-Exclusive
License will be limited to Targets that are on the Reserved Target List at the time of exercise of the Option. The Non-Exclusive License will also include Omega’s right to replace such Licensed Product
with a Backup Licensed Product at any time prior to the initiation by Omega of the first Phase 1 Study (as such term is defined in the Non-Exclusive License) of a Licensed Product, not to exceed [***]
([***]) such replacement Backup Licensed Products. Once an Option has been exercised with respect to Licensed Products directed to a Reserved Target, the Reserved Target will no longer be included in the Workplan and except as set forth in the Non-Exclusive License all further development work on Licensed Products directed to such Reserved Target and any Backup Licensed Products will be undertaken solely by Omega. 

(b) Option Limit. Omega will have the right to exercise Options with respect to a maximum of two (2) Reserved Targets (the
“Option Limit”). 
 (c) Form of Non-Exclusive License Agreement. The
form of Non-Exclusive License agreement attached hereto as Exhibit 5.2(b) will be used for all licenses granted upon the exercise of an Option hereunder. Each
Non-Exclusive License will grant rights for Licensed Products directed to the Reserved Target specified in the Option Notice. 

5.2 Omega’s Exercise of Option. Omega may exercise each such Option by delivering to Acuitas an Option Notice and paying to
Acuitas the Option Exercise Fee in accordance with this Section 5.2. If not exercised prior to the expiration of the Term, the Options granted to Omega under this ARTICLE 5 with respect to all Reserved Targets will terminate in full and will no
longer be exercisable. 

  
 17 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (a) Option Notice. Omega has the right to deliver to the Escrow Agent, prior to
the expiration of the Term, a Target Notice including the information set forth in Exhibit 4.2(c), as applicable, for the Licensed Products directed to the Reserved Target for which Omega wishes to exercise an Option (each such Target Notice,
an “Option Notice”). Omega will submit one (1) Option Notice for the Licensed Products directed to each Reserved Target for which Omega wishes to exercise the Option. 

(b) Non-Exclusive License Agreement. Within [***] ([***]) Business Days of the Escrow
Agent’s receipt of an Option Notice, Omega and Acuitas will enter into a Non-Exclusive License using the form attached hereto as Exhibit 5.2(b) for the Licensed Products directed to the Reserved Target specified in the relevant Option
Notice. 
 (c) Option Exercise Fee. Within [***] ([***]) Business Days after the effective date of a Non-Exclusive License and [***], Acuitas will issue an invoice to Omega for the Option Exercise Fee less any amounts creditable against such Option Exercise Fee for such Non-Exclusive License pursuant to
Section 4.4(b). Each such payment will be due within [***] days ([***]) days after Omega’s receipt of such invoice from Acuitas. A separate Option Exercise Fee will be required for each
Non-Exclusive License executed by the Parties in accordance with this ARTICLE 5. 
 ARTICLE 6

 Ownership of Program Technology 

6.1 Disclosure of LNP Know-How. Notwithstanding anything to the contrary in this
Agreement, Acuitas will not disclose to Omega any Know-How within the Acuitas LNP Technology without Omega’s prior written consent other than pursuant to a
Non-Exclusive License following Omega’s exercise of an Option. 
 6.2 Ownership.

 (a) Omega Owned Technology. As between the Parties, Omega will own all right, title and interest in and to the Omega Technology.

 (b) Acuitas Owned Technology. As between the Parties, Acuitas will own all right, title and interest in and to the Acuitas LNP
Technology. 
 (c) Jointly Owned Technology. The Parties will jointly own any and all Joint IP. Each Party will have an undivided one-half interest in and to such Joint IP. Subject to the terms of this Agreement and any Non-Exclusive License agreement, each Party will exercise its ownership rights in and
to such Joint IP, including the right to license and sublicense or otherwise to exploit, transfer or encumber its ownership interest, without an accounting or obligation to, or consent required from, the other Party, but subject to the licenses
hereunder and the other terms and conditions of this Agreement. At the reasonable written request of a Party, the other Party will in writing grant such consents and confirm that no such accounting is required to affect the foregoing regarding Joint
IP. Neither Party will file any Patent application or otherwise seek to protect any Joint IP without the prior written consent of the other Party. 

(d) Assignment of Technology. Each Party, for itself and on behalf of its Affiliates, hereby assigns (and to the extent such assignment
can only be made in the future, hereby agrees to assign), to the other Party (i) any Technology that is solely owned by such other Party under this Section 6.2, and (ii) a joint and undivided interest in and to all Joint IP. The
Parties will reasonably cooperate to more fully document the rights of each Party as defined in this Section 6.2, including by executing all lawful papers and instruments, obtaining and executing necessary powers of attorney and assignments by
the named inventors, making all rightful oaths and declarations and providing consultation and assistance as may be necessary. 

  
 18 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 6.3 Assignment. Each Party will require, to the extent legally possible under relevant
national or local Laws and subject to Section 3.1(h) and Section 3.1(i), all of its employees, Affiliates and any Third Parties working pursuant to this Agreement on its behalf, to assign, or otherwise convey rights to such Party
in, its right, title and interest in any invention or Patent conceived, reduced to practice, created or otherwise made in performance of the Workplan or work conducted under the Evaluation Agreement, in order to accomplish the ownership provisions
set forth in this ARTICLE 6. Each Party will be responsible for any compensation payable by such Party to its employees, Affiliates or any Third Parties working pursuant to this Agreement on its behalf. 

6.4 Prosecution and Maintenance. 

(a) General. As between the Parties and subject to any Non-Exclusive License, (i) Omega will have the sole right but not the
obligation, at its expense, to prosecute and maintain Patents within the Omega Technology and (ii) Acuitas will have the sole right but not the obligation, at its expense, to prosecute and maintain Patents within the Acuitas LNP Technology.
Upon request by either Party, the Parties will promptly enter into a joint prosecution and maintenance agreement (“Joint Prosecution and Maintenance Agreement”) with respect to the Joint IP that, unless otherwise agreed by the
Parties, shall provide at a minimum that the Party with the responsibility to prosecute and maintain the Patents within the Joint IP will (i) keep the other Party reasonably informed of its prosecution and maintenance activities,
(ii) provide the other Party with a reasonable opportunity to review and comment on any material submissions or correspondence with a patent office and incorporate in good faith any comments from the other Party, and (iii) provide to the
other Party copies of all correspondence sent to or received from a patent office with respect to such Patents. 
 (b) Cooperation.
Each Party will reasonably cooperate with the other Party in the prosecution and maintenance of the Patents within the Joint IP. Such cooperation includes promptly executing all documents, or requiring inventors, subcontractors, employees and
consultants to execute all documents, as reasonable and appropriate so as to enable the prosecution and maintenance of any such Patents in any country. 

6.5 Patent Enforcement and Defense. 

(a) Notice. During the Term, to the extent not in breach of an obligation of confidentiality, Acuitas will promptly notify, in
writing, Omega upon learning of any claim of invalidity or unenforceability of any Patents included in the Acuitas LNP Technology or any claim that the practice of the Acuitas LNP Technology infringes Third Party Patents, and will, along with such
notice, supply Omega with any evidence in its possession pertaining thereto. 
 (b) Enforcement. As between the Parties and subject
to any Non-Exclusive License Acuitas will have the sole right, but not the obligation, to seek to abate any infringement of the Patents included in the Acuitas LNP Technology by a Third Party, or to file suit
against any such Third Party for such infringement. As between the Parties, Omega will have the sole right but not the obligation, at its expense, to enforce and defend any Patents within the Omega Technology. 

(c) Defense. As between the Parties and subject to any Non-Exclusive License agreement, Acuitas will have the sole right, but not the
obligation, to defend against a declaratory judgment action or other action challenging any Patents included in the Acuitas LNP Technology. 

  
 19 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 ARTICLE 7 

Confidentiality 

7.1 Confidential Information. Each Party (“Disclosing Party”) may disclose to the other Party (“Receiving
Party”), and the Receiving Party may acquire during the course and conduct of activities under the Agreement, certain non-public confidential information of the Disclosing Party in connection with
this Agreement or the Evaluation Agreement. The term “Confidential Information” means all information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or
proprietary, that is disclosed or made available by or on behalf of the Disclosing Party to or on behalf of the Receiving Party in connection with this Agreement or the Evaluation Agreement; provided, that (a) the Acuitas Sole Technology
will be the Confidential Information of Acuitas and the Omega Sole Technology will be the Confidential Information of Omega, (b) the Joint IP will be Confidential Information of both Parties, and either Party may use and disclose Joint
IP in connection with such Party’s permitted exploitation of such Technology, provided that the recipient is bound by confidentiality and non-use obligations corresponding to the obligations
under this Agreement and any Non-Exclusive License agreement, and (c) the data and results generated from the Workplan and the work conducted under the Evaluation Agreement shall be subject to
Section 3.3(b), which shall supersede any other provisions of this Agreement to the contrary. For the avoidance of doubt, the identity of potential Reserved Targets or any Omega Reserved Targets and the information contained in any
Target Notice submitted by Omega to the Escrow Agent, including any Omega Controller sequence information and the Human Genome Target(s) any such Omega Controller is designed to Genome Modulate, are the Confidential Information of Omega.
Confidential Information includes Confidential Information disclosed by either Party pursuant to the Confidential Disclosure Agreement. 

7.2 Restrictions. During the Term and for [***] ([***]) years thereafter, or with respect to any trade secret included in the
Confidential Information for so long as such trade secret is protected under applicable Laws (provided, that Receiving Party has not publicly disclosed such trade secret in breach of its obligations under this Article 7), the
Receiving Party will keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information, but in no event less than reasonable care. Receiving Party
will not use Disclosing Party’s Confidential Information except for in connection with the performance of its obligations and exercise of its rights under this Agreement or any Non-Exclusive License.
Receiving Party has the right to disclose Disclosing Party’s Confidential Information without Disclosing Party’s prior written consent to (a) Receiving Party’s Affiliates, and (b) each of Receiving Party’s
employees, permitted subcontractors (subject to Section 3.1(i)) and Collaboration Partners, consultants or agents who have a need to know such Confidential Information in order to perform (or for such entities to determine their interest
in performing) Receiving Party’s obligations or in the exercise of the Receiving Party’s rights under this Agreement and who are under written obligations to comply with the restrictions on use and disclosure that are no less restrictive
than those set forth in this Article 7. Receiving Party assumes responsibility for such persons maintaining Disclosing Party’s Confidential Information in confidence and using same only for the purposes described herein. 

7.3 Exceptions. Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the Disclosing
Party’s Confidential Information will not apply to a specific portion of the Disclosing Party’s Confidential Information to the extent that Receiving Party can demonstrate that such portion: (a) was known to Receiving Party or
any of its Affiliates prior to the time of disclosure by the Disclosing Party without obligation of confidentiality; (b) is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates;
(c) is obtained on a non-confidential basis by Receiving Party or any of its Affiliates from a Third Party who to Receiving Party’s knowledge is lawfully in possession thereof and under no
obligation of confidentiality to Disclosing Party; or (d) has been independently developed by or on behalf of Receiving Party or any of its Affiliates without the aid, application or use of Disclosing Party’s Confidential Information. 

  
 20 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 7.4 Permitted Disclosures. Receiving Party may disclose Disclosing Party’s
Confidential Information to the extent (and only to the extent) such disclosure is permitted under Section 7.2 or is reasonably necessary in the following instances: 

(a) in order and to the extent required to comply with applicable Laws (including any securities Laws or the regulations or rules of a
securities exchange applicable to Receiving Party) or with a legal or administrative proceeding or as required by a court or administrative order; 

(b) in connection with prosecuting or defending litigation including responding to a subpoena in a Third Party litigation; 

(c) in connection with filing, prosecuting and enforcing Patents in connection with Receiving Party’s rights and obligations pursuant to
this Agreement; 
 (d) to actual or potential: acquirers or permitted assignees, investment bankers, investors lenders, and other financing
sources, and to consultants and advisors of the Receiving Party; and 
 (e) in the case of Omega, to Collaboration Partners, but in case the
Collaboration Partner is only a potential licensee, partner or assignee, only such information that is reasonably necessary or useful for the potential licensee, partner or assignee to evaluate the Technology of interest, including design of
experiments conducted under the Workplan, data and results generated under the Workplan and LNP/Licensed Product manufacturing processes, but if a Non-Exclusive License agreement has not been executed,
excluding the particular chemical structure and formulation of any lipid nanoparticles (which excluded information may be disclosed to such potential licensee, partner or assignee upon Acuitas’ prior written consent); 

provided, that (1) where reasonably possible, Receiving Party will notify Disclosing Party of Receiving Party’s intent to make any disclosure
pursuant to subsections (a) or (b) above sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be
disclosed, and (2) with respect to subsections (d) or (e) above, each of those entities are required to comply with the restrictions on use and disclosure in Section 7.2 (other than investment bankers, investors, lenders, and other
financing sources which must be bound prior to disclosure by commercially reasonable obligations of confidentiality). Confidential Information that is required to be disclosed pursuant to subsections (a) or (b) will remain otherwise subject to
the confidentiality and non-use provisions of Section 7.1 and Section 7.2. If either Party concludes that a copy of this Agreement must be filed with the United States Securities and Exchange
Commission or similar regulatory agency in a country other than the United States, at least [***] ([***]) Business Days in advance of any such filing such Party will provide the other Party with a copy of this Agreement showing any provisions hereof
as to which the Party proposes to request confidential treatment, will provide the other Party with a reasonable opportunity to comment on any such proposed redactions and to suggest additional redactions, and will take such Party’s reasonable
and timely comments into consideration before so filing the Agreement. 
 7.5 Return of Confidential Information. Upon expiry or
earlier termination of the Agreement, upon written request of a Party (such request, if made, to be made within [***] ([***]) months of such expiry or termination) the other Party will destroy or return (as specified in such request) to the
requesting Party all copies of the Confidential Information of the requesting Party; provided, that a Party may retain: (a) one copy of such Confidential Information for record-keeping purposes, for the sole purpose of ensuring

  
 21 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 
compliance with this Agreement; (b) any copies of such Confidential Information as are required to be retained under applicable Laws; (c) any copies of such Confidential Information as
are necessary or useful for such Party to exercise a right or fulfill an obligation under this Agreement, including any Non-Exclusive License; and (d) any copies of any computer records and files
containing Confidential Information that have been created by such Party’s routine archiving/backup procedures, in each case provided that such copies are maintained in accordance with this ARTICLE 7. 

7.6 Publications. Notwithstanding anything in this Agreement to the contrary, each Party shall be permitted to publish the results of
the Program including Workplan Data that constitute the other Party’s or joint Confidential Information only with the prior written consent of the other Party, subject to Section 7.3 and Omega’s right to publish such results of its
development under the applicable Non-Exclusive License agreement in accordance with Section 8.6 thereof. Either Party wishing to make a publication or public presentation of Program results that
contains the Confidential Information of the other Party will deliver to the other Party a copy of any proposed written publication or presentation of Program results at least [***] ([***]) days prior to submission for publication or presentation.
Each Party will have the right to (a) remove its Confidential Information from the other Party’s proposed publications, (b) propose modifications to the publication or presentation for patent reasons, trade secret reasons or business
reasons, which proposals the publishing Party will consider in good faith, and (c) request a reasonable delay in publication or presentation in order to protect patentable information in accordance with Article 6. Following the expiration
of the applicable time period for review, the publishing Party will be free to submit for publication or otherwise disclose to the public such results, subject to the procedures set forth in the remainder of this Section 7.6. If the
nonpublishing Party provides written notice to the publishing Party requesting a delay pursuant to clause (iii) in this Section 7.6, the publishing Party will delay such submission or presentation for a period of an additional [***]
([***]) days to enable the nonpublishing Party to file patent applications on the disclosed subject matter. The publishing Party will thereafter be free to publish or disclose such information, except that subject to Section 7.3 the publishing
Party may not disclose any Confidential Information of the nonpublishing Party. Expedited reviews for abstracts or poster presentations, or for other publications that may relate to potential patent applications, may be arranged only with the prior
written consent of both Parties. Omega and Acuitas will each comply with standard academic practice regarding authorship of scientific publications and recognition of the contributions of other parties in any publications relating to studies
conducted under the Workplan. 
 7.7 Patents. Except as expressly permitted under this Agreement, neither Party will file a patent
application that includes or discloses the Confidential Information of the other Party without the consent of such other Party. 
 7.8
Terms of this Agreement; Publicity. The Parties agree that the material terms of this Agreement will be treated as Confidential Information of both Parties, and thus may be disclosed only as permitted by Sections 7.2, 7.3 and 7.4. Except
as required by applicable Laws (including any securities Laws or the regulations or rules of a securities exchange) or otherwise agreed by the Parties in writing, each Party agrees not to issue any press release or public statement disclosing
information relating to the existence of this Agreement or the transactions contemplated hereby or the terms hereof without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed. 

ARTICLE 8 

Warranties; Covenants; Limitations of Liability; Indemnification 

8.1 Representations and Warranties. Each Party represents and warrants to the other as of the Effective Date that (a) it is a
corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated, (b) it has the legal right and power to enter into this Agreement, to extend the rights, licenses and
options granted or to be granted to the other in this Agreement, 

  
 22 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 
and to fully perform its obligations hereunder, (c) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the
performance of its obligations hereunder, (d) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with
its terms limited by applicable bankruptcy, insolvency, reorganization, moratorium and other Laws of general application affecting the enforcement of creditors’ rights generally and as may be limited by Laws relating to the availability of
specific performance, injunctive relief or other equitable remedies, (e) the execution, delivery and performance of this Agreement by such Party does not violate any Law of any court, governmental body or administrative or other agency having
jurisdiction over such Party, (f) no government authorization, consent, approval, license, exemptions of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or
foreign, under any applicable Laws currently in effect, is necessary for the transactions contemplated by this Agreement or for the performance of its obligations under this Agreement, and (g) and during the Term, that its Affiliates, its and
their employees, and their consultants and agents have executed agreements or have existing obligations under Law requiring assignment to such Party of all intellectual property and proprietary rights made during the course of and as the result of
their association with such Party, and obligating such individuals to maintain as confidential the Confidential Information of a Disclosing Party under this Agreement or any Non-Exclusive License agreement,
and of any Third Party which such Party may receive. 
 8.2 Additional Representations and Warranties of Acuitas. Acuitas hereby
represents and warrants to Omega as of the Effective Date as follows: 
 (a) Impairment. Neither Acuitas nor any of its Affiliates has
entered into any agreement or otherwise licensed, granted, assigned, transferred, conveyed or otherwise encumbered or disposed of any right, title or interest in or to any of its assets, including any Technology, that would in any way conflict with
or impair the scope of any rights, licenses or options granted to Omega hereunder or that would be granted to Omega under any Non-Exclusive License agreement. 

(b) Patents and Know-How. Exhibit 1.1 sets forth a complete and accurate list of all
Patents included in the Acuitas Background Technology. Acuitas Controls the Acuitas Background Technology. All Acuitas inventors of the Acuitas Background Technology have validly assigned their rights to such Technology to Acuitas. Acuitas is and
will remain entitled to grant to Omega the licenses and rights specified herein or under a Non-Exclusive License during the Term as contemplated by this Agreement, to the Patents and the Know-How within the Acuitas Background Technology. To Acuitas’ knowledge, the Patents listed on Exhibit 1.1 have been diligently prosecuted and maintained in accordance with applicable Law. None of the
Patents included in the Acuitas Background Technology listed on Exhibit 1.1 are or have been involved in any opposition, cancellation, interference, reissue or reexamination proceeding, and to Acuitas’ knowledge as of the Effective Date,
no Acuitas Background Technology is the subject of any judicial, administrative or arbitral order, award, decree, injunction, lawsuit, proceeding or stipulation. As of the Effective Date, neither Acuitas nor any of its Affiliates has received any
notice alleging that the Patents in the Acuitas Background Technology listed on Exhibit 1.1 are invalid or unenforceable, or challenging Acuitas’ ownership of or right to use the Acuitas Background Technology. 

(c) Entire LNP Technology. The Acuitas Background Technology licensed to Omega under this Agreement or any Non-Exclusive License agreement comprises all LNP Technology owned or Controlled by Acuitas. [***]. 
 (d)
Encumbrances. Acuitas and its Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or performance of this Agreement or the Evaluation Agreement. As of the Effective Date, neither Acuitas
nor any of its Affiliates has granted any liens or security interests on the Acuitas Background Technology, and the Acuitas Background Technology is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance,
lien or charge of any kind. 

  
 23 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (e) Defaults. The execution, delivery and performance by Acuitas of this Agreement and
the consummation of the transactions contemplated hereby will not result in any violation of, conflict with, result in a breach of or constitute a default under any understanding, contract or agreement to which Acuitas is a party or by which it is
bound, including the [***], in each case as would reasonably be expected to have a material adverse effect on the rights granted to Omega hereunder or under any Non-Exclusive License agreement. 

(f) Litigation. There is no action, suit, proceeding or investigation pending or, to the knowledge of Acuitas, currently threatened in
writing against or affecting Acuitas that questions the validity of this Agreement, the right of Acuitas to enter into this Agreement or consummate the transactions contemplated hereby or that relates to the Acuitas LNP Technology. 

(g) Infringement. Neither Acuitas nor any of its Affiliates has received any notice of any claim, nor does Acuitas or its Affiliates
have any knowledge of any basis for any claim, that any Patent, Know-How or other intellectual property owned or controlled by a Third Party would be infringed or misappropriated by the practice of any Acuitas
LNP Technology. 
 (h) Third Party Infringement. To Acuitas’ knowledge, no Third Party is infringing or has infringed any Patent
within the Acuitas LNP Technology or is misappropriating or has misappropriated any Know-How within the Acuitas LNP Technology. 

(i) No Debarment. Neither Acuitas, nor to Acuitas’ knowledge any of its employees, have been Debarred or are subject to
Debarment. 
 8.3 Disclaimers. Without limiting the respective rights and obligations of the Parties expressly set forth
herein, each Party specifically disclaims any guarantee that the Program will be successful, in whole or in part. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTY OF ANY KIND,
EITHER EXPRESS OR IMPLIED. 
 8.4 No Consequential Damages. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY
WILL BE LIABLE TO THE OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT, PUNITIVE, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES; PROVIDED THAT THIS SECTION 8.4 WILL NOT APPLY TO
BREACHES OF ARTICLES 6 OR 7 OR THE PARTIES’ INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER ARTICLE 8. 
 8.5 Performance by
Others. The Parties recognize that each Party may perform some or all of its obligations under this Agreement through Affiliates, or permitted subcontractors in accordance with Section 3.1(i); provided, however, that each
Party will remain responsible and liable for the performance by its Affiliates or permitted subcontractors and will cause its Affiliates and permitted subcontractors to comply with the provisions of this Agreement in connection therewith. 

  
 24 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 8.6 Indemnification. 

(a) Indemnification by Acuitas. Acuitas will indemnify Omega, its Affiliates and their respective directors, officers, employees, Third
Party licensors, licensees, permitted subcontractors, Collaboration Partners and agents, and their respective successors, heirs and assigns (collectively, “Omega Indemnitees”), and defend and hold each of them harmless, from and
against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third
Parties (collectively, “Third Party Claims”) against the Omega Indemnitees to the extent arising from or occurring as a result of: (i) the breach by Acuitas of any provision of this Agreement or the Evaluation Agreement;
or (ii) any negligence or willful misconduct on the part of any Acuitas Indemnitee in the conduct of the Workplan or the work conducted under the Evaluation Agreement; or (iii) the use, practice, license or other exploitation
of the Joint IP by or on behalf of Acuitas for its own or a Third Party’s account except in each case (i)-(iii) to the extent Omega is obligated to indemnify an Acuitas Indemnitee in accordance with Section 8.6(b). 

(b) Indemnification by Omega. Omega will indemnify Acuitas, its Affiliates and their respective directors, officers, employees and
agents, and their respective successors, heirs and assigns (collectively, “Acuitas Indemnitees”), and defend and hold each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims
against Acuitas Indemnitees to the extent arising from or occurring as a result of: (i) the breach by Omega of any provision of this Agreement or the Evaluation Agreement; or (ii) any negligence or willful misconduct on the part of
any Omega Indemnitee in the conduct of the Workplan or the work conducted under the Evaluation Agreement; or (iii) any alleged infringement or misappropriation of Patents or other intellectual property rights by Acuitas in the conduct of
the Workplan or the work conducted under the Evaluation Agreement based solely on Acuitas’ use of Omega Technology, (iv) the use, practice, license or other exploitation of the Joint IP by or on behalf of Omega for its own or a
Third Party’s account (other than in connection with any Licensed Product that is the subject of a Non-Exclusive License agreement) except in each case (i)-(iv) to the extent Acuitas is obligated to
indemnify Omega in accordance with Section 8.6(a). 
 (c) Notice of Claim. All indemnification claims provided for in
subsections (a) and (b) above will be made solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party will promptly notify the indemnifying Party (the “Indemnifying Party”)
in writing of any Losses or the discovery of any fact upon which the Indemnified Party intends to base a request for indemnification under subsections (a) or (b) above (each such notice, an “Indemnification Claim
Notice”), provided that the failure to promptly provide such notice and details will not relieve the Indemnifying Party of any of its indemnification obligations hereunder, except to the extent that the Indemnifying
Party’s defense of the relevant Third Party Claim is prejudiced by such failure. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such
Loss is known at such time). The Indemnified Party will furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. 

(d) Defense, Settlement, Cooperation and Expenses. 

(i) Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third Party Claim by giving written notice
to the Indemnified Party within [***] ([***]) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the
defense of the Third Party Claim any legal counsel selected by the Indemnifying Party (the Indemnifying Party will consult with the Indemnified Party with respect to such legal counsel and a possible conflict of interest of such counsel retained by
the Indemnifying Party). In the event the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party will immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by
the Indemnified Party in connection with the Third Party Claim. 

  
 25 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (ii) Right to Participate in Defense. Without limiting subsection (i) above, any
Indemnified Party will be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment will be at the Indemnified
Party’s own cost and expense unless (A) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with subsection (i) above (in which case the Indemnified Party will control the defense) or (B) the
Indemnified Party has received a written opinion of counsel, reasonably acceptable to the Indemnifying Party, to the effect that the interests of the Indemnified Party and the Indemnifying Party with respect to such Third Party Claim are
sufficiently adverse to prohibit the representation by the same counsel of both Parties under applicable Law, ethical rules or equitable principles, [***]. 

(iii) Settlement. With respect to any Third Party Claims that relate solely to the payment of money damages in connection with a Third
Party Claim and that will not (A) result in the Indemnified Party’s becoming subject to injunctive or other relief, (B) include any admission or concession of liability or wrongdoing on the part of the Indemnified Party, or
(C) otherwise adversely affect the business or Patents of the Indemnified Party in any manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the
Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate. With respect to
all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with subsection (i) above, the Indemnifying Party will have authority to consent to the entry of
any judgment, enter into any settlement or otherwise dispose of such Loss; provided it obtains the prior written consent of the Indemnified Party (which consent will not be unreasonably withheld, conditioned or delayed). Where the
Indemnifying Party has assumed the defense of the Third Party Claim in accordance with subsection (i) above, the Indemnifying Party will not be liable for any settlement or other disposition of a Loss by an Indemnified Party that is reached
without the written consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnified Party will admit any liability with respect to or settle, compromise or
discharge, any Third Party Claim without the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, conditioned or delayed. 

(iv) Cooperation. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified
Party will cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably
requested in connection therewith at the Indemnifying Party’s expense. Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and
information that are reasonably relevant to such Third Party Claim, and making indemnified parties and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided
hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket costs and expenses in connection therewith. 

(v) [***]. 
 8.7
Insurance. Each Party will maintain at its sole cost and expense, an adequate liability insurance or self-insurance program to protect against potential liabilities and risk arising out of activities to be performed under this Agreement and
upon such terms (including coverages, deductible limits and self-insured retentions) as are customary in the respective industry of such Party for the activities to be conducted by such Party under this Agreement. The coverage limits set forth
herein will not create any limitation on a Party’s liability to the other under this Agreement. Upon the request of a Party, the other Party will provide evidence of the insurance coverage required by this Section 8.7. 

  
 26 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 ARTICLE 9 

Term and Termination 

9.1 Term. This Agreement will commence as of the Effective Date and, unless sooner terminated in accordance with the terms of this
Article 9 or by mutual written consent of the Parties, will terminate on the first to occur of (a) Omega has reached the Option Limit and
(b) third (3rd) anniversary of the Effective Date; provided, Omega will have one (1) option to extend the initial three (3) year term for an
additional two (2) year period by providing written notice thereof to Acuitas at least six (6) months prior to the third (3rd) anniversary of the Effective Date
(such three (3) year period, together with any such two (2) year extension if such extension is requested in accordance with the foregoing, and any extension of an Option exercise period pursuant to Section 10.15, the
“Term”). 
 9.2 Termination by Omega. 

(a) Breach. Omega will have the right to terminate this Agreement or the Program in full upon delivery of written notice to Acuitas in
the event of a material breach by Acuitas of its representations, warranties or obligations under this Agreement or any Non-Exclusive License agreement, provided that such breach has not been
cured within [***] ([***]) days after written notice thereof is given by Omega to Acuitas specifying the nature of the alleged breach. In the event of a termination of the Program for Acuitas’ uncured material breach, the JDC will be
disbanded, Acuitas will receive no further reimbursement for FTE Costs or external expenses and Acuitas will conduct a technology transfer in accordance with Section 3.1(f) and provide necessary licenses to Omega or its Third Party designee
each as reasonably necessary for Omega or such Third Party designee to complete the conduct of the Program. For avoidance of doubt, termination of the Program pursuant to this Section 9.2(a) will not terminate Omega’s reservation of
Reserved Targets or the Options, subject to the payment of all fees associated therewith. Unless terminated earlier by Omega in its sole discretion by written notice to Acuitas, any Option that is in effect as of the effective date of termination
pursuant to Section 9.2(a), will continue in effect until the earlier of (i) such Option exercise and (ii) expiration of the Term. 

(b) Discretionary Termination. Omega will have the right to terminate this Agreement in full at any time without cause or for any or no
reason by giving [***] ([***]) days’ prior written notice to Acuitas. Upon termination by Omega pursuant to this subsection, Omega will pay to Acuitas all accrued, then-unpaid Target Reservation and Maintenance Fees, and any amounts
payable to Acuitas for any Works and Services performed pursuant to the Workplan up through the date of such termination and provided however, that if Omega terminates the Agreement within the first year after the Effective Date for
any reason other than an acquisition or other change of control of Acuitas or the failure by Acuitas to perform any obligations under this Agreement for a period of more than three (3) months due to a force majeure condition described in
Section 10.15, [***]. 
 9.3 Termination by Acuitas. Acuitas will have the right to terminate this Agreement in full upon
delivery of written notice to Omega in the event of a material breach by Omega of its representations, warranties or obligations under this Agreement or any Non-Exclusive License (subject to
Section 10.2(b) of such Non-Exclusive License), provided that such breach has not been cured within [***] ([***]) days after written notice thereof is given by Acuitas to Omega
specifying the nature of the alleged breach. Omega hereby agrees that Acuitas is entitled to receive payment of any amounts payable to Acuitas for any Works and Services performed pursuant to the Workplan up through the date of such termination. If
Omega disputes in good faith the existence or materiality of a breach specified in a notice provided in accordance with this Section 9.3, and Omega provides Acuitas notice of such dispute within such [***] ([***]) day

  
 27 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 
cure period, then Acuitas will not have the right to terminate this Agreement under this Section 9.3 unless and until it is finally determined, in accordance with Section 10.1, that
Omega has materially breached this Agreement and Omega has failed to cure such breach within [***] ([***]) days following such decision. It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this
Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations (including payment obligations) hereunder. If Acuitas terminates this Agreement pursuant to this Section 9.3, then Acuitas will have
the right, but not the obligation, to terminate any then-existing Non-Exclusive License. 
 9.4
Termination Upon Bankruptcy. If either Party makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or
insolvency act in any state or country or has any such petition filed against it which is not discharged within [***] ([***]) days of the filing thereof, then the other Party may thereafter terminate this Agreement effective immediately upon written
notice to such Party. All rights and licenses granted under or pursuant to this Agreement by Acuitas are, and will otherwise be deemed to be, for purposes of the relevant provisions of the Bankruptcy and Insolvency Act, R.S.C. 1985, c. B-3 (“BIA”), including Sections 65.11(7), 65.13(9), 72.1 and 246.1 of the BIA; and the relevant provisions of the Companies’ Creditors Arrangement Act, R.S.C. 1985, c. C-36 (“CCAA”), including Sections 32(6) and 36(8) of the CCAA (the BIA and CCAA being referred to collectively as the “Insolvency Legislation”), a grant of a “right
to use” “intellectual property” as used in the Insolvency Legislation. The Parties agree that Omega and its Affiliates, as licensees of such rights under this Agreement, will retain and may fully exercise all of their rights and
elections under the Insolvency Legislation subject to the payment of amounts provided for herein. Without limiting Omega’s rights under the Insolvency Legislation, if Acuitas becomes insolvent or makes an assignment for the benefit of its
creditors or there is filed by or against the Acuitas any bankruptcy, receivership, reorganization or similar proceeding pursuant to or under the Insolvency Legislation or otherwise, Omega will be entitled to a copy of any and all such intellectual
property and all embodiments of such intellectual property, and the same, if not already in the possession of Omega, will be promptly delivered to Omega (a) if requested by Omega, before this Agreement is rejected, disclaimed,
repudiated, rescinded or terminated by or on behalf of Acuitas, within [***] ([***]) days after Omega’s written request, unless Acuitas, or its trustee or receiver, elects within [***] ([***]) days to continue to perform all of
its obligations under this Agreement, or (b) forthwith, if requested by Omega after any rejection, disclaimer, repudiation, recission or termination of this Agreement by or on behalf of Acuitas, if not previously delivered as provided under
clause (a) above. All rights of the Parties under this Section 9.4 and under the relevant intellectual property provisions of the Insolvency Legislation are in addition to and not in substitution of any and all other rights,
powers, and remedies that each Party may have under this Agreement, the Insolvency Legislation, and any other applicable Laws. 
 9.5
Effects of Termination. 
 (a) In the event of a dispute as to whether Omega has materially breached its payment obligations
or Acuitas has materially breached its obligations under the Workplan, Omega will [***]. Upon the request of Omega, the following will apply to any dispute described in the first sentence of this Section 9.5(a): the informal dispute resolution
process in Section 10.1(a) will not apply; or the negotiation period for the Executive Officers in Section 10.1(b) will be limited to [***] ([***]) Business Days. 

(b) Upon termination by either Party under Sections 9.2, 9.3 or 9.4, (i) Acuitas will terminate all Works and Services in progress
in an orderly manner as soon as practical and in accordance with a schedule agreed to by Omega, (ii) Acuitas will use commercially reasonable efforts to terminate or limit any outstanding commitments and costs associated with the Workplan,
(iii) Acuitas will deliver to Omega any of Omega’s Materials in its possession or control and all deliverables developed through termination or expiration, (iv) [***], and (v) Acuitas will promptly issue a final invoice to Omega and
Omega will pay Acuitas within [***] ([***]) days of receipt of such invoice any monies due and owing Acuitas, up to the time of termination or expiration, for Works and Services actually performed and all authorized expenses actually incurred (as
specified in the Workplan). 

  
 28 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 9.6 Survival. In addition to the termination consequences set forth in
Section 9.5, the following provisions will survive termination or expiration of this Agreement, as well as any other provision which by its terms or by the context thereof, is intended to survive such termination: Article 1 (to the
extent applicable to any other surviving provisions), Article 6, Article 7 and Article 10 and Section 3.1(f) (with respect to Acuitas’ obligation to complete a technology transfer, as applicable),
Section 3.3(a), Section 3.3(b) (with respect to the Parties’ permitted disclosure and use of Workplan Data), Section 3.3(c)(i) (with respect to the Parties’ obligation to return or destroy Materials
after expiration or termination of this Agreement), Section 4.2(a), Section 4.2(d)(ii) (in accordance with its terms), Section 5.1(c), Section 5.2 (to the extent that Omega exercises an Option, as
applicable), Section 8.3, Section 8.4, Section 8.5, Section 8.6, Section 9.4, Section 9.5 and this Section 9.6. Termination or expiration of this Agreement will not
relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at Law or in equity
with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. All other rights and obligations will terminate upon expiration of this Agreement. 

ARTICLE 10 

Miscellaneous 
 10.1
Dispute Resolution. 
 (a) Disputes. Disputes arising under or in connection with this Agreement (other than
disputes regarding issues within the purview of the JDC which will be resolved pursuant to Section 2.2(d)) will be resolved pursuant to this Section 10.1; provided, however, that in the event a dispute cannot be resolved
without an adjudication of the rights or obligations of a Third Party (other than any Omega Indemnitees or Acuitas Indemnitees identified in Section 8.6), the dispute procedures set forth Sections 10.1(b) and 10.1(c) will be
inapplicable as to such dispute. 
 (b) Dispute Escalation. In the event of a dispute between the Parties, the Parties will first
attempt in good faith to resolve such dispute by negotiation and consultation between themselves or the Workplan Leaders. In the event that such dispute is not resolved on an informal basis within [***] ([***]) days, any Party may, by written
notice to the other, have such dispute referred to each Party’s Chief Executive Officer or his or her designee (who will be a senior executive), who will attempt in good faith to resolve such dispute by negotiation and consultation for a
[***] ([***]) day period following receipt of such written notice. 
 (c) Dispute Resolution. In the event the Chief Executive
Officers of the Parties are not able to resolve such dispute as set forth above, the Chief Executive Officers will together elect whether to submit the dispute to mediation, litigation or arbitration. In the absence of such an agreement, either
Party may elect to initiate litigation. 
 (d) Injunctive Relief. Notwithstanding the dispute resolution procedures set forth in this
Section 10.1, in the event of an actual or threatened breach hereunder, the aggrieved Party may seek equitable relief (including restraining orders, specific performance or other injunctive relief) in any court or other forum, without first
submitting to any dispute resolution procedures hereunder. 

  
 29 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 (e) Tolling. The Parties agree that all applicable statutes of limitation and
time-based defenses (such as estoppel and laches) will be tolled while the dispute resolution procedures set forth in this Section 10.1 are pending, and the Parties will cooperate in taking all actions reasonably necessary to achieve such a
result. 
 (f) Prevailing Party. The prevailing Party in any suit related to this Agreement will be entitled to recover from the
losing Party [***]. 
 (g) Cumulative Remedies and Irreparable Harm. All rights and remedies of the Parties hereunder will be
cumulative and in addition to all other rights and remedies provided hereunder or available by agreement, at Law or otherwise. Each Party acknowledges and agrees that breach of any of the terms or conditions of this Agreement may cause irreparable
harm and damage to the other and that such damage may not be ascertainable in money damages and that as a result thereof the non-breaching Party may be entitled to seek from a court equitable or injunctive
relief restraining any breach or future violation of the terms contained herein by the breaching Party. Such right to equitable relief is in addition to whatever remedies either Party may be entitled to as a matter of Law or equity, including money
damages. 
 10.2 Invoices and Payments. All invoices to be delivered to Omega hereunder shall be delivered in accordance with
Section 10.11 or in such other manner specified by Omega from time to time. All amounts specified in, and all payments to be made by Omega under, this Agreement will be in U.S. dollars and will be paid by wire transfer to such bank account as
Acuitas may designate at least [***] ([***]) Business Days before such payment is due. Omega may withhold from payments due to Acuitas amounts for payment of any withholding tax that is required by Law to he paid to any taxing authority with
respect to such payment. Omega will provide Acuitas all relevant documents and correspondence, and will also provide to Acuitas any other cooperation or assistance on a reasonable basis as may be necessary to enable Acuitas to claim exemption from
such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. Upon the request of Acuitas, Omega will give proper evidence from time to time as to the payment of any such tax. 

10.3 Relationship of Parties. Nothing in this Agreement is intended or will be deemed to constitute a partnership, agency,
employer-employee or joint venture relationship between the Parties. No Party will incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided therein. There are no express or implied Third Party
beneficiaries hereunder. 
 10.4 Compliance with Law. Each Party will perform or cause to be performed any and all of its obligations
or the exercise of any and all of its rights hereunder in good scientific manner and in compliance with all applicable Law. 
 10.5
Governing Law. This Agreement will be governed by and construed in accordance with the Laws of the state of New York, United States of America, without respect to its conflict of Laws rules, excluding (a) any of its conflicts of laws
principles to the contrary; (b) the United Nations Conventions on Contracts for the International Sale of Goods; (c) the 1974 Convention on the Limitation Period in the International Sale of Goods; and (d) the Protocol amending the
1974 Convention on the Limitation Period in the International Sale of Goods, done at Vienna, April 11, 1980; and provided that any dispute relating to the scope, validity, enforceability or infringement of any Patents or Know-How will be governed by, and construed and enforced in accordance with, the substantive Laws of the jurisdiction in which such Patents or Know-How apply. 

10.6 Counterparts; Facsimiles. This Agreement may be executed in one or more counterparts, each of which will be deemed an original,
and all of which together will be deemed to be one and the same instrument. Facsimile or PDF execution and delivery of this Agreement by either Party will constitute a legal, valid and binding execution and delivery of this Agreement by such Party.

  
 30 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 10.7 Headings; Rule of Construction; Interpretation. 

(a) Headings. All headings in this Agreement are for convenience only and will not affect the meaning of any provision hereof. 

(b) Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting
and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply. 

(c) Interpretation. Whenever any provision of this Agreement uses the term “including” (or “includes”), such term
will be deemed to mean “including without limitation” (or “includes without limitation”). “Herein,” “hereby,” “hereunder,” “hereof” and other equivalent words refer to this Agreement as an
entirety and not solely to the particular portion of this Agreement in which any such word is used. In this Agreement, the word “or” means “and/or”. All definitions set forth herein will be deemed applicable whether the words
defined are used herein in the singular or the plural. Unless otherwise provided, all references to Sections and Exhibits in this Agreement are to Sections and Exhibits of this Agreement. References to any Sections include
Sections and subsections that are part of the related Section. 
 10.8 Further Assurances. Each Party shall take all customary
and reasonable actions and do all things reasonably necessary or proper, including under applicable Law, to make effective and further the intents and purposes of the transactions contemplated by this Agreement, including executing any further
instruments reasonably requested by the other Party. 
 10.9 Binding Effect. This Agreement will inure to the benefit of and be
binding upon the Parties, their Affiliates, and their respective lawful successors and assigns. 
 10.10 Assignment. This Agreement
may not be assigned by either Party, nor may either Party delegate its obligations or otherwise transfer licenses or other rights created by this Agreement, except as expressly permitted hereunder, without the prior written consent of the other
Party, which consent will not be unreasonably withheld, conditioned or delayed; provided, that either Party may assign this Agreement in whole or in part without such consent to an Affiliate or to its successor in connection with the sale of
all or substantially all of its assets or business or that portion of its business pertaining to the subject matter of this Agreement (whether by merger, consolidation or otherwise); provided that such Affiliates or Third Party agree
to be bound by this Agreement. 
 10.11 Notices. All notices, requests, demands and other communications required or permitted to be
given pursuant to this Agreement will be in writing and will be deemed to have been duly given upon the date of receipt if delivered by hand, email, recognized international overnight courier, or registered or certified mail, return receipt
requested, postage prepaid to the following addresses: 
  

					
	                	  	If to Omega:	  	 Omega Therapeutics, Inc.
 20 Acorn Park
Drive
 Cambridge, MA 02140
 U.S.A.

Attention: Chief Executive Officer
 Email:
[***]

  
 31 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

					
	                	  	With a copy to:	  	 Omega Therapeutics, Inc.
 20 Acorn Park
Drive
 Cambridge, MA 02140
 U.S.A.

Attention: Legal Department
 Email: [***]

			
		  	If to Acuitas:	  	 Acuitas Therapeutics Inc.
 6190 Agronomy Road,
Suite 405
 Vancouver, B.C.
 Canada V6T 1Z3

Attention: President and CEO
 Email: [***]

			
		  	With a copy to:	  	 McCarthy Tetrault LLP
 Suite 2400 745 Thurlow
Street
 Vancouver, B.C.
 Canada V6E 0C5

Attention: [***]
 Email: [***]

 Either Party may change its designated address by notice to the other Party in the manner provided in this Section 10.11.

 10.12 Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified only by means of a written
instrument signed by both Parties; provided that any unilateral undertaking or waiver made by one Party in favor of the other will be enforceable if undertaken in a writing signed by the Party to be charged with the undertaking or
waiver. Any waiver of any rights or failure to act in a specific instance will relate only to such instance and will not be construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar. 

10.13 Severability. In the event that any provision of this Agreement will, for any reason, be held to be invalid or unenforceable in
any respect, such invalidity or unenforceability will not affect any other provision hereof, and the Parties will negotiate in good faith to modify the Agreement to preserve (to the extent possible) their original intent. 

10.14 Entire Agreement. The Parties agree that the Evaluation Agreement terminates as of the Effective Date. This Agreement together
with any Non-Exclusive License agreements and the Joint Prosecution and Maintenance Agreement (including all appendices and exhibits hereto and thereto) entered into during the Term are the sole agreements
with respect to their subject matter and supersede all other agreements and understandings between the Parties with respect to same, including the Evaluation Agreement and the Confidential Disclosure Agreement. 

10.15 Force Majeure. Neither Acuitas nor Omega will be liable for failure of or delay in performing obligations set forth in this
Agreement (other than any obligation to pay monies when due), and neither will be deemed in breach of such obligations, if such failure or delay is due to natural disasters or any causes reasonably beyond the control of such Party; provided
that the Party affected will promptly notify the other of the force majeure condition and will exert reasonable efforts to eliminate, cure or overcome any such causes and to resume performance of its obligations as soon as possible. If such
force majeure event affects Acuitas’ ability to timely perform its obligations under the Workplan, then [***]. 

  
 32 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 [Signature page to follow] 

  
 33 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 IN WITNESS WHEREOF, the Parties have caused this Development and Option Agreement to
be executed by their respective duly authorized officers as of the Effective Date. 
  

			
	ACUITAS THERAPEUTICS, INC.

 
			
		
	By:	 	/s/ Thomas Madden

 
			
	(Signature)

 
			
		
	Name:	 	Thomas Madden
		
	Title:	 	President & CEO

 
			
	
	OMEGA THERAPEUTICS, INC.

 
			
		
	By:	 	/s/ Mahesh Karande

 
			
	(Signature)

 
			
		
	Name:	 	Mahesh Karande
		
	Title:	 	President & CEO

  
 34 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 EXHIBIT 1.1 

PATENTS IN THE ACUITAS BACKGROUND TECHNOLOGY 

[***] 
 TBD = To Be Determined 

NP-filed = Non-provisional filed 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 EXHIBIT 3.1(a) 

WORKPLAN 
 [***] 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 EXHIBIT 3.1(f) 

[***] 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 EXHIBIT 4.2 

FORM OF TARGET NOTICE: HUMAN GENOME TARGET(S) 

[***] 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 FORM OF TARGET NOTICE: PROTEIN TARGET(S) (OMEGA CONTROLLER(S)) 

[***] 

 EXECUTION COPY 

CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 EXHIBIT 5.2(b) 

FORM OF NON-EXCLUSIVE LICENSE AGREEMENT 

 CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

 AMENDMENT ONE TO DEVELOPMENT AND OPTION AGREEMENT 

Amendment One dated June 20, 2021 (this “Amendment”) to Development and Option Agreement dated October 5, 2020 (the
“Development and Option Agreement”) is made by and between Omega Therapeutics, Inc. a Delaware corporation (“Omega”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). 

WHEREAS, Omega and Acuitas have entered into the Development and Option Agreement and wish to amend that agreement. 

NOW THEREFORE in consideration of the foregoing, the promises, mutual covenants and obligations set forth below, and other good and
valuable consideration, the Parties agree as follows. 
 1.        Definitions. Capitalized terms used herein
and not otherwise defined shall have the meanings set forth in the Development and Option Agreement. 

2.        Amendment of Section 5.2(c). Section 5.2(c) of the Development and Option Agreement is hereby amended
as set forth below. 
  

	 	(c)	 Option Exercise Fee. Within [***] ([***]) Business Days after the effective date of a
Non-Exclusive License, Acuitas will issue an invoice to Omega for the Option Exercise Fee less any amounts creditable against such Option Exercise Fee for such Non-Exclusive License pursuant to Section 4.4(b). Such payment will be due within [***]
days ([***]) days after Omega’s receipt of such invoice from Acuitas. A separate Option Exercise Fee will be required for each Non-Exclusive License executed by the Parties in accordance with this Article 5. 

3.        Miscellaneous. 
  

	 	3.1	 Governing Law. Section 10.5 of the Development and Option Agreement shall apply to this Amendment.

  

	 	3.2	 Entire Agreement. Except as amended, modified and supplemented by the terms of this Amendment, the
provisions of the Development and Option Agreement are and shall remain in full force and effect. This Amendment and the Development and Option Agreement (as amended by this Amendment) contain the entire understanding of the Parties with respect to
the subject matter hereof. All express or implied agreements and understandings, either oral or written, with regard to such subject matter are superseded by the terms of this Amendment and the Development and Option Agreement (as amended by this
Amendment). 

  

	 	3.3	 Counterparts. This Amendment may be executed in any number of counterparts, each of which will be deemed
an original, and all of which together will constitute one and the same instrument. 

 IN WITNESS WHEREOF, Omega
and Acuitas have set their hands to the Amendment as of the date first written above. 

 CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 
  

	
	OMEGA THERAPEUTICS, INC.
	
	/s/ Mahesh Karande
	By: Mahesh Karande, President & CEO
	
	ACUITAS THERAPEUTICS, INC.
	
	/s/ Thomas Madden
	By: Thomas Madden, President & CEO

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]